Document:

exv10w2

Exhibit 10.2

Execution Version

***Text Omitted and Filed Separately

with the Securities and Exchange Commission.

Confidential Treatment Requested

Under 17 C.F.R. Sections 200.80(b)(4)

and 240.24b-2.

LICENSE & DEVELOPMENT AGREEMENT

     This License & Development Agreement (the “Agreement”) is entered into as of August
25, 2010 (the “Effective Date”) by and between Alexza Pharmaceuticals, Inc., a Delaware
corporation with a principal place of business at 2091 Stierlin Court, Mountain View, CA 94043
(“Alexza”), and Cypress Bioscience, Inc., a Delaware corporation with a principal place of
business at 4350 Executive Drive, Suite 325, San Diego, CA 92121 (“Cypress”). Alexza and Cypress
are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.

RECITALS

     A. Alexza is a pharmaceutical company that is developing products based on its proprietary
Staccato® system, a drug delivery system that provides rapid systemic delivery of drugs
through inhalation.

     B. Cypress desires to obtain from Alexza certain exclusive, worldwide rights and licenses to
develop, manufacture and commercialize products consisting of the Staccato® system
solely for use in delivery of nicotine, and Alexza is willing to grant to Cypress such rights and
licenses, all on the terms and conditions set forth in this Agreement.

     C. Cypress and Alexza desire that Alexza conduct certain development activities for Cypress
with respect to licensed products for a limited time period.

     NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein
contained, and for other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, Alexza and Cypress hereby agree as follows:

ARTICLE 1

DEFINITIONS

     As used in this Agreement, the following initially capitalized terms, whether used in the
singular or plural form, shall have the meanings set forth in this Article 1. In addition, the
terms “includes,” “including,” “include” and derivative forms of them shall be deemed followed by
the phrase “without limitation” (without implication from the actual inclusion of such phrase in
some instances after such terms, but not in other instances).

     1.1 “Affiliate” means, with respect to a particular Party, a person, corporation, partnership,
or other entity that controls, is controlled by or is under common control with such Party. For
the purposes of this definition, the word “control” (including, with correlative meaning, the terms
“controlled by” or “under the common control with”) means the actual power, either directly or
indirectly through one or more intermediaries, to direct or cause the

1

 

direction of the management and policies of such entity, whether by the ownership of more than
fifty percent (50%) of the voting stock of such entity, or by contract or otherwise.

     1.2 “Aggregate Development Expenses” shall mean the Alexza Development Expenses and the
Cypress Development Expenses.

     1.3 “Alexza” shall have the meaning described in the first paragraph of this Agreement and
shall include its successors and assigns as contemplated by Section 13.7.

     1.4 “Alexza Background Patents” means all Patents that: (a) are necessary or reasonably useful
for the research, development, importation, use, manufacture, sale or offering for sale of any
Product worldwide, (b) are Controlled by Alexza or its Affiliates as of the Effective Date or
during the Term, and (c) cover or claim the Device or its manufacture or use and/or Staccato
Technology generally, but excluding the Alexza Product Patents, the [...***...]
Patents and the Joint Patents.

     1.5 “Alexza Development Expenses” has the meaning set forth in Section 5.4(a).

     1.6 “Alexza Development Plan” shall mean the plan and budget for development of the Product,
including the Device, by Alexza under this Agreement, as such plan may be amended in accordance
with Section 3.2.

     1.7 “Alexza Funded Incremental Development Expenses” shall have the meaning set forth in
Section 5.4(d).

     1.8 “Alexza Indemnitees” has the meaning set forth in Section 10.1.

     1.9 “Alexza Know-How” means all Know-How (other than Joint Inventions) Controlled by Alexza or
its Affiliates as of the Effective Date or during the Term that is necessary or reasonably useful
for the research, development, importation, use, manufacture, having manufactured, sale or offering
for sale of any Product.

     1.10 “Alexza Nicotine Product Patents” means any of the Alexza Product Patents that are
directed solely and specifically toward a Product or its manufacture or use (which shall include,
without limitation, any Patent claims that have been separated into distinct divisional (or
equivalent) patent applications pursuant to Section 7.2(a)(ii)). Without limiting the foregoing,
the patent application set forth on Exhibit A entitled [...***...] is included in Alexza Nicotine
Product Patents.

     1.11 “Alexza Patents” means the Alexza Product Patents and Alexza Background Patents. A list
of the Alexza Patents existing as of the Effective Date is set forth on Exhibit A.

     1.12 “Alexza Product License” has the meaning set forth in Section 11.3(b)(iii)(1).

 

			
	***	 	Confidential Treatment Requested

2

 

     1.13 “Alexza Product Patents” means all Patents (other than Joint Patents) that: (a) are
necessary or reasonably useful for the research, development, importation, use, manufacture, sale
or offering for sale of any Product worldwide, (b) are Controlled by Alexza or its Affiliates as of
the Effective Date or during the Term, and (c) specifically claim (i) any Product or its
manufacture or use or (ii) any combination product consisting of Nicotine and any API(s) other than
Nicotine and a Device that delivers such APIs or its manufacture or use.

     1.14 “Alexza Product Sale” has the meaning set forth in Section 11.3(b)(iii)(1).

     1.15 “Alexza Sublicense Agreement” has the meaning set forth in Section 2.4.

     1.16 “Alexza Technology” means the Alexza Know-How, Alexza Patents and Alexza’s interest in
the Joint Inventions and Joint Patents.

     1.17 “Alexza Trademarks” means the Trademarks owned by Alexza set forth on Exhibit B,
individually and/or collectively.

     1.18 “API” means an active pharmaceutical ingredient. For clarity, API does not include any
agent that does not independently provide pharmacological activity or other effect in the
diagnosis, cure, mitigation, treatment or prevention of disease, and that does not affect structure
or function of the body of a human or other animal, and whose primary effect or purpose is to
facilitate the delivery or mask the taste or other effect associated with the Product.

     1.19 “Applicable Laws” means the applicable provisions of any and all national, supranational,
regional, state and local laws, treaties, statutes, rules, regulations, administrative codes,
guidance, ordinances, judgments, decrees, directives, injunctions, orders, permits (including
Marketing Approvals) of or from any court, arbitrator, Regulatory Authority or governmental agency
or authority having jurisdiction over or related to the subject item.

     1.20 “Asset Commercialization Date” shall mean the earlier of: (a) the date, if ever, on
which Cypress notifies Alexza in writing that Cypress has affirmatively determined to commercialize
any Product in any country; or (b) the date of NDA approval in any given country in which Cypress
has not entered into a Cypress Sublicense Agreement or otherwise entered into an Asset License or
Asset Sale.

     1.21 “Asset License” shall mean any transaction (including licensing and collaboration
transactions and joint ventures involving a license or sublicense, but excluding any Change of
Control of Cypress) pursuant to which rights under the Cypress Technology, Cypress Product
Invention Technology and/or Alexza Technology to commercialize any Product are licensed or
sublicensed by Cypress or any of its Affiliates to any Third Party; provided, however, that any
such license or sublicense solely to manufacture or develop any Product for Cypress or its
Affiliate where Cypress or its Affiliate commercializes such Product shall not be an Asset License.

     1.22 “Asset License Consideration” shall mean the net monetary and non-monetary consideration
actually received by Cypress or any of its Affiliates in connection with any Asset License, after
deducting any investment banking, broker, accounting, tax and legal fees paid by Cypress directly
related to such Asset License, including net licensing fees, royalties, milestones

3

 

or similar amounts to the extent actually paid to Cypress or any of its Affiliates (but
excluding (a) amounts paid to Cypress by the licensee or any of its Affiliates for research and
development activities (at actual fully burdened cost) conducted by Cypress or any of its
Affiliates during the term of the Asset License, for the supply of goods (at actual fully burdened
cost) by Cypress or any of its Affiliates in connection with any such Asset License or for
promotion activities with respect to the Product of sales representatives of Cypress or any of its
Affiliates, (b) any bona fide loan made to Cypress or any of its Affiliates in connection with any
such Asset License (except to the extent forgiven without being paid), (c) amounts paid for debt or
equity securities of Cypress or its Affiliates to the extent of fair market value of such debt or
equity securities and (d) in the event that an Asset License includes the right for Cypress or any
of its Affiliates to incur expenses related to the commercialization of a Product (including
expenses related to the launch and preparation for launch of such Product), amounts paid to Cypress
or any of its Affiliates by the licensee or any of its Affiliates to reimburse any such expenses
incurred by Cypress or any of its Affiliates).

     1.23 “Asset Sale” shall mean any transaction (including a sale of assets, merger, sale of
stock or other equity interests), other than an Asset License or a Change of Control of Cypress,
pursuant to which Cypress or any of its Affiliates sells, transfers or otherwise disposes of all or
a substantial portion of the Cypress Technology, the Cypress Product Invention Technology and/or
the rights to the Alexza Technology to a Third Party. Any license or sublicense under Cypress
Technology or Alexza Technology solely to manufacture or develop any Product for Cypress or its
Affiliate where Cypress or its Affiliate commercializes such Product shall not be an Asset Sale.

     1.24 “Asset Sale Consideration” shall mean the net monetary and non-monetary consideration
actually received by Cypress or any of its Affiliates in connection with an Asset Sale, after
deduction of any investment banking, broker, accounting, tax and legal fees and expenses paid by
Cypress or any of its Affiliates in connection with such Asset Sale, including milestone, escrow,
holdback and other contingent payments payable in connection with such Asset Sale to the extent
actually paid to Cypress or any of its Affiliates.

     1.25 “Asset Sale/License Payment” has the meaning set forth in Section 5.5.

     1.26 “Buy-Out” shall mean Cypress’ buying out of its obligations to Alexza pursuant to Section
6.5 by paying to Alexza, in cash, an amount equal to the then-current fair market value of the
Payment Rights.

     1.27 “Buy-Out Option Notice” shall have the meaning set forth in Section 6.3.

     1.28 “Calendar Half” shall mean (a) with respect to the first Calendar Half, the period
beginning on the Effective Date and ending on December 31, 2010, (b) with respect to each
subsequent Calendar Half (other than the last Calendar Half), the six-month period beginning on the
day following the end of the first Calendar Half and each succeeding six-month period thereafter,
and (c) with respect to the last Calendar Half, the period from the day following the end of the
immediately preceding Calendar Half to the date of expiration or termination of this Agreement.

4

 

     1.29 “Calendar Half Development Expenses” has the meaning set forth in Section 5.4(c).

     1.30 “Carry Credit Applicable Percentage” shall be determined as follows:

          (a) prior to the date of receipt by Alexza of the Technology Transfer Payment, 50%; or

          (b) on or after the date of receipt by Alexza of the Technology Transfer Payment, either (i)
10%, if Alexza has funded the full amount of its Offered Incremental Development Expenses, if any;
or (ii) if Alexza has funded less than the full amount of its Offered Incremental Development
Expenses as provided in Section 5.4(c), [...***...].

     1.31 “Change of Control” means, with respect to a Party, (a) a sale or other disposition
of all or substantially all of the assets of such Party on a consolidated basis (other than to any
Affiliate (direct or indirect) of such Party), (b) a merger or consolidation in which such Party is
not the surviving entity and in which the stockholders of such Party immediately prior to such
consolidation or merger own less than 50% of the surviving entity’s voting power immediately after
the transaction, and (c) a reverse merger in which such Party is the surviving entity but the
shares of such Party’s common stock outstanding immediately preceding the merger are converted by
virtue of the merger into other property, whether in the form of securities, cash or otherwise, and
in which the stockholders of such Party immediately prior to such reverse merger own less than 50%
of the voting power of such Party (or its parent entity) immediately after the transaction.

     1.32 “Change of Control Notice” has the meaning set forth in Section 6.4.

     1.33 “Commercially Reasonable Efforts” means, with respect to the Parties’ obligations under
this Agreement to research, develop or commercialize the Product, that level of efforts and
resources that is consistent with the commercially reasonable practices of the pharmaceutical
industry for the research, development or commercialization of a similarly situated pharmaceutical
product as such Product at a similar stage of research, development or commercialization, taking
into account measures of patent coverage, relative safety and efficacy, product profile, the
competitiveness of the marketplace, the proprietary position of such product, the regulatory
structure involved, the market potential of such product, the availability and level of
reimbursement for such product by Third Party payors or health insurance plans, the potential total
profitability of such product and other relevant factors, including comparative technical, legal,
scientific, and/or medical factors. [...***...].

     1.34 “Confidential Information” has the meaning set forth in Section 8.1.

     1.35 “Control” (including any variations such as “Controlled”), in the context of intellectual
property rights, Know-How and Confidential Information, means possession (whether by ownership or
license, other than pursuant to licenses granted by the other Party under this Agreement) by a
Party of the ability to grant the applicable license or other rights under this Agreement, without
violating the terms of an agreement with a Third Party.

 

			
	***	 	Confidential Treatment Requested

5

 

     1.36 “Cumulative Aggregate Development Expenses” has the meaning set forth in Section 5.4(c).

     1.37 “Cypress” shall have the meaning described in the first paragraph of this Agreement and
shall include its successors and assigns as contemplated by Section 13.7.

     1.38 “Cypress Development Expenses” shall mean the sum of (a) all of Cypress’ and its
Affiliates’ expenses of FTEs for the performance of development activities with respect to
Products, at a rate of $[...***...] per FTE for
non-administrative personnel, (b) all amounts paid as compensation (including, without limitation,
salary and benefits, severance payments and/or consulting fees) by Cypress to [...***...], and (c) all
other reasonable costs and expenses incurred by Cypress or any of its Affiliates in the performance
of Product development activities (which may include reasonable costs and expenses for
administrative personnel). For clarity, the Cypress Development Expenses does not include the
Alexza Development Expenses, the Technology Transfer Payment or the upfront payment under Section
5.1.

     1.39 “Cypress Indemnitees” has the meaning set forth in Section 10.2.

     1.40 “Cypress Know-How” means all Inventions (other than Joint Inventions) Controlled by
Cypress or its Affiliates during the Term related to the Device or Staccato Technology, but
excluding any Cypress Product Inventions.

     1.41 “Cypress Patents” means all Patents (other than Joint Patents) Controlled by Cypress or
its Affiliates during the Term that claim any Invention related to the Device or Staccato
Technology, but excluding any Cypress Product Invention Patents.

     1.42 “Cypress Product Inventions” means all Inventions (other than Joint Inventions) that
(a) are made, created, discovered, conceived or reduced to practice by or on behalf of Cypress or
its Affiliates during the Term in the course of development activities conducted with respect to
any Product, and (b) relate specifically to any Product or its manufacture or use and are not
usable with any product that delivers or administers any API other than Nicotine using the Staccato
Technology.

     1.43 “Cypress Product Invention Patents” means all Patents (other than Joint Patents)
Controlled by Cypress or its Affiliates during the Term that claim specifically a Cypress Product
Invention and do not claim Inventions that are usable with any product that delivers or administers
any API other than Nicotine using the Staccato Technology.

     1.44 “Cypress Product Invention Technology” means the Cypress Product Inventions and the
Cypress Product Invention Patents.

     1.45 “Cypress Sublicense Agreement” has the meaning set forth in Section 2.4.

     1.46 “Cypress Technology” means the Cypress Know-How, Cypress Patents and Cypress’ interest in
the Joint Inventions and Joint Patents.

 

			
	***	 	Confidential Treatment Requested

6

 

     1.47 “Determined Fair Market Value” shall have the meaning set forth in Section 6.4.

     1.48 “Development Committee” shall have the meaning set forth in Section 3.3(a).

     1.49 “Development Expense Summary” has the meaning set forth in Section 5.4(c).

     1.50 “Device” means a hand-held, multi-dose, electric device for the administration of API(s),
which device relies on, incorporates or uses Staccato Technology and may or may not be referred to
as the Staccato® system.

     1.51 “Disclosing Party” has the meaning set forth in Section 8.1.

     1.52 “FDA” means the United States Food and Drug Administration and its successor.

     1.53 “FTE” shall mean the equivalent of the work time of a full-time employee of Cypress or
its Affiliate actually spent on the performance of development or regulatory activities (including
clinical supply activities) with respect to Products over a 12-month period (including normal
vacations, sick days and holidays) based on 1,800 hours worked per 12-month period.

     1.54 “GAAP” shall mean United States generally accepted accounting principles, consistently
applied, and will mean the international financial reporting standards (IFRS) at such time as IFRS
becomes the generally accepted accounting standard in the United States and applicable securities
laws in the United States require use of IFRS.

     1.55 “Indemnitee” has the meaning set forth in Section 10.3.

     1.56 “Indemnitor” has the meaning set forth in Section 10.3.

     1.57 “Inventions” means any and all Know-How (including all inventions, discoveries,
improvements, processes and techniques) that are (a) made, created, discovered, conceived or
reduced to practice by or on behalf of Alexza or its Affiliates and/or Cypress or its Affiliates
during the Term in the course of development activities conducted with respect to any Product,
including activities under the Alexza Development Plan and (b) relate to the Alexza Technology,
Device, Product or Staccato Technology (including the manufacture or use thereof), whether or not
patentable or included in any claim of a patent or patent application, together with all
intellectual property rights therein.

     1.58 “Joint Inventions” means any and all Inventions made jointly by or on behalf of Cypress
or its Affiliates, on the one hand, and by or on behalf of Alexza or its Affiliates, on the other
hand.

     1.59 “Joint Patents” means all Patents claiming any Joint Inventions.

     1.60 “Know-How” means all tangible and intangible scientific, technical, clinical, regulatory,
trade, marketing, commercial, financial or business information and materials, including compounds,
solid state forms, compositions of matter, formulations, devices, techniques, processes, methods,
trade secrets, formulae, procedures, tests, data, results, analyses,

7

 

documentation, reports, information (including pharmacological, toxicological, non-clinical
(including chemistry, manufacturing and control)), and clinical test design, methods, protocols,
data, results, analyses, and conclusions, quality assurance and quality control information,
regulatory documentation, information and submissions pertaining to, or made in association with,
filings with any Regulatory Authority, knowledge, know-how, skill and experience.

     1.61 “License Consideration” has the meaning set forth in Section 11.3(b)(iii)(2).

     1.62 “Marketing Approval” of a Product means all approvals, licenses, registrations or
authorizations of Regulatory Authorities in a country necessary for the manufacture, use, storage,
import, export, distribution, promotion, marketing, offer for sale and sale of such Product in such
country.

     1.63 “NDA” of a Product means a New Drug Application, as defined in the United States Federal
Food, Drug and Cosmetic Act, as amended, and applicable regulations promulgated thereunder by the
FDA, or the equivalent application filed with a Regulatory Authority in any other regulatory
jurisdiction, including all documents, data, and other information concerning such Product thus
filed that are necessary for gaining Marketing Approval for such Product.

     1.64 “Nicotine” means nicotine and any free base form, salt, solvate, clathrate, metal
coordination complex, prodrug, and/or metabolite of nicotine, as well as any amorphous,
crystalline, polymorphic form, of any of the foregoing.

     1.65 “Offered Incremental Development Expenses” shall have the meaning set forth in Section
5.4(c).

     1.66 “Option Triggering Event” shall mean any of (a) [...***...], (b) [...***...], or (c) [...***...].

     1.67 “Option Triggering Event Window” has the meaning set forth in Section 6.3.

     1.68 “Orange Book Alexza Background Patents” has the meaning set forth in Section 7.2(b)(i).

     1.69 “Patent(s)” means (a) all patents, including, without limitation, design patents,
certificates of invention, applications for certificates of invention, priority patent filings and
patent applications, including, without limitation, provisional patent applications and design
patent applications, and (b) any renewal, divisional, continuation, continuation-in-part, or
request for continued examination of any of such patents, certificates of invention and patent
applications, and any and all patents or certificates of invention issuing thereon, and any and all
reissues, reexaminations, extensions, certificates of correction, divisions, renewals,
substitutions, confirmations, registrations, revalidations, revisions, and additions of or to any
of the foregoing.

 

			
	***	 	Confidential Treatment Requested

8

 

     1.70 “Patent Term Extension” means any term extensions, supplementary protection certificates,
regulatory exclusivity and equivalents thereof offering patent protection beyond the initial term
with respect to any issued Patents.

     1.71 “Payment Rights” has the meaning set forth in Section 6.3.

     1.72 [...***...]

     1.73 [...***...].

     1.74 [...***...]

     1.75 “Product(s)” means (a) a product consisting of a Device that delivers or administers
Nicotine (as the sole API), (b) a container, cartridge and/or carrier that delivers Nicotine (as
the sole API) using the Staccato Technology, which container, cartridge and/or carrier is designed
for use with a Device or (c) a composition including Nicotine as the sole API and suitable to be
delivered by or used in a Device. For clarity, a Product may include any agent that does not
independently provide pharmacological activity or other effect in the diagnosis, cure, mitigation,
treatment or prevention of disease, and that does not affect structure or function of the body of a
human or other animal.

     1.76 “Put Option Notice” shall have the meaning set forth in Section 6.4.

     1.77 “Regulatory Authority” means any national, regional, state or local regulatory agency,
department, bureau, commission, council or other governmental entity whose review and/or approval
is necessary for the manufacture, packaging, use, storage, import, export, distribution, promotion,
marketing, offer for sale and sale of a Product.

     1.78 “Regulatory Filings” means all applications, approvals, licenses, registrations,
notifications, registrations, submissions and authorizations made to or received from a Regulatory
Authority in a country necessary for the development, manufacture and/or commercialization of a
pharmaceutical product, including any INDs, NDAs and Marketing Approvals.

     1.79 “Regulatory Requirements” means (a) with respect to Product supplied by Alexza under the
Alexza Development Plan [...***...]; and (b) with respect to Product supplied by Alexza under the
Alexza Development Plan [...***...].

     1.80 “Sale Consideration” has the meaning set forth in Section 11.3(b)(iii)(2).

     1.81 “SEC” has the meaning set forth in Section 8.5(a).

     1.82 “Senior Executives” means the Chief Executive Officer of Alexza and the Chief Executive
Officer of Cypress or their respective designees.

 

			
	***	 	Confidential Treatment Requested

9

 

     1.83 [...***...]

     1.84 “[...***...] Patents” means all Patents that (a) are Controlled by Alexza or its Affiliates
as of the Effective Date or during the Term, and (b) are directed solely toward [...***...]. For
clarity, the [...***...] Patents are not within the Alexza Patents.

     1.85 “Staccato Technology” means technology Controlled by Alexza or its Affiliates for the
vaporization of a pharmaceutical composition via rapid heating to form a condensation aerosol that
allows rapid systemic drug delivery to humans through deep lung inhalation.

     1.86 “Sublicensee” means an Affiliate or Third Party to whom Cypress grants a sublicense under
the Alexza Technology or to whom Alexza grants a sublicense under the Cypress Technology as
permitted under Section 2.4.

     1.87 “Technology Transfer Payment” has the meaning set forth in Section 5.2.

     1.88 “Term” has the meaning set forth in Section 11.1.

     1.89 “Third Party” means any entity other than Alexza or Cypress or their respective
Affiliates.

     1.90 “Third Party Claim” has the meaning set forth in Section 10.1.

     1.91 “Trademarks” means trademarks, trade names, trade dress, domain names, logos and
brandings.

     1.92 “Valuation Firm” shall have the meaning set forth in Section 6.5.

     1.93 “Valuation Notice” shall have the meaning set forth in Section 6.5.

ARTICLE 2

LICENSES

     2.1 License to Cypress Under Alexza Technology.

          (a) Subject to the terms and conditions of this Agreement, Alexza hereby grants Cypress an
exclusive (even as to Alexza), worldwide, royalty-free license, with the right to grant multiple
tiers of sublicenses pursuant to Section 2.4, under the Alexza Technology to research, develop,
make, have made, use, sell, offer for sale and import Products for any and all purposes.

          (b) Alexza further covenants that during the Term, to the extent that any Patents Controlled
by Alexza or any of its Affiliates, including [...***...] Patents, cover or claim the Product or its manufacture or use (other than Patents Controlled by a
Third Party that becomes an Affiliate of Alexza as a result of an acquisition of Alexza, whether by
merger, sale

 

			
	***	 	Confidential Treatment Requested

10

 

of stock, sale of assets or other form of acquisition), then Alexza shall, without further
consideration or action by Cypress, take such actions as may be reasonably necessary to confirm
such Patents shall be included as “Alexza Patents” hereunder.

     2.2 Trademark License to Cypress. Subject to the terms and conditions of this Agreement,
Alexza hereby grants Cypress an exclusive, worldwide, royalty-free license, with the right to grant
multiple tiers of sublicenses pursuant to Section 2.4, to use the Alexza Trademarks solely in
connection with the use, marketing, distribution, offer for sale and sale of Products.

     2.3 Alexza License under Cypress Technology. Subject to the terms and conditions of this
Agreement, Cypress hereby grants to Alexza (a) a non-exclusive, non-sublicensable (except to
subcontractors as permitted under Section 3.4(c), solely to permit such subcontractors to perform
Alexza’s assigned responsibilities under the Alexza Development Plan), royalty-free, fully-paid
license, under the Cypress Technology to conduct any and all activities assigned to Alexza under
the Alexza Development Plan during the term of the Alexza Development Plan and (b) an exclusive,
worldwide, [...***...] license, with the right to grant multiple tiers of sublicenses pursuant to
Section 2.4, under the Cypress Technology to research, develop, make, have made, use, sell, offer
for sale and import any and all products that deliver or administer any API other than Nicotine
using the Staccato Technology, including, without limitation, a Device that delivers any API other
than Nicotine, for any and all purposes. [...***...]

     2.4 Sublicenses. The licenses granted by Alexza to Cypress in Sections 2.1 and 2.2 may
be sublicensed by Cypress to its Affiliates and to Third Parties, and may be further sublicensed by
a Sublicensee [...***...]. Each agreement under which Cypress grants a sublicense under the licenses
set forth in Sections 2.1 and 2.2 (each, a “Cypress Sublicense Agreement”) shall be consistent
with, and subject to the applicable terms and conditions of, this Agreement. With respect to any
vendors or subcontractors who receive a sublicense pursuant to this Section 2.4 (it being
understood that a strategic partner, collaborator or commercial licensee shall not be considered a
vendor or subcontractor), such Sublicensee shall be required to assign or exclusively license (with
the right to grant a sublicense to Alexza) to Cypress all Patents and Know-How made by such
Sublicensee related to the Device or Staccato Technology, to the extent useful for products other
than the Product; provided that if such Sublicensee shall not agree to such obligation, Cypress
shall notify Alexza and Alexza shall have the right to negotiate for such rights with respect to
such other products other than Product as part of such Cypress negotiations for a period of 45
days; provided further, that Cypress shall not otherwise be limited in entering into an agreement
with such Sublicensee with respect to the Product. Promptly after the execution thereof, Cypress
shall provide a copy of each Cypress Sublicense Agreement to Alexza, provided that Cypress may
redact from such copy financial and other terms not relevant for purposes of confirming the Cypress
Sublicense Agreement’s compliance with the terms of this Agreement. For clarity, a material breach
of this Agreement by the acts or omissions of a Sublicensee under a Cypress Sublicense Agreement
shall be deemed a material breach of this Agreement and shall require Cypress to cure such breach
or terminate such Cypress Sublicense Agreement. The license granted by Cypress to Alexza in
Section 2.3(b) may be sublicensed by Alexza to its Affiliates and to Third Parties, and may be
further sublicensed by a Sublicensee

 

			
	***	 	Confidential Treatment Requested

11

 

[...***...]. Each agreement under which Alexza
grants a sublicense under the license set forth in Section 2.3(b) (each, an “Alexza Sublicense
Agreement”) shall be consistent with, and subject to the applicable terms and conditions of, this
Agreement. With respect to any vendors or subcontractors who receive a sublicense pursuant to this
Section 2.4 (it being understood that a strategic partner, collaborator or commercial licensee
shall not be considered a vendor or subcontractor), such Sublicensee shall be required to assign or
exclusively license (with the right to grant a sublicense to Alexza) to Alexza all Patents and
Know-How made by such Sublicensee related to the Product, to the extent useful for Product;
provided that if such Sublicensee shall not agree to such obligation, Alexza shall notify Cypress
and Cypress shall have the right to negotiate for such rights with respect to the Product as part
of such Alexza negotiations for a period of 45 days; provided further, that Alexza shall not
otherwise be limited in entering into an agreement with such Sublicensee with respect to the
Product. Promptly after the execution thereof, Alexza shall provide a copy of each Alexza
Sublicense Agreement to Cypress, provided that Alexza may redact from such copy financial and other
terms not relevant for purposes of confirming the Alexza Sublicense Agreement’s compliance with the
terms of this Agreement. For clarity, a material breach of this Agreement by the acts or omissions
of a sublicensee under an Alexza Sublicense Agreement shall be deemed a material breach of this
Agreement by Alexza and shall require Alexza to cure such breach or terminate such Alexza
Sublicense Agreement.

     2.5 Alexza Retained Rights. Notwithstanding anything to the contrary in Section 2.1, Alexza
retains the right under the Alexza Technology to conduct any and all activities assigned to it
under the Alexza Development Plan.

     2.6 Rights Reserved. Except for the rights and licenses expressly granted in this Agreement,
and subject to Section 2.7, Alexza retains all rights under its intellectual property, including
the Alexza Technology, and Cypress retains all rights under its intellectual property, including
the Cypress Technology and Cypress Product Invention Technology, and no rights shall be deemed
granted by one Party to the other Party by implication, estoppel or otherwise. For the avoidance
of doubt, the licenses granted to Cypress under Sections 2.1 and 2.2 do not confer any rights to
Cypress with respect to any product other than Products, and the license granted to Alexza under
Section 2.3 does not confer any rights to Alexza with respect to any product other than products
that deliver or administer any API other than Nicotine using the Staccato Technology.

     2.7 Negative Covenant. Alexza covenants that, except pursuant to the Alexza Development Plan,
it will not, itself or through a Third Party, research, develop, make, have made, use, sell, offer
for sale or import any product using the Staccato Technology, [...***...]Patents, Alexza Patents or
Joint Patents (a) that delivers Nicotine (alone or in combination with one or more other API(s)) or
(b) that delivers any other API(s) and that is indicated as an aid to smoking cessation treatment.

     2.8 Covenant Not to Sue. Alexza hereby covenants that it, its Affiliates and licensees and
all successors-in-interest thereto will not sue, bring an action against, or otherwise assert any
claim against Cypress or any of its Sublicensees (and all successors of any of the

 

			
	***	 	Confidential Treatment Requested

12

 

foregoing) for infringement of any [...***...] Patent by Cypress’ or any of its Sublicensees’
development, manufacture, or commercialization of Products.

ARTICLE 3

DEVELOPMENT

     3.1 Overview. The Parties agree that Alexza will conduct certain development activities and
will supply certain clinical trial materials and other test materials to Cypress [...***...], as and to
the extent set forth in the Alexza Development Plan. Cypress shall be solely responsible for all
regulatory and clinical activities for Products, and shall conduct [...***...] using Product supplied
by Alexza pursuant to the Alexza Development Plan.

     3.2 Alexza Development Plan. All activities conducted by Alexza under this Agreement for the
development of the Product will be conducted pursuant to the Alexza Development Plan. The Parties
have agreed to the Alexza Development Plan attached hereto as Exhibit C as of the Effective Date,
which describes the plan for development of the Product, including the Device, by Alexza from the
Effective Date through completion by Cypress of [...***...]. All amendments to the Alexza Development
Plan shall be subject to the prior written approval of the Development Committee. At least 30 days
prior to the beginning of each calendar quarter in which Alexza will conduct activities under the
Alexza Development Plan, the Development Committee shall review Alexza’s progress under the Alexza
Development Plan and determine whether to amend the Alexza Development Plan, including the payment
to Alexza under Section 5.4(a) for the subsequent calendar quarter.

     3.3 Development Committee.

          (a) Establishment; Members. Within 30 days following the Effective Date, Cypress and Alexza
shall establish a joint development committee (“Development Committee”) to oversee, review and
coordinate the activities of the Parties under the Alexza Development Plan. The Development
Committee shall be composed of an equal number of representatives of each of Cypress and Alexza.
In addition, [...***...] shall be entitled to attend
meetings of the Development Committee as a non-voting member for so long as he remains an employee
or contractor of Cypress and is performing development activities with respect to Products on
behalf of Cypress. A representative of Cypress shall act as the chairperson of the Development
Committee.

          (b) Duties. The Development Committee shall:

               (i) review the Alexza Development Plan and review and approve amendments to the Alexza
Development Plan;

               (ii) provide a forum for the Parties to exchange information and coordinate their respective
activities under the Alexza Development Plan; and

 

			
	***	 	Confidential Treatment Requested

13

 

               (iii) perform such other duties as are specifically assigned to the Development Committee
pursuant to this Agreement.

          (c) Meetings; Minutes. All Development Committee meetings shall be held as often as the
members may determine, but in any event Development Committee meetings shall occur not less than
once per calendar quarter. Such meetings may be held in person, or by any means of
telecommunications or video conference, as the members deem necessary or appropriate. A quorum for
Development Committee meetings shall be 4 members (not including any non-voting member), with at
least 2 members from each Party. Within 30 days after each meeting, the chairperson of the
Development Committee will provide the Parties with a written report describing, in reasonable
detail, the issues requiring resolution and the agreed resolution of previously reported issues.
The Development Committee shall disband upon Alexza’s receipt of the Technology Transfer Payment.

          (d) Decisions of the Development Committee. All actions of the Development Committee
(including, without limitation, any action to amend the Alexza Development Plan) shall be made
following a unanimous vote, with the representatives of Cypress on the Development Committee having
one vote, collectively, and the representatives of Alexza on the Development Committee having one
vote, collectively. If the Development Committee fails to reach unanimous agreement on a matter
before it, then (a) with respect to matters regarding Alexza’s activities under the Alexza
Development Plan, the Senior Executives shall negotiate in good faith to resolve the dispute within
30 days, and (b) with respect to matters regarding Cypress’ development activities for the Product,
the vote of the representatives of Cypress on the Development Committee shall be the deciding vote.

     3.4 Conduct of Development Activities under the Alexza Development Plan.

          (a) Compliance with Alexza Development Plan and Applicable Laws. All development activities
conducted by Alexza with respect to the Product will be conducted in accordance with the Alexza
Development Plan and the other provisions of this Agreement. Each Party shall conduct those
Product development activities for which it is responsible under this Agreement in compliance in
all material respects with all Applicable Laws and in accordance with good scientific and clinical
practices, applicable under the Applicable Laws of the country in which such activities are
conducted. Without limiting the foregoing, all Products and other clinical trial and test
materials supplied by Alexza pursuant to this Agreement shall be manufactured in accordance with
the specifications therefor, as agreed upon by the Parties, and applicable Regulatory Requirements.

          (b) Diligence. Alexza shall use Commercially Reasonable Efforts to conduct and complete the
activities assigned to it in the Alexza Development Plan in order to achieve the goals of the
Alexza Development Plan. Alexza shall proceed diligently and in a timely manner with the studies
and activities for which it is responsible with respect to the development of the Product under the
Alexza Development Plan by using its good faith efforts to allocate sufficient time, effort,
equipment and facilities to such development activities and to use personnel with sufficient skills
and experience as are required to accomplish such studies and activities in accordance with the
terms of this Agreement. Alexza’s performance is in part dependent and

14

 

conditioned upon Cypress’ timely and effective completion of the activities and obligations
assigned to it under this Agreement. To the extent that Alexza’s inability to perform or complete
the activities assigned to it pursuant to the Alexza Development Plan is caused by Cypress’ failure
to carry out its activities and responsibilities with respect to the development of the Product,
such failure by Alexza to perform or complete such activities shall be excused. For clarity, the
failure of Alexza to achieve any scientific or technical result contemplated under the Alexza
Development Plan, or to conduct any activity or provide any deliverable set forth in the Alexza
Development Plan that depends on the successful achievement of any such result that is not
achieved, shall not be a breach of the foregoing so long as Alexza uses Commercially Reasonable
Efforts to achieve such result in accordance with the first sentence of this Section 3.4(a).

          (c) Use of Subcontractors. Alexza may perform some or all of its obligations under the Alexza
Development Plan through one or more subcontractors, provided that (i) none of the rights of either
Party hereunder are diminished or otherwise adversely affected as a result of such subcontracting
and (ii) the subcontractor undertakes in writing obligations of confidentiality and non-use
regarding Confidential Information which are substantially the same as those undertaken by the
Parties pursuant to Article 8 hereof. In the event Alexza performs any of its obligations under
the Alexza Development Plan through a subcontractor, then Alexza will at all times be responsible
for the performance and payment of such subcontractor, except as otherwise agreed in writing by the
Parties.

          (d) Materials Transfer. In order to facilitate the development activities contemplated by
this Agreement, either Party may provide to the other Party certain biological materials or
chemical compounds controlled by the supplying Party (collectively, “Materials”) for use by the
other Party in furtherance of such development activities. Except as otherwise provided for under
this Agreement, to the extent that either Party provides Materials to the other Party, all such
Materials shall be the sole property of Cypress (regardless of which Party supplies such
Materials), subject to Alexza’s intellectual property rights in such Materials, will be used by the
Parties only in furtherance of the development activities with respect to the Product, will not be
used or delivered by Alexza to or for the benefit of any Third Party, except for subcontractors
pursuant to Section 3.4(c), without the prior written consent of Cypress, and will be used by each
Party in compliance with all Applicable Laws. The Materials supplied under this Agreement must be
used by each Party with prudence and appropriate caution in any experimental work because not all
of their characteristics may be known. Except as expressly set forth in this Agreement, ALL
MATERIALS ARE PROVIDED “AS IS” AND WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED,
INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY
PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE MATERIALS WILL NOT INFRINGE OR VIOLATE ANY
PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTY.

          (e) Information Regarding Development Activities. Each Party shall maintain records, in
sufficient detail and in good scientific manner appropriate for patent and regulatory purposes,
which shall fully and properly reflect all work done and results achieved by or on behalf of such
Party in the performance of its development activities with respect to the Product. Each Party
shall keep the other appropriately informed of the status of Product

15

 

development activities conducted by it or on its behalf. Within 30 days following the end of
each calendar quarter prior to completion of activities under the Alexza Development Plan, without
limiting the foregoing, each Party shall promptly provide the Development Committee with summaries
in reasonable detail of all data and results generated or obtained in the course of such Party’s
performance of development activities under this Agreement.

          (f) Termination of Alexza Development Plan. Cypress may terminate the Alexza Development Plan
and its obligations under Section 3.4(b) and Section 4.2 in the event of any material breach by
Alexza of its obligations under this Section 3.4 or Section 3.5 of this Agreement, which breach is
not cured within [...***...] after notice from Cypress
requesting cure of the breach, provided that such breach was not caused by Cypress’ breach of its
obligation under Section 3.4(b) or Section 5.4(a) of this Agreement. Termination of the Alexza
Development Plan shall not relieve the Parties of any rights or obligation under this Article 3
accruing prior to such termination.

     3.5 Regulatory Filings and Marketing Approvals. Alexza shall conduct those regulatory support
activities, including assisting Cypress in preparing Regulatory Filings, for the Product as set
forth in the Alexza Development Plan. Cypress shall be responsible for all other regulatory
activities with respect to Products, including preparing and filing regulatory filings, including
INDs, in the name of Cypress, seeking all Marketing Approvals, communicating with Regulatory
Authorities, and holding all Marketing Approvals for Products.

ARTICLE 4

FURTHER DEVELOPMENT; COMMERCIALIZATION

     4.1 Product Development. As between the Parties, Cypress shall have sole control, authority,
and discretion over the research, development and commercialization of Products throughout the
world, subject to Article 3.

     4.2 Diligence. Cypress shall use Commercially Reasonable Efforts to research, develop and
commercialize Products, whether alone or with or through one or more Sublicensees, including using
Commercially Reasonable Efforts to provide to Alexza those deliverables necessary for Alexza to
conduct its activities under the Alexza Development Plan; provided that, to the extent that
Cypress’ inability to perform or complete Product research or development activities is caused by
Alexza’s failure to carry out its activities and responsibilities assigned to it pursuant to the
Alexza Development Plan, Cypress’ failure to perform or complete such Product research or
development activities shall be excused; provided further that Cypress may discontinue development
of Products, subject to compliance with Section 11.2. For clarity, the failure of Cypress to
achieve any scientific or technical result in the research or development of Products, or to
conduct any activity or provide any deliverable that depends on the successful achievement of any
such result that is not achieved, shall not be a breach of the foregoing so long as Cypress uses
Commercially Reasonable Efforts to achieve such result in accordance with the first sentence of
this Section 4.2. No later than each anniversary of the Effective Date, until the

 

			
	***	 	Confidential Treatment Requested

16

 

first commercial sale of the Product, Cypress shall submit to Alexza a written annual progress
report summarizing Cypress’ and its Sublicensees’ research and development of Products and efforts
toward commercialization of the Product in the previous year. Each such report shall be the
Confidential Information of Cypress.

     4.3 Compliance with Applicable Laws. Cypress shall comply in all material respects with all
Applicable Laws in performing its obligations under this Agreement and with respect to its use,
sale and disposition of Products.

ARTICLE 5

PAYMENTS; TECHNOLOGY TRANSFER; ROYALTIES

     5.1 Upfront Payment. In consideration for the licenses and rights granted to Cypress under
this Agreement, Cypress shall pay to Alexza on the Effective Date a non-refundable, non-creditable
payment of $5,000,000.

     5.2 Technology Transfer Payment. Within [...***...]
days after [...***...], Cypress shall notify Alexza in writing of its decision either (a) to continue
development of Products or (b) to discontinue development of Products. If Cypress decides to
continue development of Products, Cypress shall pay Alexza a non-refundable, non-creditable payment
of $1,000,000 (the “Technology Transfer Payment”) within [...***...] days after [...***...].

     5.3 Technology Transfer. As soon as reasonably practicable after receipt by Alexza of the
Technology Transfer Payment, Alexza shall work with Cypress, at no cost to Cypress, to facilitate
the timely transfer to Cypress of all Know-How and materials relating specifically to the Product
that are then in Alexza’s possession and Control, in a format to be agreed between the Parties.
Such Product-specific Know-How and materials shall include data and reports, retained clinical
trial toxicology study materials, analytical methods, process development methods and stability
reports and samples. Such transfer shall occur in a manner and following a reasonable schedule to
be established by the Parties and shall be completed within [...***...] days after Alexza’s receipt of
the Technology Transfer Payment. Subject to Alexza’s intellectual property rights in the Alexza
Technology, Cypress shall own all materials transferred to Cypress under this Section 5.3,
including those items specifically included as deliverables in the Alexza Development Plan.

     5.4 Funding Obligations. The funding of Product development expenses shall be as follows:

          (a) Funding of Alexza Development Expenses. On the Effective Date and on the first day of
each of the 3 calendar quarters thereafter, Cypress shall make a payment to Alexza in the amount
specified in the budget in the then-current Alexza Development Plan (the “Alexza Development
Expenses”), which amount is intended to reimburse Alexza’s internal and external costs and expenses
to conduct its activities under the Alexza Development Plan in such calendar

 

			
	***	 	Confidential Treatment Requested

17

 

quarter, including, as applicable, the costs of all clinical trial materials provided by
Alexza to Cypress. Except for such payments, Alexza shall be solely responsible for all expenses
it incurs to conduct its activities under the Alexza Development Plan, including any amounts Alexza
incurs to conduct activities under the Alexza Development Plan in excess of the amount set forth in
the budget in the then-current Alexza Development Plan for such activities, subject to adjustment
as a result of any amendments to the Alexza Development Plan pursuant to Section 3.2.

          (b) Funding of Development Expenses. Cypress shall fund 100% of Aggregate Development
Expenses, provided that in no event shall Cypress be obligated to fund more than a total of
$22,000,000 in Aggregate Development Expenses, including all Alexza Development Expenses funded
under Section 5.4(a). Cypress may, in its sole discretion, invest additional amounts to develop
the Products, subject to Alexza’s funding option set forth in Section 5.4(c) and 5.4(d), which
funding option shall terminate on the first Marketing Approval of a Product.

          (c) Reporting of Development Expenses. Within [...***...] days following the end of each Calendar
Half prior to or containing the date of first Marketing Approval of a Product, Cypress shall
deliver to Alexza a written summary (a “Development Expenses Summary”) that indicates (i) the
Aggregate Development Expenses incurred during that Calendar Half (such amount, the “Calendar Half
Development Expenses”) and (ii) the Aggregate Development Expenses incurred from the Effective Date
to the end of that Calendar Half (such amount, the “Cumulative Aggregate Development Expenses”),
and includes reasonable detail describing the related development efforts and related Aggregate
Development Expenses incurred in the applicable Calendar Half to permit their identification as
such. The Development Expenses Summary delivered by Cypress to Alexza for the Calendar Half in
which the Cumulative Aggregate Development Expenses exceed a total of $22,000,000 shall also
indicate the amount that is 10% of such excess, and all subsequent Development Expenses Summaries
delivered by Cypress to Alexza pursuant to this Section 5.4(c) shall also indicate the amount that
is 10% of the Calendar Half Development Expenses for such Calendar Half (in each case, the “Offered
Incremental Development Expenses”).

          (d) Alexza Funding Option. Alexza may, at its option, within [...***...] days of receiving any
Development Expenses Summary that includes any Offered Incremental Development Expenses, reimburse
Cypress for all or any portion of any Offered Incremental Development Expenses indicated on such
Development Expenses Summary by paying all or any portion of such amount by United States Federal
Reserve electronic wire transfer in immediately available funds to the following bank account:

     [...***...]

To the extent Alexza reimburses Cypress for all or any portion of the Offered Incremental
Development Expenses indicated on any Development Expenses Written Summary prior to the expiration
of such [...***...]-day period, the amount reimbursed by Alexza shall be “Alexza Funded Incremental
Development Expenses” for all purposes of this Agreement from and after

 

			
	***	 	Confidential Treatment Requested

18

 

the expiration of such [...***...]-day period. If Alexza fails to reimburse Cypress any Offered
Incremental Development Expenses, the Carry Credit Applicable Percentage shall be reduced for any
unfunded Offered Incremental Development Expenses as provided in the definition of Carry Credit
Applicable Percentage. For clarity, this Section 5.4(d), Alexza’s option to fund any Offered
Incremental Development Expenses, and the accrual of unfunded Offered Incremental Development
Expenses shall apply only with respect to development expenses incurred prior to the first
Marketing Approval of a Product.

     5.5 Reports. In connection with any payment made by Cypress to Alexza under Section 6.1 or
6.2, Cypress shall also deliver with payments to Alexza a written report (the “Asset Sale/License
Payment Report”) containing reasonable detail so as to permit Alexza to confirm the amounts paid
and the form of consideration received, as applicable.

     5.6 Alexza Account Information. All payments due from Cypress to Alexza under this Agreement
shall be made by United States Federal Reserve electronic wire transfer in immediately available
funds to the following bank account:

     [...***...]

     5.7 Withholding of Taxes. A Party receiving payments under this Agreement will pay any
and all taxes levied on account of such payment. If any taxes are required to be withheld by the
paying Party, it will (a) deduct such taxes from the remitting payment, (b) timely pay the taxes to
the proper taxing authority, and (c) send proof of payment to the other Party and certify its
receipt by the taxing authority within 60 days following such payment.

     5.8 Audits. Cypress shall keep complete and accurate records of the Cypress Development
Expenses, Asset Sale Consideration and Asset License Consideration data relating to the
calculations of payments required by this Agreement in sufficient detail to permit Alexza to
confirm the accuracy of the calculations with respect to payments by the respective Parties under
this Agreement. Cypress shall retain and maintain such records for the minimum period required by
applicable laws, rules and regulations but in any event at least 3 years from the end of the
calendar year to which they pertain. Alexza shall have the right to have an independent, certified
public accountant, selected by Alexza and reasonably acceptable to Cypress, review any such records
of Cypress in the location(s) where such records are maintained by Cypress upon not less than 4
weeks prior notice and during regular business hours and under obligations of confidentiality
hereunder, for the sole purpose of verifying the basis and accuracy of payments made or due under
this Agreement. If the review of such records reveals that Cypress has failed to accurately
calculate any payment to or from Alexza due under this Agreement, then Cypress shall promptly pay
to Alexza any resulting amounts due hereunder, or Cypress or Alexza shall promptly refund
overpayments made by the other Party, together with interest calculated in the manner provided in
Section 5.9. If any such audit reveals an underpayment or error by Cypress in any calendar year in
an amount greater than 5% of the amounts actually presented or due for a calendar year, then
Cypress shall reimburse Alexza for the cost of the audit. Such audit shall be conducted no more
than once per calendar year.

 

			
	***	 	Confidential Treatment Requested

19

 

     5.9 Late Payments. In the event that any payment due hereunder is not made when due, the
payment shall accrue interest from the date due at the rate of 1.5% per month; provided, however,
that in no event shall such rate exceed the maximum legal annual interest rate; provided further
that no such interest shall accrue until the other Party has provided written notice of such late
payment or during any period that any dispute with respect to a payment is being diligently pursued
in good faith by the Party from whom such payment is claimed. The payment of such interest shall
not limit a Party from exercising any other rights it may have as a consequence of the lateness of
any payment.

ARTICLE 6

PAYMENT TO ALEXZA FOR ASSET LICENSE OR ASSET SALE; CYPRESS BUY-OUT

OPTION; ALEXZA PUT OPTION

     6.1 Payment to Alexza for Asset License or Asset Sale. If Cypress completes an Asset License
or Asset Sale, then Cypress shall make payments to Alexza as provided in this Section 6.1. The
amount of consideration payable to Alexza with respect to the Asset License or Asset Sale shall be
calculated as follows:

          (a) Asset Sale. In the event that Cypress or any of its Affiliates completes an Asset Sale,
Cypress shall pay to Alexza, within [...***...] days of
Cypress or any of its Affiliates receiving any Asset Sale Consideration for such Asset Sale, an
amount equal to the product of (i) the Asset Sale Consideration so received multiplied by (ii) the
Carry Credit Applicable Percentage at such time. For purposes of clarity, the Parties acknowledge
and agree that Cypress and its Affiliates may receive Asset Sale Consideration in the form of
payments made at more than one time, and that Cypress’ obligation to pay Alexza any Asset Sale
Consideration at each time Asset Sale Consideration is received, as determined by application of
the formula set forth in this Section 6.1(a), shall only apply with respect to the Asset Sale
Consideration amounts actually received by Cypress or any of its Affiliates at that time. For
purposes of calculating any Asset Sale Consideration received by Cypress or any of its Affiliates,
to the extent the consideration received consists of property other than cash, such non-cash
consideration shall be valued at the fair value of that property, as determined in good faith by
the Board of Directors of Cypress, as of the date on which Cypress or any of its Affiliates, as
applicable, is obligated to value such non-cash consideration pursuant to the definitive agreements
executed in connection with the applicable Asset Sale, or if no such date is stated therein, the
date on which Cypress or any of its Affiliates receives such non-cash consideration.

          (b) Asset License. In the event that Cypress or any of its Affiliates, completes an Asset
License, Cypress shall pay to Alexza, within [...***...]days of it or any of its Affiliates receiving
any Asset License Consideration for such Asset License, an amount equal to the product of (i) the
Asset License Consideration so received multiplied by (ii) the Carry Credit Applicable Percentage
at such time. For purposes of clarity, the Parties acknowledge and agree that Cypress and its
Affiliates may receive Asset License Consideration in the form of payments made at more than one
time, and that Cypress’s obligation to pay Alexza any Asset License

 

			
	***	 	Confidential Treatment Requested

20

 

Consideration at each time Asset License Consideration is received, as determined by
application of the formula in this Section 6.1(b), shall only apply with respect to the Asset
License Consideration actually received by Cypress or any of its Affiliates at that time. For
purposes of calculating any Asset License Consideration received by Cypress or any of its
Affiliates, to the extent the consideration received consists of property other than cash, such
non-cash consideration shall be valued at the fair value of that property, as determined in good
faith by the Board of Directors of Cypress, as of the date on which Cypress or any of its
Affiliates receives such non-cash consideration.

     6.2 Form of Consideration. All non-cash consideration payable by Cypress to Alexza pursuant
to Section 6.1 shall be paid by Cypress to Alexza in the same form as the non-cash consideration
received by Cypress or any of its Affiliates in connection with the applicable Asset Sale or Asset
License in an amount that, on a proportional basis, equals the percentage of non-cash consideration
received by Cypress or any of its Affiliates in connection with such applicable Asset Sale or Asset
License. In the event that Cypress makes any payments to Alexza pursuant to Section 6.1 using
non-cash consideration, Cypress shall use its good faith efforts to limit any restrictions
applicable to Cypress or any of its Affiliates, as applicable, or Alexza on selling, assigning or
otherwise transferring such non-cash consideration to commercially reasonable restrictions,
appropriate to the circumstances of the applicable Asset Sale or Asset License. Notwithstanding
anything to the contrary set forth in this paragraph, in the event that Cypress determines,
following consultation with its outside legal counsel, that payment to Alexza of non-cash
consideration would result in a violation of federal or state securities laws or a similar legal
requirement, then Cypress shall be entitled to pay such amount to Alexza in cash.

     6.3 Cypress Buy-Out Option. Within [...***...] days
after each Option Triggering Event (each, an “Option Triggering Event Window”), Cypress shall have
the option, in its sole and absolute discretion and without obligation, to deliver written notice
(the “Buy-Out Option Notice”) to Alexza of Cypress’ irrevocable election to buy out all of its
obligations to Alexza under this Agreement pursuant to this Article 6 by paying to Alexza, in cash,
an amount equal to the product of (a) the then-current fair market value of the future Asset
License Consideration and/or Asset Sale Consideration and (b) the Carry Credit Applicable
Percentage then in effect (the “Payment Rights”). In addition, Cypress shall have the option, in
its sole and absolute discretion and without obligation, to deliver a Buy-Out Option Notice to
Alexza of Cypress’ irrevocable election to buy out Alexza’s Payment Rights in cash at any time
other than during an Option Triggering Event Window, provided that if Cypress delivers such Buy-Out
Option Notice to Alexza other than during an Option Triggering Event Window then [...***...], solely
for purposes of calculating the Payment Rights pursuant to this paragraph. If Cypress completes the
Buy-Out as described in Section 6.5 below, this Agreement (together with all of Cypress’s
obligations hereunder) shall expire under Section 11.1, subject to the terms of Section 11.4 hereof
and provided that Article 7 would survive any expiration of this Agreement triggered by the
completion of the Buy-Out.

     6.4 Alexza Put Option. Cypress shall notify Alexza in writing promptly upon [...***...] a Change
of Control of Cypress (a “Change of Control Notice”). Provided that as of

 

			
	***	 	Confidential Treatment Requested

21

 

the date that such Change of Control Notice is delivered by Cypress both (a) Cypress has made
the Technology Transfer Payment and (b) the Carry Credit Applicable Percentage has not been reduced
pursuant to Section 5.4(c), then Alexza shall have the option, in its sole and absolute discretion
but without obligation, to deliver, within [...***...] days following receipt of the Change of Control
Notice, irrevocable written notice (the “Put Option Notice”) to Cypress requiring Cypress to buy
out its Payment Rights in cash immediately prior to the closing of the Change of Control of
Cypress. If Cypress completes the Buy-Out as described in Section 6.5 below, this Agreement
(together with all of Cypress’s obligations hereunder) shall expire under Section 11.1, subject to
the terms of Section 11.4 hereof and provided that Article 7 would survive any expiration of this
Agreement triggered by the completion of the Buy-Out.

     6.5 Valuation. Following receipt of the Buy-Out Option Notice or Put Option Notice,
authorized representatives of Cypress and Alexza shall promptly meet, at a time and place mutually
agreeable to both Cypress and Alexza, for the purpose of negotiating in good faith to determine the
fair market value of the Payment Rights. In the event that the authorized representatives of
Cypress and Alexza are able to agree on a fair market value for the Payment Rights within [...***...]
days following the date the Buy-Out Option Notice is delivered by Cypress to Alexza or the Put
Option Notice is delivered by Alexza to Cypress, as the case may be, Cypress shall complete the
Buy-Out by paying such agreed-upon fair market value in cash to Alexza within [...***...] days of the
date on which the Cypress and Alexza authorized representatives are so able to reach agreement. In
the event that the authorized representatives of Cypress and Alexza are unable to agree upon the
fair market value of the Payment Rights within [...***...] days following the date the Buy-Out Option Notice is delivered by Cypress to Alexza
or the Put Option Notice is delivered by Alexza to Cypress, as the case may be, the Parties shall
engage a mutually agreeable independent third party valuation expert (a “Valuation Firm”). In the
event that Cypress and Alexza are unable to select a mutually agreeable Valuation Firm within
[...***...] days, then promptly following such date each Party shall select a Valuation Firm, and such
Valuation Firms shall select a mutually agreeable Valuation Firm. The engagement of the Valuation
Firm selected shall be limited to the determination of the fair market value of the Payment Rights.
The Valuation Firm selected to conduct the valuation shall agree to complete the terms of its
engagement within [...***...] days following its formal engagement as Valuation Firm, subject in all
respects to the compliance by Cypress and Alexza of the terms of this paragraph. In determining
such fair market value, the Valuation Firm selected shall be entitled to apply discounted cash flow
models and such other valuation models as it determines are appropriate under the circumstances,
together with any other valuation models as may be mutually agreed upon by both Cypress and Alexza.
Each of Cypress and Alexza shall provide reasonable access to its information and personnel at
reasonable times and on a reasonable number of occasions to the Valuation Firm as may be reasonably
necessary for the Valuation Firm to determine such fair market value upon such Valuation Firm
entering into a confidentiality agreement on terms satisfactory to the applicable Party. Following
its determination, the Valuation Firm shall deliver to each of Cypress and Alexza a valuation
notice (the “Valuation Notice”), setting forth the fair market value of the Payment Rights (the
“Determined Fair Market Value”). Within [...***...] days following receipt by Cypress of the

 

			
	***	 	Confidential Treatment Requested

22

 

Valuation Notice, Cypress shall complete the Buy-Out by paying an amount in cash to Alexza
equal to the Determined Fair Market Value.

ARTICLE 7

INTELLECTUAL PROPERTY

     7.1 Ownership of Intellectual Property.

          (a) Alexza Technology and Cypress Technology. Alexza has and shall retain all right, title
and interest in and to the Alexza Technology and [...***...] Patents. Cypress has and shall retain all right, title and interest in and to the
Cypress Technology and Cypress Product Invention Technology.

          (b) Inventions. Each Party shall have and retain all right, title and interest in and to all
Inventions that are made solely by one or more employees or agents of such Party or its Affiliates.
Inventorship shall be determined in accordance with U.S. patent law. The Parties shall jointly
own all right, title and interest in and to all Joint Inventions, and Joint Patents resulting
therefrom, in accordance with joint ownership interests of co-inventors under U.S. patent laws
(that is, each Party shall have full rights to license, assign and exploit such Joint Inventions
and Joint Patents anywhere in the world, without any requirement of gaining the consent of, or
accounting to, the other Party), subject to the licenses granted herein and subject to any other
intellectual property held by the other Party.

          (c) Disclosure. Each Party shall promptly disclose to the other all Inventions, including any
invention disclosures or other similar documents, submitted to it by its or its Affiliates’
employees, agents or independent contractors describing such Inventions, and all information
relating to such inventions to the extent necessary for the preparation, filing and maintenance of
any Patent with respect to such Invention.

     7.2 Patent Prosecution and Maintenance.

          (a) Alexza Patents.

               (i) Alexza Background Patents. Except as otherwise provided in this Section 7.2(a)(i), Alexza
shall have the first right to prepare, file, prosecute (including any interferences, reissue
proceedings and reexaminations) and maintain the Alexza Background Patents in any jurisdiction in
the world, at its sole expense. Alexza shall keep Cypress reasonably informed of its prosecution
activities with respect to the Alexza Background Patents. If, in accordance with Section 7.8, the
Parties agree that a particular Alexza Background Patent will be listed or would reasonably be
expected to be listed in the Orange Book (an “Orange Book Alexza Background Patent”), then Alexza
shall provide Cypress with a copy of material communications from any patent authority regarding
such Orange Book Alexza Background Patent, and shall provide drafts of any material filings or
responses to be made to such patent authorities regarding the Orange Book Alexza Background Patent
a reasonable amount of time in

 

			
	***	 	Confidential Treatment Requested

23

 

advance of submitting such filings or responses so that Cypress may have an opportunity to
review and comment thereon. Alexza shall discuss and reasonably consider any comments received
from Cypress. If Alexza abandons, ceases prosecution or does not maintain any Orange Book Alexza
Background Patent anywhere in the world, then Alexza shall provide Cypress written notice thereof
at least [...***...] days before any deadline for taking
action to avoid abandonment (or other loss of rights) and, subject to any rights granted by Alexza
to a Third Party as of the Effective Date, Cypress (or its Sublicensee) shall have the right, in
its sole discretion, to file for or continue prosecution and/or maintenance of such Orange Book
Alexza Background Patent at Cypress’ own expense.

               (ii) Alexza Product Patents other than Alexza Nicotine Product Patents. Except as otherwise
provided in this Section 7.2(a)(ii), Alexza shall have the first right to prepare, file, prosecute
(including any interferences, reissue proceedings and reexaminations) and maintain the Alexza
Product Patents, excluding the Alexza Nicotine Product Patents which are addressed in Section
7.2(a)(iii), in any jurisdiction in the world, at its sole expense. Alexza shall keep Cypress
reasonably informed of its prosecution activities with respect to such Alexza Product Patents.
Alexza shall provide Cypress with a copy of material communications from any patent authority
regarding such Alexza Product Patents, and shall provide drafts of any material filings or
responses to be made to such patent authorities regarding such Alexza Product Patent a reasonable
amount of time in advance of submitting such filings or responses so that Cypress may have an
opportunity to review and comment thereon. Alexza shall use commercially reasonable efforts to
separate any Alexza Patent claims directed primarily toward a Product into distinct divisional (or
equivalent) patent applications, to the extent feasible and permitted under Applicable Laws, and to
the extent Alexza does not reasonably believe that such separation would materially adversely
affect the claim scope or likelihood or timing of patent issuance of any Alexza Patent, and such
distinct divisional (or equivalent) patent applications shall be Alexza Nicotine Product Patents.
If Alexza abandons, ceases prosecution or does not maintain any Alexza Product Patent (other than
any Alexza Nicotine Product Patent) anywhere in the world, then Alexza shall provide Cypress
written notice thereof at least [...***...]days before any deadline for taking action to avoid
abandonment (or other loss of rights) and Cypress (or its Sublicensee) shall have the right, in its
sole discretion, to file for or continue prosecution and/or maintenance of such Alexza Product
Patent at Cypress’ own expense, in which event Alexza shall assign all of its right, title and
interest in and to such Alexza Product Patent to Cypress and such Alexza Product Patent shall
thereafter be a Cypress Patent.

               (iii) Alexza Nicotine Product Patents. Except as otherwise provided in this Section
7.2(a)(iii), Cypress shall have the first right to prepare, file, prosecute (including any
interferences, reissue proceedings and reexaminations) and maintain the Alexza Nicotine Product
Patents in any jurisdiction in the world, at its sole expense. Cypress shall keep Alexza
reasonably informed of its prosecution activities with respect to the Alexza Nicotine Product
Patents. Cypress shall provide Alexza with a copy of material communications from any patent
authority regarding the Alexza Nicotine Product Patents, and shall provide drafts of any material
filings or responses to be made to such patent authorities regarding the Alexza Nicotine Product
Patents a reasonable amount of time in advance of submitting such filings or responses so that

 

			
	***	 	Confidential Treatment Requested

24

 

Alexza may have an opportunity to review and comment thereon; provided that with respect to
the patent application entitled [...***...]. If Cypress
abandons, ceases prosecution or does not maintain any Alexza Nicotine Product Patent anywhere in
the world, then Cypress shall provide Alexza written notice thereof at least [...***...] days before
any deadline for taking action to avoid abandonment (or other loss of rights) and Alexza (or its
Affiliates or Third Party licensees) shall have the right, in Alexza’s sole discretion, to file for
or continue prosecution and/or maintenance of such Alexza Nicotine Product Patent at Alexza’s own
expense.

          (b) Cypress Patents. Except as otherwise provided in this Section 7.2(b), Cypress shall have
the first right (but not the obligation) and authority to prepare, file, prosecute (including any
interferences, reissue proceedings and reexaminations) and maintain the Cypress Patents in any
jurisdiction in the world, at its sole expense. Cypress shall keep Alexza reasonably informed of
its prosecution activities with respect to the Cypress Patents. Cypress shall provide Alexza with
a copy of material communications from any patent authority regarding the Cypress Patents, and
shall provide drafts of any material filings or responses to be made to such patent authorities
regarding the Cypress Patents a reasonable amount of time in advance of submitting such filings or
responses so that Alexza may have an opportunity to review and comment thereon. If Cypress
abandons, ceases prosecution or does not maintain any Cypress Patent anywhere in the world, then
Cypress shall provide Alexza written notice thereof at least [...***...] days before any deadline for
taking action to avoid abandonment (or other loss of rights) and Alexza (or its Affiliates or their
respective Third Party licensees) shall have the right, in Alexza’s sole discretion, to file for or
continue prosecution and/or maintenance of such Cypress Patent at Alexza’s own expense.

          (c) Joint Patents.

               (i) Except as otherwise provided in this Section 7.2(c), as between the Parties, Cypress shall
have the first right and authority to prepare, file, prosecute (including any interferences,
reissue proceedings and reexaminations) and maintain the Joint Patents in any jurisdiction in the
world, and the Parties shall share equally all reasonable Third Party expenses incurred in
connection with the preparation, prosecution and maintenance of the Joint Patents. Cypress shall
provide Alexza reasonable opportunity to review and comment on its filing and prosecution efforts
regarding the Joint Patents reasonably prior to any submissions with applicable patent authorities.
Cypress shall provide Alexza with a copy of material communications from any patent authority
regarding the Joint Patents, and shall provide drafts of any material filings or responses to be
made to such patent authorities regarding the Joint Patents a reasonable amount of time in advance
of submitting such filings or responses so that Cypress may have an opportunity to review and
comment thereon. If Cypress abandons, ceases prosecution or does not maintain any Joint Patent
anywhere in the world, then Cypress shall provide Alexza written notice thereof at least
[...***...]days before any deadline for taking action to avoid abandonment (or other loss of rights)
and Alexza (or its Affiliates or their respective Third Party licensees) shall have the right, in
Alexza’s sole discretion, to file for or continue prosecution and/or maintenance of such Joint
Patent on behalf of the Parties.

 

			
	***	 	Confidential Treatment Requested

25

 

               (ii) Either Party may determine that it is no longer interested in supporting the continued
prosecution or maintenance of a particular Joint Patent in a country or jurisdiction, in which
case: (A) the disclaiming Party shall, if requested in writing by the other Party, assign its
ownership interest in such Joint Patent in such country or jurisdiction to the other Party for no
additional consideration; (B) if such assignment is effected, the other Party shall be solely
responsible for the prosecution and maintenance of such Joint Patent, at its sole expense; (C) such
Joint Patent shall thereafter no longer be deemed a Joint Patent; and (D) such Joint Patent shall
not be included in the licenses granted under this Agreement in the applicable jurisdiction.

     7.3 Infringement by Third Parties.

          (a) Notice. If either Party becomes aware of any infringement or threatened infringement of
any Alexza Patent, Cypress Patent or Joint Patent, such Party shall promptly notify the other Party
in writing to that effect. Any such notice shall include evidence to support an allegation of such
infringement by such Third Party.

          (b) Alexza Patents.

               (i) Alexza Background Patents. Subject to this Section 7.3(b)(i), Alexza shall have the first
right, as between the Parties, to bring and control any action or proceeding with respect to
infringement by a Third Party of any Alexza Background Patent worldwide as a result of the
research, development, manufacture, use, distribution, handling, storage, offer for sale, sale,
import or any other disposition of any Products, at its own expense and by counsel of its own
choice. Cypress shall have the right, at its own expense, to be represented in any such action
with respect to the Orange Book Alexza Background Patents by counsel of its own choice, and Alexza
and its counsel shall reasonably cooperate with, and take into account the view of, Cypress and its
counsel in strategizing, preparing and presenting any such action or proceeding. If Alexza fails
to bring an action or proceeding with respect to such infringement of any such Orange Book Alexza
Background Patent within (i) [...***...] days following
notice of alleged infringement under Section 7.3(a) or (ii) [...***...] days before the time limit, if
any, under Applicable Laws for the filing of such action, whichever comes first, and Cypress
believes that the failure to bring such an action or proceeding may result in a material diminution
in value of any Product, then subject to any rights granted by Alexza to a Third Party as of the
Effective Date, Cypress shall have the right, but not the obligation, to bring and control any such
action at its own expense and by counsel of its own choice. If required under Applicable Laws,
Alexza shall timely join as party plaintiff in any such litigation and shall cooperate with Cypress
in connection with such infringement action, at Cypress’ expense. Except as otherwise agreed by
the Parties, any recovery or damages realized as a result of any action or proceeding under this
Section 7.3(b)(i) [...***...].

               (ii) Alexza Product Patents other than Alexza Nicotine Product Patents. Subject to this
Section 7.3(b)(ii), Alexza shall have the first right, as between the Parties, to bring and control
any action or proceeding with respect to infringement by a Third

 

			
	***	 	Confidential Treatment Requested

26

 

Party of any Alexza Product Patent excluding an Alexza Nicotine Product Patent, which is
handled in Section 7.3(b)(iii), worldwide as a result of the research, development, manufacture,
use, distribution, handling, storage, offer for sale, sale, import or any other disposition of any
Products, at its own expense and by counsel of its own choice. Cypress shall have the right, at
its own expense, to be represented in any such action by counsel of its own choice, and Alexza and
its counsel shall reasonably cooperate with, and take into account the reasonable view of, Cypress
and its counsel in strategizing, preparing and presenting any such action or proceeding. If Alexza
fails to bring an action or proceeding with respect to such infringement of any such Alexza Product
Patent within (i) [...***...] days following notice of alleged infringement under Section 7.3(a) or
(ii) [...***...] days before the time limit, if any, under Applicable Laws for the filing of such
action, whichever comes first, Cypress shall have the right, but not the obligation, to bring and
control any such action at its own expense and by counsel of its own choice. If required under
Applicable Laws, Alexza shall timely join as party plaintiff in any such litigation and shall
cooperate with Cypress in connection with such infringement action, at Cypress’ expense. Except as
otherwise agreed by the Parties, any recovery or damages realized as a result of any action or
proceeding under this Section 7.3(b)(ii) [...***...].

               (iii) Alexza Nicotine Product Patents. Subject to this Section 7.3(b)(iii), Cypress
shall have the first right, as between the Parties, to bring and control any action or proceeding
with respect to infringement by a Third Party of any Alexza Nicotine Product Patent worldwide as a
result of the research, development, manufacture, use, distribution, handling, storage, offer for
sale, sale, import or any other disposition of any Products, at its own expense and by counsel of
its own choice. Alexza shall have the right, at its own expense, to be represented in any such
action by counsel of its own choice, and Cypress and its counsel shall reasonably cooperate with,
and take into account the reasonable view of, Alexza and its counsel in strategizing, preparing and
presenting any such action or proceeding. If Cypress fails to bring an action or proceeding with
respect to such infringement of any such Alexza Nicotine Product Patent within (i) [...***...] days
following notice of alleged infringement under Section 7.3(a) or (ii) [...***...] days before the time
limit, if any, under Applicable Laws for the filing of such action, whichever comes first, Alexza
shall have the right, but not the obligation, to bring and control any such action at its own
expense and by counsel of its own choice. If required under Applicable Laws, Cypress shall timely
join as party plaintiff in any such litigation and shall cooperate with Alexza in connection with
such infringement action, at Alexza’s expense. Except as otherwise agreed by the Parties, any
recovery or damages realized as a result of any action or proceeding under this Section 7.3(b)(iii)
[...***...].

          (c) Cypress Patents.

               (i) Cypress shall have the sole right, as between the Parties, to bring and control any action
or proceeding with respect to infringement by a Third Party of any Cypress Patent worldwide as a
result of the research, development, manufacture, use, distribution, handling, storage, offer for
sale, sale, import or any other disposition of any Product, at its own expense and by counsel of
its own choice, and any recovery or damages realized as a result of any action or proceeding shall
be retained by Cypress.

 

			
	***	 	Confidential Treatment Requested

27

 

               (ii) Subject to this Section 7.3(c)(ii), Cypress shall have the first right, as between the
Parties, to bring and control any action or proceeding with respect to infringement by a Third
Party of any Cypress Patent worldwide as a result of the research, development, manufacture, use,
distribution, handling, storage, offer for sale, sale, import or any other disposition of any
product that delivers or administers any API using the Staccato Technology, other than the Product,
at its own expense and by counsel of its own choice. Alexza shall have the right, at its own
expense, to be represented in any such action by counsel of its own choice, and Cypress and its
counsel shall reasonably cooperate with, and take into account the reasonable view of, Alexza and
its counsel in strategizing, preparing and presenting any such action or proceeding. If Cypress
fails to bring an action or proceeding with respect to such infringement of any such Cypress Patent
within (A) [...***...] days following notice of alleged infringement under Section 7.3(a) or
(B) [...***...] days before the time limit, if any, under Applicable Laws for the filing of such
action, whichever comes first, Alexza shall have the right, but not the obligation, to bring and
control any such action at its own expense and by counsel of its own choice. If required under
Applicable Laws, Cypress shall timely join as party plaintiff in any such litigation and shall
cooperate with Alexza in connection with such infringement action, at Alexza’s expense. Except as
otherwise agreed by the Parties, any recovery or damages realized as a result of any action or
proceeding under this Section 7.3(c)(ii) [...***...].

          (d) Joint Patents.

               (i) Subject to this Section 7.3(d)(i), Cypress shall have the first right, as between the
Parties, to bring and control any action or proceeding with respect to infringement by a Third
Party of any Alexza Nicotine Product Patent worldwide as a result of the research, development,
manufacture, use, distribution, handling, storage, offer for sale, sale, import or any other
disposition of any Products, at its own expense and by counsel of its own choice. Alexza shall
have the right, at its own expense, to be represented in any such action by counsel of its own
choice, and Cypress and its counsel shall reasonably cooperate with, and take into account the
reasonable view of, Alexza and its counsel in strategizing, preparing and presenting any such
action or proceeding. If required under Applicable Laws, Alexza shall timely join as party
plaintiff in any such litigation and shall cooperate with Cypress in connection with such
infringement action, at Cypress’ expense. If Cypress fails to bring an action or proceeding with
respect to such infringement of any such Joint Patent within (i) [...***...] days following notice of
alleged infringement under Section 7.3(a) or (ii) [...***...] days before the time limit, if any, under
Applicable Laws for the filing of such action, whichever comes first, Alexza shall have the right,
but not the obligation, to bring and control any such action at its own expense and by counsel of
its own choice. If required under Applicable Laws, Cypress shall timely join as party plaintiff in
any such litigation and shall cooperate with Alexza in connection with such infringement action, at
Alexza’s expense. Except as otherwise agreed by the Parties, any recovery or damages realized as a
result of any action or proceeding under this Section 7.3(d)(i) [...***...].

               (ii) Subject to this Section 7.3(d)(ii), Alexza shall have the first right, as between the
Parties, to bring and control any action or proceeding with respect to infringement by a Third
Party of any Joint Patent worldwide as a result of the research, development,

 

			
	***	 	Confidential Treatment Requested

28

 

manufacture, use, distribution, handling, storage, offer for sale, sale, import or any other
disposition of any product that delivers or administers any API using the Device, other than the
Product, at its own expense and by counsel of its own choice. Cypress shall have the right, at its
own expense, to be represented in any such action by counsel of its own choice, and Alexza and its
counsel shall reasonably cooperate with, and take into account the reasonable view of, Cypress and
its counsel in strategizing, preparing and presenting any such action or proceeding. If required
under Applicable Laws, Cypress shall timely join as party plaintiff in any such litigation and
shall cooperate with Alexza in connection with such infringement action, at Alexza’s expense. If
Alexza fails to bring an action or proceeding with respect to such infringement of any such Joint
Patent within (A) [...***...] days following notice of alleged infringement under Section 7.3(a) or
(B) [...***...] days before the time limit, if any, under Applicable Laws for the filing of such
action, whichever comes first, Cypress shall have the right, but not the obligation, to bring and
control any such action at its own expense and by counsel of its own choice. If required under
Applicable Laws, Alexza shall timely join as party plaintiff in any such litigation and shall
cooperate with Cypress in connection with such infringement action, at Cypress’ expense. Except as
otherwise agreed by the Parties, any recovery or damages realized as a result of any action or
proceeding under this Section 7.3(d)(ii) [...***...].

          (e) Cooperation. In the event a Party brings an infringement action in accordance with
this Section 7.3, the other Party shall cooperate fully, including, if required to bring such
action, the furnishing of a power of attorney or being named as a Party to such action.

     7.4 Patent Oppositions and Other Proceedings. If an Alexza Patent other than an Alexza
Nicotine Product Patent becomes the subject of any proceeding commenced by a Third Party in
connection with an opposition, action for declaratory judgment, nullity action, interference or
other attack upon the validity, title or enforceability thereof, then as between the Parties,
Alexza shall have the first right, but not the obligation, to control such defense at its own
expense using counsel of its own choice. If Alexza decides that it does not wish to defend against
such action with respect to such Alexza Patent, it shall notify Cypress reasonably in advance of
all applicable deadlines, and Cypress (or its Sublicensee) shall thereafter have the right, but not
the obligation, to assume defense of such action at its own expense. If an Alexza Nicotine Product
Patent or Joint Patent becomes the subject of any proceeding commenced by a Third Party in
connection with an opposition, action for declaratory judgment, nullity action, interference or
other attack upon the validity, title or enforceability thereof, then as between the Parties,
Cypress shall have the first right, but not the obligation, to control such defense at its own
expense using counsel of its own choice. If Cypress decides that it does not wish to defend
against such action with respect to an Alexza Nicotine Product Patent or Joint Patent, it shall
notify Alexza reasonably in advance of all applicable deadlines, and Alexza shall thereafter have
the right, but not the obligation, to assume defense of such action at its own expense. The Party
controlling any defense under this Section 7.4 shall permit the non-controlling Party to
participate in the proceedings to the extent permissible under Applicable Laws and to be
represented by its own counsel at the non-controlling Party’s expense. Notwithstanding any of the
foregoing, the Party controlling any infringement action with respect to any Alexza Patent or Joint
Patent pursuant to Section 7.3 shall also have the sole right to control the response to any

 

			
	***	 	Confidential Treatment Requested

29

 

attack on the validity, title, or enforceability of such Patent that is asserted by the
alleged infringer(s) as a counterclaim or affirmative defense in such action.

     7.5 Infringement of Third Party Rights. If any product that delivers or administers API using
the Staccato Technology is manufactured, used or sold by either Party or its Affiliates or their
respective Third Party licensees (in the case of Alexza) or its Sublicensees (in the case of
Cypress) becomes the subject of a Third Party’s claim or assertion of infringement of a Patent
owned by such Third Party, the Party first having notice of the claim or assertion shall promptly
notify the other Party, and the Parties shall promptly meet to consider the claim or assertion and
the appropriate course of action. Unless they otherwise mutually agree in writing, the Party
against which such claim or assertion is made shall have the sole right to defend itself in such
action.

     7.6 Consent for Settlement. Neither Party shall enter into any settlement or compromise of
any action or proceeding under this Article 6 that would impose any material non-monetary
obligations or any restrictions on the substantive rights of other Party without the prior written
consent of such other Party, which consent shall not be unreasonably withheld.

     7.7 Patent Term Extensions. The Parties shall discuss which, if any, of the Patents within
the Alexza Patents and Joint Patents the Parties should seek Patent Term Extensions with respect to
any Product. Alexza, in the case of the Alexza Patents other than the Alexza Nicotine Product
Patents, and Cypress, in the case of the Alexza Nicotine Product Patents and Joint Patents, shall
have the final decision-making authority with respect to applying for any such Patent Term
Extensions, and shall act with reasonable promptness in light of the development stage of the
Product to apply for any such Patent Term Extensions, where it so elects; provided, however, that
if in a particular country or jurisdiction only one such Patent can obtain a Patent Term Extension,
then the Parties shall consult in good faith to determine which such Patent should be the subject
of efforts to obtain a Patent Term Extension. The Party that does not apply for an extension
hereunder shall cooperate fully with the other Party in making such filings or actions. All
expenses incurred in connection with activities of a Party with respect to the Patent(s) for which
such Party seeks Patent Term Extensions pursuant to this Section 7.7 shall be borne solely by such
Party.

     7.8 Orange Book Listing. Alexza and Cypress shall use good faith efforts to agree as to which
of the Alexza Patents and Joint Patents shall be listed in the Orange Book for a Product. Alexza
shall notify Cypress of the issuance of any Alexza Patent within 10 days after issuance. Cypress
shall be responsible for any listings of Alexza Patents, Cypress Patents and Joint Patents in the
Orange Book for a Product; provided, that Cypress shall provide Alexza with written notice of its
intent to list appropriate Alexza Patents in the Orange Book, and shall provide Alexza with a copy
of all draft submissions 5 days before the deadline for such listing and, with respect to Alexza
Background Patents only, obtain Alexza’s approval (which approval shall not be unreasonably
withheld, conditioned or delayed) of such listing. Cypress shall be responsible for all such
listings of any Alexza Patents or other Patents for Products in the Orange Book, and shall comply
with all Applicable Laws with respect to such listings.

30

 

     7.9 Paragraph IV Notices. Each Party shall inform the other of any certification regarding
any Alexza Patent it receives pursuant to either 21 U.S.C. §§ 355(b)(2)(A)(iv) or
(j)(2)(A)(vii)(IV) or its successor provisions or any similar provisions in a country other than
the United States, and shall provide the other Party with a copy of such certification within five
days after receipt. The Parties’ rights with respect to the initiation and prosecution of any
legal action as a result of such certification or any recovery obtained as a result of such legal
action shall be as provided in Section 7.3.

     7.10 Personnel Obligations. Prior to beginning work under this Agreement relating to any
research, development or commercialization of a Product, each employee, agent or independent
contractor of each Party or its respective Affiliates shall be bound by non-disclosure and
invention assignment obligations which are consistent with the obligations of the Parties under
this Agreement, including without limitation: (a) promptly reporting any invention, discovery,
process or other intellectual property right; (b) assigning to the applicable Party all of his or
her right, title and interest in and to any invention, discovery, process or other intellectual
property right; (c) cooperating in the preparation, filing, prosecution, maintenance and
enforcement of any patent and patent application; (d) performing all acts and signing, executing,
acknowledging and delivering any and all documents required for effecting the obligations and
purposes of this Agreement; and (e) abiding by the obligations of confidentiality and non-use at
least as stringent as those set forth in Article 8.

     7.11 Trademarks.

          (a) Quality Control. Cypress shall use the Alexza Trademarks in connection with the marketing
and sale of the Product and in compliance with all Applicable Laws and market practices in the
applicable country. Cypress shall provide Alexza with samples of any materials that incorporate
the Alexza Trademarks prior to distributing such materials for use. Cypress shall comply with
reasonable policies provided by Alexza from time to time to maintain the goodwill and value of the
Alexza Trademarks. Cypress agrees that it will not at any time during or after the Term assert or
claim any interest in or do anything to adversely affect the validity or enforceability of any
Alexza Trademark.

          (b) Ownership. Cypress acknowledges Alexza’s exclusive ownership of the Alexza Trademarks and
agrees not to take any action inconsistent with such ownership and that any goodwill arising
through use of the Alexza Trademarks by Cypress shall inure to the benefit of Alexza.

          (c) Confusing or Similar Marks. Cypress covenants that it shall not use any trademark
confusingly similar to any Alexza Trademark in connection with any products (including the
Product), provided that, however, Cypress may use the Alexza Trademarks with other marks or names
if such other marks or names are sufficiently separated from the Alexza Trademarks and sufficiently
distinctive to avoid the consumer impression that such other marks or their owners are associated
with Alexza.

31

 

ARTICLE 8

CONFIDENTIALITY

     8.1 Confidential Information. Except to the extent expressly authorized by this Agreement or
otherwise agreed in writing by the Parties, the receiving Party (the “Receiving Party”) shall keep
confidential and shall not publish or otherwise disclose or use for any purpose other than as
provided for in this Agreement any confidential or proprietary information and materials,
patentable or otherwise, in any form (written, oral, photographic, electronic, visual or
otherwise), that is disclosed to it by the other Party (the “Disclosing Party”), including all
information concerning the Device and/or Product and any other technical or business information of
whatever nature (collectively, “Confidential Information”).

     8.2 Exceptions. Notwithstanding Section 8.1, the obligations of confidentiality and non-use
shall not apply to any specific portion of Confidential Information that, in each case as
demonstrated by competent evidence:

          (a) was already known to the Receiving Party or any of its Affiliates, other than under an
obligation of confidentiality, at the time of disclosure by the Disclosing Party;

          (b) was generally available to the public or was otherwise part of the public domain at the
time of its disclosure to the Receiving Party;

          (c) became generally available to the public or otherwise part of the public domain after its
disclosure by the Disclosing Party and other than through any act or omission of the Receiving
Party or any of its Affiliates in breach of this Agreement;

          (d) was subsequently lawfully disclosed to the Receiving Party or any of its Affiliates by a
Third Party who, to the best knowledge of the Receiving Party, did not directly or indirectly
receive such information from the Disclosing Party under an obligation of confidence; or

          (e) was developed by the Receiving Party or its Affiliate without use of or reference to any
Confidential Information of the Disclosing Party.

     8.3 Permitted Disclosures. Notwithstanding Section 8.1, each Party may disclose Confidential
Information belonging to the other Party as expressly permitted by this Agreement or if and to the
extent such disclosure is reasonably necessary in the following instances:

          (a) filing or prosecuting Patents as permitted by this Agreement;

          (b) prosecuting or defending litigation as permitted by this Agreement;

          (c) complying with applicable court orders or governmental regulations; and

          (d) disclosure to its Affiliates and sublicensees and its and their respective employees,
agents, and independent contractors only on a need-to-know basis and solely in connection with the
exercise of its rights or performance of its obligations under this Agreement,

32

 

provided that each disclosee must be bound by obligations of confidentiality and non-use at
least as stringent as those set forth in this Article 7 prior to any such disclosure;

          (e) disclosure to Third Parties in connection with due diligence or similar investigations by
or on behalf of a Third Party in connection with a potential license to or collaboration with such
Third Party (including entry into any such agreement), or a potential merger or acquisition by such
Third Party, and disclosure to potential Third Party investors in confidential financing documents,
provided, in each case, that any such Third Party agrees to be bound by similar terms of
confidentiality and non-use at least as stringent as those set forth in this Article 7.

Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other
Party’s Confidential Information pursuant to Section 8.3(b) or 8.3(c), it shall, except where
impracticable, give reasonable advance notice to the other Party of such disclosure and use efforts
to secure confidential treatment of such information at least as diligent as such Party would use
to protect its own confidential information, but in no event less than reasonable efforts; provided
that any Confidential Information so disclosed shall still be subject to the restrictions on use
set forth in this Article 7. In any event, the Parties agree to take all reasonable action to
avoid disclosure of Confidential Information hereunder.

     8.4 Terms of this Agreement. Except as otherwise provided in this Article 7, each Party
agrees not to disclose the terms of this Agreement to any Third Party without the prior written
consent of the other Party, except that each Party may disclose the terms of this Agreement as
contemplated by Section 8.5 and as permitted under Section 8.3.

     8.5 Public Announcements.

          (a) Except as required by Applicable Laws (including disclosure requirements of the U.S.
Securities and Exchange Commission (“SEC”), the NASDAQ stock exchange or any other stock exchange
on which securities issued by a Party or its Affiliates are traded), neither Party shall make any
public announcement concerning this Agreement or the subject matter hereof without the prior
written consent of the other, which shall not be unreasonably withheld or delayed; provided that it
shall not be unreasonable for a Party to withhold consent with respect to any public announcement
containing any of such Party’s Confidential Information. In the event of a required public
announcement, to the extent practicable under the circumstances, the Party making such announcement
shall provide the other Party with a copy of the proposed text of such announcement sufficiently in
advance of the scheduled release to afford such other Party a reasonable opportunity to review and
comment upon the proposed text.

          (b) The Parties acknowledge that each Party may be obligated to file a copy of this Agreement
with the SEC or other government authorities. Each Party shall be entitled to make such a required
filing, provided that it requests confidential treatment of at least the commercial terms and
sensitive technical terms hereof and thereof to the extent such confidential treatment is
reasonably available. In the event of any such filing, each Party shall provide the other Party
with a copy of the Agreement marked to show provisions for which it intends to seek confidential
treatment and shall reasonably consider and incorporate the other Party’s comments

33

 

thereon to the extent consistent with the legal requirements governing redaction of
information from material agreements that must be publicly filed.

ARTICLE 9

REPRESENTATIONS, WARRANTIES AND COVENANTS

     9.1 Mutual Representations and Warranties. Each Party hereby represents and warrants to the
other Party that, as of the Effective Date:

          (a) it is duly organized and validly existing under the laws of its state of incorporation,
and has full corporate power and authority to enter into this Agreement and to carry out the
provisions hereof;

          (b) it is has taken all corporate action necessary to authorize the execution and delivery of
this Agreement and the performance its obligations under this Agreement;

          (c) this Agreement is legally binding upon it and enforceable in accordance with its terms;

          (d) its execution, delivery and performance of this Agreement does not conflict with,
constitute a breach of, or in any material way violate any arrangement, understanding or agreement
to which it is a party or by which it is bound; and

          (e) it is not debarred under the United States Federal Food, Drug and Cosmetic Act and does
not employ or use the services of any person who is debarred.

     9.2 By Alexza. Alexza hereby represents and warrants that, as of the Effective Date:

          (a) it has the full right to grant to Cypress the licenses it purports to grant as provided in
this Agreement;

          (b) Exhibit A lists all Patents Controlled by Alexza or its Affiliates that are necessary or
reasonably useful for the research, development, importation, use, manufacture, sale and offer for
sale of Products;

          (c) except as expressly set forth in Section 9.2(d), it is the exclusive owner of the Alexza
Technology, including the Staccato Technology, and Alexza Trademarks;

          (d) it is co-owner with [...***...] of U.S. Patent No. [...***...];

          (e) there exist no outstanding liens, encumbrances, agreements or understandings of any
kind, either written, oral or implied, with respect to the Alexza Technology that are inconsistent
with any provision of this Agreement, and Alexza covenants

 

			
	***	 	Confidential Treatment Requested

34

 

that it will not grant (or purport to grant) during the Term any right to any Affiliate or
Third Party that conflicts with the rights granted to Cypress hereunder;

          (f) to Alexza’s knowledge, there are no activities by Third Parties that would constitute
infringement of the Alexza Patents or Alexza Trademarks or misappropriation of the Alexza Know-How;

          (g) to Alexza’s knowledge, the research, development, importation, use, manufacture, sale and
offer for sale of the Device or Products as contemplated by the Parties as of the Effective Date
will not infringe or misappropriate any Patent or other intellectual property rights of a Third
Party;

          (h) neither Alexza nor any of its Affiliates has received any written notice from any entity,
or has knowledge, of any actual or threatened claim or assertion that the use or practice of the
Alexza Patents, Alexza Trademarks or Alexza Know-How infringes or misappropriates the intellectual
property rights of a Third Party; and

          (i) there are no actual, pending, or to Alexza’s knowledge, alleged or threatened adverse
actions, suits, claims, interferences or formal governmental investigations (i) involving any
Alexza Technology (to the extent related to any Product), the Device or any Product, including in
connection with the conduct of any clinical trials or manufacturing activities, or (ii) questioning
the validity of this Agreement or any action taken by Alexza in connection with the execution of
this Agreement, in each case, by or against Alexza or any of its Affiliates in or before any court,
Regulatory Authority or other governmental authority, and there are no material unsatisfied
judgments or outstanding orders, injunctions, decrees, stipulations or awards (whether rendered by
a court, an administrative agency or an arbitrator) against Alexza with respect to any Alexza
Technology, the Device or any Product.

     9.3 Covenants.

          (a) Each Party covenants that (i) it will not grant (or purport to grant) during the Term any
right to any Affiliate or Third Party that conflicts with the rights granted to the other Party
hereunder, (ii) to the extent it subcontracts to any Third Party to perform its development
activities under this Agreement, such Party will use Commercially Reasonable Efforts to cause such
Third Party subcontractor to assign to such Party all Inventions made, created, discovered,
conceived or reduced to practice by such subcontractor that are subject to licenses granted by such
Party under this Agreement, and (iii) it will not, during the Term, employ or use the services of
any person who is debarred in connection with the activities for which it is responsible under this
Agreement. In the event that a Party becomes aware of the debarment or threatened debarment of any
person providing services to such Party that directly or indirectly relate to activities for which
it is responsible under Agreement, such Party shall immediately notify the other Party in writing.

          (b) Cypress covenants that during the Term it will not take any action to materially adversely
affect the scope of rights licensed to Alexza under this Agreement.

35

 

          (c) Alexza covenants that during the Term (i) all Products and other clinical trial and test
materials supplied by Alexza pursuant to this Agreement will be manufactured in accordance with
specifications therefor, as agreed upon by the Parties, and the applicable Regulatory Requirements,
and will not be adulterated or misbranded within the meaning of the U.S. Federal Food, Drug and
Cosmetic Act, as amended from time to time, (ii) it will not take any action to materially
adversely affect the scope of rights licensed to Cypress under this Agreement, and (iii) it will
not assign any of its right, title and interest in and to any Alexza Patents encumbered by a
terminal disclaimer or any Patents over which a terminal disclaimer has been or will be filed in
connection with an Alexza Patent, except in accordance with Section 13.7.

     9.4 Disclaimer. EXCEPT AS EXPRESSLY STATED IN THIS ARTICLE 9, NO REPRESENTATIONS OR
WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS
FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL
PROPERTY RIGHTS, ARE MADE OR GIVEN BY OR ON BEHALF OF A PARTY. EXCEPT AS EXPRESSLY STATED IN THIS
AGREEMENT, ALL REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE,
ARE HEREBY EXPRESSLY EXCLUDED.

ARTICLE 10

INDEMNIFICATION

     10.1 Indemnification of Alexza. Cypress shall indemnify and hold harmless each of Alexza and
its Affiliates and their respective directors, officers, employees and agents, and the successors
and assigns of any of the foregoing, (the “Alexza Indemnitees”) from and against any and all
losses, liabilities, damages, penalties, fines, costs and expenses (including reasonable attorneys’
fees and other expenses of litigation) (“Losses”) from any claims, actions, suits or proceedings
brought by a Third Party (a “Third Party Claim”) incurred by any Alexza Indemnitee, arising from or
occurring as a result of (a) the gross negligence or willful misconduct of Cypress or its
Affiliates or Sublicensees, (b) any material breach of any representations, warranties or covenants
by Cypress under this Agreement, or (c) the research, development, manufacture, use, distribution,
handling, storage, offer for sale, sale, import or any other disposition of a Product by Cypress or
its Sublicensees, except in each case (a)-(c) to the extent any such Third Party Claim falls within
the scope of the indemnification obligations of Alexza set forth in Section 10.2(a), (b) or (c).

     10.2 Indemnification of Cypress. Alexza shall indemnify and hold harmless each of Cypress and
its Affiliates and their respective directors, officers, employees and agents, and the successors
and assigns of any of the foregoing, (the “Cypress Indemnitees”), from and against any and all
Losses from any Third Party Claims incurred by any Cypress Indemnitee, arising from or occurring as
a result of (a) the gross negligence or willful misconduct of Alexza or its Affiliates, (b) any
material breach of any representations, warranties or covenants by Alexza under this Agreement, or
(c) the research, development, manufacture, use, distribution, handling, storage, offer for sale,
sale, import or any other disposition of products that deliver or administer

36

 

API using the Staccato Technology by Alexza or its Affiliates or Sublicensees, except in each
case (a)-(c) to the extent any such Third Party Claim falls within the scope of the indemnification
obligations of Cypress set forth in Section 10.1(a), (b) or (c).

     10.3 Procedure. A Party that intends to claim indemnification (the “Indemnitee”) under this
Article 10 shall promptly notify the indemnifying Party (the “Indemnitor”) in writing of any Third
Party Claim in respect of which the Indemnitee intends to claim such indemnification. The
Indemnitee shall provide the Indemnitor with reasonable assistance, at the Indemnifying Party’s
expense, in connection with the defense of the Third Party Claim for which indemnity is being
sought. The Indemnitee may participate in and monitor such defense with counsel of its own
choosing at its sole expense; provided, however, the Indemnitor shall have the right to assume and
conduct the defense of the Third Party Claim with counsel of its choice. The Indemnitor shall not
settle any Third Party Claim without the prior written consent of the Indemnitee, not to be
unreasonably withheld, unless the settlement involves only the payment of money. So long as the
Indemnitor is actively defending the Third Party Claim in good faith, the Indemnitee shall not
settle any such Third Party Claim without the prior written consent of the Indemnitor. If the
Indemnitor does not assume and conduct the defense of the Third Party Claim as provided above, (a)
the Indemnitee may defend against, and consent to the entry of any judgment or enter into any
settlement with respect to, the Third Party Claim in any manner the Indemnitee may deem reasonably
appropriate (and the Indemnitee need not consult with, or obtain any consent from, the Indemnitor
in connection therewith), and (b) the Indemnitor will remain responsible to indemnify the
Indemnitee as provided in this Article 10. The failure to deliver written notice to the Indemnitor
within a reasonable time after the commencement of any action with respect to a Third Party Claim
shall only relieve the Indemnitor of its indemnification obligations under this Article 9 if and to
the extent the Indemnitor is actually prejudiced thereby.

     10.4 Limitation of Liability. EXCEPT FOR LIABILITY FOR BREACH OF ARTICLE 8 AND
INDEMNIFICATION OBLIGATIONS UNDER THIS ARTICLE 10, NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM
THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS
AGREEMENT.

ARTICLE 11

TERM; REMEDIES

     11.1 Term. This Agreement shall commence on the Effective Date and, unless terminated earlier
as provided in this Article 11, shall continue in full force and effect until the expiration of all
of Cypress’ payment obligations to Alexza under this Agreement (the “Term”). Upon the expiration
of this Agreement, the licenses granted under Section 2.1 and Section 2.2 and rights granted under
Sections 2.7 and 2.8 shall become perpetual and irrevocable.

     11.2 Termination.

          (a) Upon the occurrence of any event set forth below in this Section 11.2(a), Cypress shall
use Commercially Reasonable Efforts to complete an Asset Sale or Asset License

37

 

[...***...]. This Agreement shall terminate automatically if Cypress does not complete an Asset
Sale or Asset License [...***...] after the occurrence of any such event. If Cypress completes an
Asset Sale or Asset License [...***...] after the occurrence of any such event, Alexza shall no longer
have any right to terminate this Agreement under this Section 11.2(a).

               (i) Cypress’ failure to pay the Technology Transfer Payment within the applicable
[...***...] time period;

               (ii) the discontinuation by Cypress of development of the Products for any reason other than
the material breach by Alexza of any of its obligations under Section 3.4, 3.5 or 5.3 of this
Agreement (which breach is not cured within [...***...] days after notice from Cypress requesting cure
of the breach), including pursuant to notice under Section 5.2(b); provided that this
subsection (ii) will no longer be applicable upon first Marketing Approval in the United States; or

               (iii) the material breach by Cypress of this Agreement (other than a failure to pay the
Technology Transfer Payment), which breach is not cured within [...***...]days after notice from Alexza
requesting cure of the breach; provided, that such material breach was not caused by the material
breach by Alexza of any of its obligations under Section 3.4, 3.5 or 5.3 of this Agreement (which
breach is not cured within [...***...] days after notice from Cypress requesting cure of the breach);
provided further, that if Cypress in good faith disputes such material breach on or before the end
of the cure period therefor and either Party requests resolution of such matter pursuant to
Article 12, then the [...***...] period described above in this Section 11.2(a) shall not commence
unless and until such matter is resolved pursuant to Section 12.1 or, if applicable, Section 12.2.

          (b) Cypress shall have the right to terminate this Agreement upon the material breach by
Alexza of any of its obligations under Section 3.4, 3.5 or 5.3 of this Agreement, which breach is
not cured within [...***...] days after notice from Cypress requesting cure of the breach.

     11.3 Effects of Termination.

          (a) Upon any termination of this Agreement under Section 11.2(a) or 11.2(b), the following
shall apply:

               (i) Licenses; Technology. All licenses from Alexza to Cypress shall immediately terminate,
provided that each Cypress Sublicense Agreement shall remain in full force and effect as a direct
agreement between Alexza and the applicable Sublicensee, provided that the applicable Sublicensee
is not in breach of its Cypress Sublicense Agreement. All licenses from Cypress to Alexza shall
immediately terminate [...***...].

               (ii) Return of Confidential Information. Except to the extent necessary or reasonably useful
for a Party to exercise its rights under any license surviving such termination or expiration, each
Party shall promptly return to the other Party, or delete or

 
 

			
	***	 	Confidential Treatment Requested

38

 

destroy, all relevant records and materials in such Party’s possession or control containing
Confidential Information of the other Party [...***...].

               (iii) Marks. Cypress shall assign to Alexza all right, title and interest in and to all
trademarks used by Cypress in connection with the Products (excluding any such trademarks that
include, in whole or part, any corporate name or logo of Cypress or its Affiliate or Sublicensee).

               (iv) Transition Assistance. Cypress shall [...***...] provide reasonable consultation and
assistance for a period of no more than [...***...] days for the purpose of transferring or
transitioning to Alexza, [...***...] relating specifically to Products hereunder that Cypress is able,
using reasonable commercial efforts to, transfer or transition to Alexza. [...***...]

          (b) In addition to the effects set forth in Section 11.3(a), upon any termination of this
Agreement under Section 11.2(a), the following shall apply:

               (i) Regulatory Filings. Cypress shall transfer and assign to Alexza all Regulatory Filings
and Regulatory Approvals for Products that are owned by Cypress or its Affiliates.

               (ii) Remaining Inventories. Cypress shall have the right to sell, for a period not to exceed
[...***...] after the effective date of termination, all inventory of Products in Cypress’ or its
Affiliates’ possession as of the effective date of termination.

               (iii) Payment Obligations.

                    (1) If the applicable event under Section 11.2(a) occurs on or after the 1st
anniversary of the Effective Date, and if Alexza subsequently completes any transaction pursuant to
which (A) rights under Alexza Technology to commercialize any Product [...***...] are licensed or
sublicensed or otherwise granted to any Third Party (including licensing and collaboration
transaction and joint ventures involving a license, but excluding a Change of Control of Alexza)
(an “Alexza Product License”) or (B) Alexza or any of its Affiliates sells, transfers or disposes
of all or a substantial portion of the [...***...] Alexza Technology related to Products to a Person
other than Alexza or an Affiliate of Alexza (including a sale of assets, merger, sale of stock or
other equity interests, including a Change of Control of Alexza) (an “Alexza Product Sale”), then
Alexza shall pay to Cypress, out of the License Consideration or Sale Consideration, as applicable,
an amount not to exceed [...***...]% of the following total: [...***...]. Such amount shall be paid within
[...***...] days after Alexza’s receipt of the applicable License Consideration or Sale Consideration,
as applicable, and shall be accompanied by a reasonably detailed statement summarizing the
calculation of the amount paid. For purposes of clarification, (y) the payment obligations of
Alexza to Cypress set forth in this Section 11.3(b)(iii) shall apply to each Alexza Product License
or Alexza Product Sale completed by Alexza on a cumulative basis, subject to the

 

			
	***	 	Confidential Treatment Requested

39

 

maximum total payment obligations of Alexza to Cypress set forth in this paragraph, and (z) a
license or sublicense solely to manufacture or develop any Product for Alexza or its Affiliate
where Alexza or its Affiliate retains rights to commercialize such Product shall not be an Alexza
Product License or Alexza Product Sale.

                    (2) As used herein, “License Consideration” means the net monetary and non-monetary
consideration actually received by Alexza or any of its Affiliates in connection with any Alexza
Product License, after deducting any investment banking, broker, accounting, tax and legal fees
paid by Alexza or any of its Affiliates in connection with an Alexza Product License, including net
licensing fees, royalties, milestones or similar amounts to the extent actually paid to Alexza or
any of its Affiliates. “Sale Consideration” means the net monetary and non-monetary consideration
actually received by Alexza or any of its Affiliates in connection with an Alexza Product Sale,
after deduction of any investment banking, broker, accounting, tax and legal fees and expenses paid
by Alexza or any of its Affiliates in connection with such Alexza Product Sale, including
milestone, escrow, holdback and other contingent payments payable in connection with such Alexza
Asset Sale to the extent actually paid to Alexza or any of its Affiliates. In each case,
non-monetary consideration received by Alexza or any of its Affiliates shall be valued by Alexza in
the same manner as non-cash consideration is valued by Cypress pursuant to Section 6.2.

          (c) In addition to the effects set forth in Section 11.3(a), immediately upon any termination
of this Agreement under Section 11.2(b), Alexza shall pay to Cypress an amount equal to the Alexza
Development Expenses previously paid by Cypress to Alexza under Section 5.4(a).

     11.4 Survival. Expiration or termination of this Agreement shall not relieve the Parties of
any rights or obligation accruing prior to such expiration or termination. In addition, upon
expiration or termination of this Agreement, the following provisions shall survive and apply after
expiration or termination of this Agreement: Sections 2.6, 7.1, 9.4, 11.1 (including the provisions
referenced therein only after expiration of this Agreement), 11.3 (only after a termination of this
Agreement), 11.4 and 11.5 and Articles 8, 10, 12 and 13.

     11.5 Rights in Bankruptcy. All rights and licenses granted under or pursuant to this
Agreement by Alexza and Cypress are, and shall otherwise be deemed to be, for purposes of Section
365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under
Section 101 of the U.S. Bankruptcy Code. The Parties agree that each Party, as licensee of certain
rights under this Agreement, shall retain and may fully exercise all of its rights and elections
under the U.S. Bankruptcy Code. The Parties further agree that, in the event of the commencement a
bankruptcy proceeding by or against a Party (such Party, the “Bankrupt Party”) under the U.S.
Bankruptcy Code, the other Party shall be entitled to a complete duplicate of (or complete access
to, as appropriate) any intellectual property licensed to such other Party and all embodiments of
such intellectual property, which, if not already in such other Party’s possession, shall be
promptly delivered to it (a) upon any such commencement of a bankruptcy proceeding upon such other
Party’s written request therefor, unless the Bankrupt Party elects to continue to perform all of
its obligations under this Agreement or (b) if not delivered under

40

 

clause (a), following the rejection of this Agreement by the Bankrupt Party upon written
request therefor by the other Party.

ARTICLE 12

DISPUTE RESOLUTION AND GOVERNING LAW

     12.1 Dispute Resolution Process. The Parties recognize that disputes as to certain matters
may from time to time arise during the Term that relate to interpretation of a Party’s rights
and/or obligations hereunder or any alleged breach of this Agreement. If the Parties cannot
resolve any such dispute within [...***...] days after written notice of a dispute from one Party to
another, either Party may, by written notice to the other Party, have such dispute referred to the
Senior Executives. The Senior Executives shall negotiate in good faith to resolve the dispute
within [...***...] days. During such period of
negotiations, any applicable time periods under this Agreement shall be tolled. If the Senior
Executives are unable to resolve the dispute within such time period, either Party may then invoke
the provisions of Section 12.2. For clarification, any disputes of the Development Committee shall
not be subject to the provisions of this Article 12, and may only be resolved in accordance with
Section 3.3(d).

     12.2 Arbitration.

          (a) General. Any dispute, controversy, difference or claim that may arise between the Parties
out of or in relation to or in connection with this Agreement (including arising out of or relating
to the validity, construction, interpretation, enforceability, breach, performance, application or
termination of this Agreement), excluding any disputes of the Development Committee, which may only
be resolved in accordance with Section 3.3(d), that is not resolved pursuant to Section 12.1,
except for a dispute, claim or controversy under Section 12.3, shall be settled by binding
arbitration administered by JAMS pursuant to its Comprehensive Arbitration Rules and Procedures of
JAMS then in effect (the “JAMS Rules”), except as otherwise provided herein. The arbitration shall
be governed by the U.S. Federal Arbitration Act, 9 U.S.C. §§ 1-16 (the “Federal Arbitration Act”),
to the exclusion of any inconsistent state laws. The U.S. Federal Rules of Civil Procedure shall
govern discovery and the rules of evidence for the arbitration. The arbitration will be conducted
in [...***...]. Any situation not expressly covered by this Agreement shall be decided in accordance
with the JAMS Rules.

          (b) Arbitrator. The arbitrator shall be one neutral, independent and impartial arbitrator
selected from a pool of retired federal judges to be presented to the Parties by JAMS. If the
Parties fail to agree on an arbitrator within [...***...] days, the arbitrator shall be appointed by
JAMS in accordance with the JAMS Rules.

          (c) Decision; Award. The power of the arbitrator to fashion procedures and remedies within
the scope of this Agreement is recognized by the Parties as essential to the success of the
arbitration process. The arbitrator shall not have the authority to fashion remedies that would
not be available to a state or federal judge hearing the same dispute. The arbitrator is

 

			
	***	 	Confidential Treatment Requested

41

 

encouraged to operate on this premise in an effort to reach a fair and just decision. Reasons
for the arbitrator’s decisions should be complete and explicit, including reasonable determinations
of law and fact. The written reasons should also include the basis for any damages awarded and a
statement of how the damages were calculated. Such a written decision shall be rendered by the
arbitrator following a full comprehensive hearing, no later than [...***...]
days following the selection of the arbitrator as provided for in Section
12.2(b). Any award shall be promptly paid in U.S. dollars free of any tax, deduction or offset;
and any costs, fees or taxes incident to enforcing the award shall, to the maximum extent permitted
by Applicable Laws, be charged against the Party resisting enforcement. Each Party agrees to abide
by the award rendered in any arbitration conducted pursuant to this Article 12 and agrees that,
subject to the Federal Arbitration Act, judgment may be entered upon the final award in any court
of competent jurisdiction.

          (d) Costs. Each Party shall bear its own legal fees in connection with the arbitration. The
arbitrator shall assess his or her costs, fees and expenses against the Party losing the
arbitration unless he or she believes that neither Party is the clear loser, in which case the
arbitrator shall divide his or her fees, costs and expenses according to his or her sole
discretion.

          (e) Injunctive Relief. Provided a Party has made a sufficient showing under the rules and
standards set forth in the Federal Rules of Civil Procedure and applicable case law, the arbitrator
shall have the freedom to invoke, and the Parties agree to abide by, injunctive measures after
either Party submits in writing for arbitration claims requiring immediate relief. Additionally,
nothing in this Article 12 will preclude either Party from seeking equitable relief or interim or
provisional relief from a court of competent jurisdiction, including a temporary restraining order,
preliminary injunction or other interim equitable relief, concerning a dispute either prior to or
during any arbitration if necessary to protect the interests of such Party or to preserve the
status quo pending the arbitration proceeding.

          (f) Confidentiality. The arbitration proceeding shall be confidential and the arbitrator
shall issue appropriate protective orders to safeguard each Party’s Confidential Information.
Except as required by law, no Party shall make (or instruct the arbitrator to make) any public
announcement with respect to the proceedings or decision of the arbitrator without prior written
consent of the other Party. The existence of any dispute submitted to arbitration, and the award,
shall be kept in confidence by the Parties and the arbitrator, except as required in connection
with the enforcement of such award or as otherwise required by Applicable Laws.

     12.3 Patent and Trademark Disputes. Any dispute, controversy or claim relating to the scope,
validity, enforceability or infringement of any Patents covering or Trademarks used in connection
with the manufacture, use, importation, offer for sale, marketing, distribution or sale of the
Product shall be submitted to a court of competent jurisdiction in the country in which such patent
or trademark rights were granted or arose.

     12.4 Governing Law. This Agreement and all questions regarding the existence, validity,
interpretation, breach or performance of this Agreement, shall be governed by, and

 

			
	***	 	Confidential Treatment Requested

42

 

construed and enforced in accordance with, the laws of the State of California, without
reference to its conflicts of law principles.

ARTICLE 13

GENERAL PROVISIONS

     13.1 Waiver of Breach. No delay or waiver by either Party of any condition or term in any one
or more instances shall be construed as a further or continuing waiver of such condition or term or
of another condition or term.

     13.2 Further Actions. Each Party agrees to execute, acknowledge and deliver such further
instruments, and to perform all such other acts, as may be necessary or appropriate in order to
carry out the purposes and intent of this Agreement.

     13.3 Modification. No amendment or modification of any provision of this Agreement shall be
effective unless in a writing signed by both Parties hereto. No provision of this Agreement shall
be varied, contradicted or explained by any oral agreement, course of dealing or performance or any
other matter not set forth in an agreement in writing and signed by both Parties hereto.

     13.4 Severability. In the event any provision of this Agreement should be held invalid,
illegal or unenforceable in any jurisdiction, the Parties shall negotiate in good faith and enter
into a valid, legal and enforceable substitute provision that most nearly reflects the original
intent of the Parties. All other provisions of this Agreement shall remain in full force and effect
in such jurisdiction. Such invalidity, illegality or unenforceability shall not affect the
validity, legality or enforceability of such provision in any other jurisdiction.

     13.5 Entire Agreement. This Agreement, including its exhibits, constitute the entire
agreement between the Parties relating to the subject matter hereof and supersede and cancel all
previous express or implied agreements and understandings, negotiations, writings and commitments,
either oral or written, in respect of the subject matter hereof.

     13.6 Notices. Any notice or communication required or permitted under this Agreement shall be
in writing, delivered personally, sent by facsimile (and promptly confirmed by personal delivery,
registered or certified mail or overnight courier), sent by nationally-recognized overnight courier
or sent by registered or certified mail, postage prepaid, to the following addresses of the Parties
(or such other address for a Party as may be at any time thereafter specified by like notice):

43

 

	 	 	 

	To Alexza:

	 	To Cypress:
	 
	 	 
	Alexza Pharmaceuticals, Inc.

	 	Cypress Bioscience, Inc.
	2091 Stierlin Court

	 	4350 Executive Drive, Suite 325
	Mountain View, CA 94043

	 	San Diego, CA 92121
	Facsimile: (650) 944-7988

	 	Facsimile: (858) 452-1222
	Attention: Chief Executive Officer

	 	Attention: Chief Executive Officer
	 
	 	 
	with a copy to:

	 	with a copy to:
	 
	 	 
	Cooley LLP

	 	Cooley LLP
	3175 Hanover St.

	 	4401 Eastgate Mall
	Palo Alto, CA 94304

	 	San Diego, CA 92121
	Facsimile: (650) 849-7400

	 	Telephone: (858) 550-6000
	Attention: Glen Y. Sato

	 	Facsimile: (858) 550-6420
	 

	 	Attention: Frederick T. Muto

     Any such notice shall be deemed to have been given (a) when delivered if personally delivered;
(b) on the next business day after dispatch if sent by confirmed facsimile or by
nationally-recognized overnight courier; or (c) on the fifth business day following the date of
mailing if sent by mail.

     13.7 Assignment. This Agreement shall be binding upon the successors and assigns of the
Parties and the name of a Party appearing herein shall be deemed to include the names of its
successors and assigns. Neither Party may assign its interest under this Agreement without the
prior written consent of the other Party; provided however, each Party may assign its interest
under this Agreement, without the prior written consent of the other Party: (a) to any of its
Affiliates, or (b) to a Third Party successor of the assigning Party’s business to which this
Agreement relates (which, in the case of Cypress, shall mean Cypress’ business relating to
Products, and in the case of Alexza, shall mean Alexza’s business relating to the Staccato
Technology, including the Alexza Technology), whether alone or together with any other portions of
the assigning Party’s business, by reason of merger, sale of stock or sale of all or substantially
all of its assets or other form of acquisition; provided that intellectual property rights that are
controlled by such Third Party acquirer (other than Alexza Technology) shall not be included in the
technology licensed hereunder. Any purported assignment without a required consent shall be null
and void. No assignment shall relieve either Party of responsibility for the performance of any
obligation that accrued prior to the effective date of such assignment.

     13.8 No Partnership or Joint Venture. Nothing in this Agreement or any action which may be
taken pursuant to its terms is intended, or shall be deemed, to establish a joint venture or
partnership between Cypress and Alexza. Neither Party to this Agreement shall have any express or
implied right or authority to assume or create any obligations on behalf of, or in the name of, the
other Party, or to bind the other Party to any contract, agreement or undertaking with any Third
Party.

44

 

     13.9 Counterparts. This Agreement may be executed in any number of counterparts each of which
shall be deemed an original, and all of which together shall constitute one and the same
instrument. Signatures provided by facsimile transmission or in AdobeTM Portable Document Format
(PDF) sent by electronic mail shall be deemed to be original signatures.

[Signature Page Follows]

45

 

     
IN WITNESS WHEREOF, the Parties have executed this License & Development Agreement as of the
Effective Date.

	 	 	 	 	 	 	 	 	 

	ALEXZA PHARMACEUTICALS, INC.	 	CYPRESS BIOSCIENCE, INC.	 	 
	 
	 	 	 	 	 	 	 	 
	By: 

Name:

	 	/s/ Thomas B. King
 

Thomas B. King
	 	By:

Name:
	 	/s/ Jay Kranzler
 

Jay D. Kranzler, M.D., PhD
	 	 
	Title:

	 	President, Chief Executive Officer
	 	Title:
	 	Chief Executive Officer	 	 

Signature Page to License & Development Agreement

 

 

Exhibit A

Alexza Patents

[...***...]

 

			
	***	 	Confidential Treatment Requested

A-1

 

Exhibit B

Alexza Trademarks

[...***...]

 

			
	***	 	Confidential Treatment Requested

B-1

 

Exhibit C

Alexza Development Plan

[...***...]

[...***...]

[...***...]

[...***...]

[...***...]

 

			
	***	 	Confidential Treatment Requested

C-1exv10w3

Exhibit 10.3

Execution Version

***Text Omitted and Filed Separately

with the Securities and Exchange Commission.

Confidential Treatment Requested

Under 17 C.F.R. Sections 200.80(b)(4)

and 240.24b-2.

ASSET PURCHASE AGREEMENT

by and between

CYPRESS BIOSCIENCE, INC.

and

MARINA BIOTECH, INC.

dated as of August 25, 2010

i

 

Table of Contents

	 	 	 	 	 
	 	 	Page
	ARTICLE 1 DEFINITIONS
	 	 	1	 
	 
	 	 	 	 
	1.1 Defined Terms
	 	 	1	 
	1.2 Construction of Certain Terms and Phrases
	 	 	1	 
	 
	 	 	 	 
	ARTICLE 2 PURCHASE AND SALE OF ASSETS
	 	 	1	 
	 
	 	 	 	 
	2.1 Purchase and Sale of Assets
	 	 	1	 
	2.2 Transition Services
	 	 	2	 
	2.3 Assignability and Consents
	 	 	2	 
	 
	 	 	 	 
	ARTICLE 3 ASSUMPTION OF ASSUMED LIABILITIES
	 	 	2	 
	 
	 	 	 	 
	ARTICLE 4 PURCHASE PRICE AND PAYMENT
	 	 	2	 
	 
	 	 	 	 
	4.1 Purchase Price
	 	 	2	 
	4.2 Royalties
	 	 	3	 
	4.3 Purchase of Product Materials
	 	 	5	 
	4.4 Payment of Sales, Use and Other Taxes
	 	 	5	 
	4.5 Allocation of Purchase Price
	 	 	5	 
	4.6 Withholding
	 	 	5	 
	 
	 	 	 	 
	ARTICLE 5 CLOSING
	 	 	6	 
	 
	 	 	 	 
	5.1 Time and Place
	 	 	6	 
	5.2 Deliveries at Closing
	 	 	6	 
	 
	 	 	 	 
	ARTICLE 6 REPRESENTATIONS AND WARRANTIES OF SELLER
	 	 	7	 
	 
	 	 	 	 
	6.1 Organization, Etc
	 	 	7	 
	6.2 Authority; Binding Nature
	 	 	7	 
	6.3 Non-Contravention; Consents
	 	 	7	 
	6.4 Purchased Assets
	 	 	8	 
	6.5 Title to Purchased Assets
	 	 	8	 
	6.6 Assumed Contracts
	 	 	8	 
	6.7 Intellectual Property Rights
	 	 	8	 
	6.8 Litigation
	 	 	9	 
	6.9 Permits; No Debarment
	 	 	9	 
	6.10 Product Materials.
	 	 	10	 
	6.11 Product Data
	 	 	10	 
	6.12 Brokers
	 	 	10	 
	6.13 Taxes.
	 	 	10	 
	6.14 No Other Representations
	 	 	11	 
	 
	 	 	 	 
	ARTICLE 7 REPRESENTATIONS AND WARRANTIES OF BUYER
	 	 	11	 
	 
	 	 	 	 
	7.1 Organization, Etc
	 	 	11	 
	7.2 Authority; Binding Nature of Agreement
	 	 	11	 
	7.3 Non-Contravention; Consents
	 	 	11	 
	7.4 Litigation
	 	 	11	 
	7.5 Brokers
	 	 	12	 
	 
	 	 	 	 
	ARTICLE 8 COVENANTS OF THE PARTIES
	 	 	12	 
	 
	 	 	 	 
	8.1 Public Announcements
	 	 	12	 

i

 

	 	 	 	 	 
	 	 	Page
	8.2 Corporate Names
	 	 	12	 
	8.3 Regulatory Matters
	 	 	12	 
	8.4 Adverse Experience Reports
	 	 	12	 
	8.5 Affiliates
	 	 	13	 
	8.6 Access
	 	 	13	 
	8.7 Additional Seller Covenants
	 	 	13	 
	8.8 Further Assurances
	 	 	14	 
	8.9 Diligence
	 	 	14	 
	8.10 Tax Matters
	 	 	15	 
	 
	 	 	 	 
	ARTICLE 9 INDEMNIFICATION
	 	 	16	 
	 
	 	 	 	 
	9.1 Survival of Representations, Warranties, Etc
	 	 	16	 
	9.2 Indemnification
	 	 	16	 
	9.3 Limitations
	 	 	19	 
	9.4 Consequential Damages
	 	 	20	 
	 
	 	 	 	 
	ARTICLE 10 MISCELLANEOUS
	 	 	20	 
	 
	 	 	 	 
	10.1 Confidentiality
	 	 	20	 
	10.2 Notices
	 	 	21	 
	10.3 Entire Agreement
	 	 	22	 
	10.4 Waiver
	 	 	22	 
	10.5 Amendment
	 	 	22	 
	10.6 Third Party Beneficiaries
	 	 	22	 
	10.7 Assignment; Binding Effect
	 	 	22	 
	10.8 Headings
	 	 	22	 
	10.9 Severability
	 	 	22	 
	10.10 Governing Law; Dispute Resolution
	 	 	23	 
	10.11 Expenses
	 	 	23	 
	10.12 Counterparts
	 	 	23	 
	10.13 Schedules, Exhibits and Other Agreements
	 	 	23	 

ii

 

ASSET PURCHASE AGREEMENT

     This Asset Purchase Agreement (this “Agreement”) is made and entered into as of
August 25, 2010, by and between Cypress Bioscience, Inc., a Delaware corporation (“Buyer”),
and Marina Biotech, Inc., a Delaware corporation (“Seller”).

RECITAL

     WHEREAS, subject to the terms and conditions of this Agreement, Seller desires to sell to
Buyer, and Buyer desires to purchase from Seller, the Purchased Assets (as defined below).

AGREEMENT

     NOW, THEREFORE, in consideration of the premises and the mutual covenants and promises
contained herein, and for other good and valuable consideration, the receipt and sufficiency of
which hereby are acknowledged, the Parties agree as follows:

ARTICLE 1

DEFINITIONS

     1.1 Defined Terms. Certain capitalized terms used in this Agreement are defined in
Exhibit A attached hereto.

     1.2 Construction of Certain Terms and Phrases. Unless the context of this Agreement otherwise
requires: (a) words of any gender include each other gender; (b) words using the singular or
plural number also include the plural or singular number, respectively; (c) the terms “hereof,”
“herein,” “hereby” and derivative or similar words refer to this entire Agreement; (d) the terms
“Article,” “Section” or “Exhibit” refer to the specified Article, Section or Exhibit of this
Agreement; (e) the term “or” has, except where otherwise indicated, the inclusive meaning
represented by the phrase, “and/or”; and (f) the term “including” means “including without
limitation.” Whenever this Agreement refers to a number of days, such number shall refer to
calendar days unless Business Days are specified. All accounting terms used but not otherwise
defined herein shall have the meanings ascribed to such terms under U.S. Generally Accepted
Accounting Principles, consistently applied.

ARTICLE 2

PURCHASE AND SALE OF ASSETS

     2.1 Purchase and Sale of Assets.

          (a) Subject to the terms and conditions of this Agreement, at the Closing, Seller shall sell,
transfer, convey, assign and deliver to Buyer, free and clear of all Encumbrances, and Buyer shall
purchase, acquire and accept from Seller, all right, title and interest, as of the Closing, in and
to the Purchased Assets.

          (b) Notwithstanding anything contained in this Agreement to the contrary, (i) from and after
the Closing, Seller shall retain all of its right, title and interest in and to the Excluded
Assets, and
(ii) Seller may retain an archival copy of all Assumed Contracts, Books and Records (excluding
any financial data relating to the Purchased Assets and the Business), and Product Data (subject to
Seller’s confidentiality obligations pursuant to Section 10.1 hereof).

1

 

     2.2 Transition Services. For three (3) months following the Closing, Seller shall provide to
Buyer, at no additional cost to Buyer, up to an aggregate of [...***...] of consulting services, such consulting services to be provided by [...***...]and [...***...]
following the Closing. The services shall be provided upon the reasonable request of Buyer during
normal business hours.

     2.3 Assignability and Consents. Notwithstanding anything to the contrary contained in this
Agreement, if the sale, assignment, transfer, conveyance or delivery or attempted sale, assignment,
transfer, conveyance or delivery to Buyer of any asset that would be a Purchased Asset is (a)
prohibited by any applicable Law or (b) would require any consents, waivers, approvals,
authorizations of or notices to a third Person or Governmental or Regulatory Authority and such
consents, waivers, approvals, authorizations or notices shall not have been obtained prior to the
Closing, then in either case the Closing shall proceed without the sale, assignment, transfer,
conveyance or delivery of such asset and this Agreement shall not constitute an agreement for the
sale, assignment, transfer, conveyance or delivery of such asset; provided that nothing in this
Section 2.3 shall be deemed to waive the rights of Buyer not to consummate the transactions
contemplated by this Agreement if the conditions to its obligations set forth in Article 10 have
not been satisfied. In the event that the Closing proceeds without the sale, assignment, transfer,
conveyance or delivery of any such asset, then following the Closing, the Parties shall use their
commercially reasonable efforts, and cooperate with each other, to obtain promptly such consents,
waivers, approvals, authorizations or notices. Pending such consents, waivers, approvals,
authorizations or notices, the Parties shall cooperate with each other in any mutually agreeable,
reasonable and lawful arrangements designed to provide to Buyer the benefits of use of such asset
and to Seller the benefits, including any indemnities, that, in each case, it would have obtained
had the asset been conveyed to Buyer at the Closing. Once consent, waiver, approval, authorization
or notice for the sale, assignment, transfer, conveyance or delivery of any such asset not sold,
assigned, transferred, conveyed or delivered at the Closing is obtained or given, Seller shall
assign, transfer, convey and deliver such asset to Buyer at no additional cost to Buyer.

ARTICLE 3

ASSUMPTION OF ASSUMED LIABILITIES

     Subject to the terms and conditions of this Agreement, as of the Closing Date, Buyer will
deliver the Assignment and Assumption Agreement to Seller pursuant to which Buyer agrees to assume,
satisfy, perform, pay, discharge and otherwise be responsible for the Assumed Liabilities subject
to and in accordance with their respective terms and conditions. Except with respect to the
Assumed Liabilities, Buyer shall not assume and shall not in any way be responsible for any of the
debts, liabilities, or obligations of Seller.

ARTICLE 4

PURCHASE PRICE AND PAYMENT

     4.1 Purchase Price. As consideration for the Purchased Assets and Seller’s full and faithful
performance of all of its obligations hereunder, Buyer shall:

          (a) pay to Seller at the Closing in cash by wire transfer of immediately available funds a
payment of Seven Hundred Fifty Thousand U.S. Dollars (U.S.$750,000);

 

			
	***	 	Confidential Treatment Requested

2

 

          (b) pay to Seller on the First Milestone in cash by wire transfer of immediately available
funds a payment of [...***...];

          (c) pay to Seller on the Second Milestone in cash by wire transfer of immediately available
funds a payment of [...***...];

          (d) if and only if the payment for the Second Milestone had not been made, pay to Seller on
the Third Milestone in cash by wire transfer of immediately available funds a payment of [...***...];

          (e) pay to Seller on the Fourth Milestone in cash by wire transfer of immediately available
funds a payment of [...***...];

          (f) if any only if the payment for the Fourth Milestone has not been made, pay to Seller on
the Fifth Milestone in cash by wire transfer of immediately available funds a payment of [...***...];

          (g) pay to Seller any Royalties due pursuant to Section 4.2(a) (with the payments made under
Sections 4.1(a), (b), (c), (d), (e), (f) and (g) the “Purchase Price”); and

          (h) at the Closing, assume the Assumed Liabilities pursuant to the Assignment and Assumption
Agreement.

     For purposes of this Section 4.1: (v) “First Milestone” means [...***...]; (w) “Second
Milestone” means [...***...]; (x) “Third Milestone” means [...***...]; (y) “Fourth
Milestone” means [...***...]; and (z) “Fifth Milestone” means [...***...]. For clarity, Buyer
shall never have to pay both the Second and the Third Milestones or both the Fourth and the Fifth
Milestones as the payment of the Third Milestone and the Fifth Milestone are only due if [...***...].

     4.2 Royalties.

          (a) In addition to the payment of the Purchase Price, Buyer shall pay to Seller a running
royalty at the rate of [...***...] of Net Sales (the “Royalties”) during the Royalty Term (as
defined below).

          (b) The royalty payment obligation under Section 4.2(a) shall apply, on a country-by-country
and Product-by-Product basis in the Territory, during the period of time beginning upon the
First Commercial Sale of such Product in such country, and ending upon the earlier of: (i) the
expiration of the last-to-expire Valid Claim of a Patent in the Intellectual Property covering the
use, import, manufacture, sale or offer for sale of such Product in such country; and (ii) the date
on which the first sale of a Generic Product takes place in such country (such period, the
“Royalty Term”).

          (c) (i) If it is necessary for Buyer or its licensee to obtain a license to know-how or
patents from any Third Party that claim or cover the composition of matter, manufacture, use,
handling, storage, sale or other disposition of a particular Product in a particular country in the
Territory in order for Buyer or its licensee to develop, manufacture or commercialize such Product
in such country in the Territory and Buyer or its licensee pays such Third Party any up-front fee,
milestone, royalty, or other payment in consideration of obtaining such license (each, a “Third
Party Payment”), then (subject to clause (iii) of this paragraph (c)) Buyer shall have the
right to deduct from milestone payments due Seller as part of

 

			
	***	 	Confidential Treatment Requested

3

 

the Purchase Price under Section 4.1
and royalty payments due Seller for Net Sales of such Product in such country under Section 4.2(a),
[...***...] of any such Third Party Payments made by Buyer.

               (ii) If Buyer or its licensee incurs costs in connection with an interference declared with
regard to a Patent included in the Intellectual Property, including any settlement or attorneys’
fees related thereto (“Third Party Interference Costs”), then (subject to clause (iii) of
this paragraph (c)) Buyer shall have the right to deduct from milestone payments due Seller as part
of the Purchase Price under Section 4.1 and royalty payments due Seller for Net Sales of such
Product under Section 4.2(a), [...***...] of any such Third Party Interference Costs paid by Buyer;
provided, however, that the aggregate amount of Third Party Interference Costs
which may be deducted pursuant to this clause (ii) shall not exceed [...***...].

               (iii) Notwithstanding the provisions of clauses (i) and (ii) of this paragraph (c), in no
event shall the permitted deductions cause either (A) any milestone payment or (B) any royalty
amount payable to Seller for Net Sales in any particular country in any particular calendar quarter
to be reduced by more than [...***...] of the milestone payment that would otherwise be payable to
Seller or the royalty amounts that would otherwise be payable for Net Sales in such country in such
period; provided, however, that (subject to the limitations of this clause (iii))
Buyer may deduct from future milestone payments and from royalty payments for Net Sales in such
country in future calendar quarters any amounts that it was previously unable to deduct due to such
limitations.

          (d) During the Royalty Term, within [...***...] days after the end of each calendar quarter, Buyer
shall deliver to Seller a report containing the following information for the prior calendar
quarter: (i) the gross sales associated with each Product sold by Buyer and its Affiliates or
licensees; (ii) a calculation of Net Sales of each Products that are sold by Buyer, its Affiliates
and (if applicable) its licensees; and (iii) a calculation of payments due to Seller with respect
to the foregoing. Concurrent with these reports, Buyer shall remit to Seller any royalty payment
due for the applicable calendar quarter. If no royalties are due to Seller for such reporting
period, the report shall so state.

          (e) Net Sales made in currencies other than dollars will be converted into dollars using the
closing exchange rates reported in The Wall Street Journal (U.S., Western Edition) on the last
business day of the applicable calendar quarter.

          (f) All payments due hereunder shall be made by wire transfer of immediately available funds
into an account designated by Seller.

          (g) Buyer will maintain complete and accurate records in sufficient detail to permit Seller to
confirm the accuracy of the calculation of payments under this Agreement. Upon reasonable prior
notice, such records shall be available during regular business hours for a period of three (3)
years from the end of the calendar year to which they pertain for examination at the expense of
Seller, and not more often than once each calendar year, by an independent certified public
accountant (“Independent Accountant”) selected by Seller and reasonably acceptable to
Buyer, for the sole purpose of verifying the accuracy of the financial reports or payments
furnished by Buyer pursuant to this Agreement. Any such auditor shall not disclose to Seller
Buyer’s Confidential Information. Any amounts shown to be owed but unpaid shall be paid within
thirty (30) days from the date of delivery of the accountant’s report. Seller shall bear the full
cost of such audit unless such audit discloses an underpayment by Buyer of more than five percent
(5%) of the amount due, in which case Buyer shall bear the full cost of such audit.

 

			
	***	 	Confidential Treatment Requested

4

 

     4.3 Purchase of Product Materials. On the Closing Date, Buyer shall take title to all Product
Materials.

     4.4 Payment of Sales, Use and Other Taxes. Seller shall be responsible for all sales, use,
transfer, value added, documentary and other related Taxes, if any, arising out of the sale of the
Purchased Assets to Buyer pursuant to this Agreement (including Taxes on Seller’s income)
(collectively, the “Transaction Taxes”). Buyer and Seller agree to cooperate to determine
the amount of any Transaction Taxes payable in connection with the transfer of the Purchased Assets
under this Agreement. Buyer and Seller agree to assist each other, to the extent reasonably
necessary and appropriate, in the preparation and filing of any and all required Tax Returns
related to Transaction Taxes. Buyer hereby waives compliance by Seller with the provisions of the
bulk transfer laws of any state.

     4.5 Allocation of Purchase Price.

          (a) The Purchase Price (plus Assumed Liabilities, to the extent properly taken into account
under the Code), shall be allocated among the Purchased Assets in accordance with Section 1060 of
the Code and the Treasury regulations promulgated thereunder (and any similar provision of state,
local or foreign law, as appropriate) (the “Allocation”). The Allocation shall be
delivered by Purchaser to Seller within sixty (60) days after the Closing Date. Seller and Buyer
shall work in good faith to resolve any disputes relating to the Allocation within twenty (20)
days. If Seller and Buyer are unable to amicably resolve any such dispute, such dispute shall be
resolved promptly by an Independent Accountant agreed upon by the parties, such agreement not to be
unreasonably withheld or delayed, the costs of which shall be borne equally by Seller and
Purchaser.

          (b) If the Purchase Price is adjusted pursuant to Sections 4.1, 4.2 or 8.10 or Article 9, the
Allocation shall be adjusted in a manner consistent with Section 1060 of the Code. However, if the
Parties are unable to amicably agree on such adjustment, such dispute shall be resolved promptly by
an Independent Accountant agreed upon by the parties, such agreement not to be unreasonably
withheld or delayed, the costs of which shall be borne equally by Buyer and Seller.

          (c) Buyer and Seller agree (i) to report the sale of the Purchased Assets for federal and
state Tax purposes in accordance with the Allocation and (ii) not to take any position inconsistent
with such Allocation on any of their respective Tax Returns.

     4.6 Withholding. Buyer shall be entitled to deduct and withhold from the consideration
otherwise payable pursuant to this Agreement such amounts as Buyer is required to deduct and
withhold
under the Code, or any Tax law, with respect to the making of such payment, provided that (x)
such amount is promptly paid for and on behalf of Seller to the appropriate tax authorities and (y)
Buyer furnishes Seller with official tax receipts or other appropriate evidence of payment issued
by the appropriate tax authorities. To the extent that amounts are so withheld and paid, such
withheld amounts shall be treated for all purposes of this Agreement as having been paid to Seller.

5

 

ARTICLE 5

CLOSING

     5.1 Time and Place. The closing of the transactions contemplated by this Agreement, including
the purchase and sale of the Purchased Assets and the assumption of the Assumed Liabilities (the
“Closing”), shall take place on the date hereof at the offices of Latham & Watkins LLP,
12636 High Bluff Drive, Suite 400, San Diego, CA 92130 unless another time or place shall be agreed
to by the Parties.

     5.2 Deliveries at Closing.

          (a) Closing Deliveries by Seller.

     At the Closing, Seller shall deliver or cause to be delivered to Buyer:

          (i) a certified copy of the Certificate of Incorporation of Seller;

          (ii) a certificate, executed by an executive officer of Seller, attaching a certified copy
of the resolutions of the Board of Directors of Seller approving the transactions contemplated
hereby; and

          (iii) an intellectual property assignment, substantially in the form of Exhibit B
hereto, assigning to Buyer all right, title and interest of Seller in the Intellectual Property
(the “Intellectual Property Assignment Agreement”);

          (iv) an assignment and assumption agreement, substantially in the form of Exhibit
C hereto, pursuant to which Buyer agrees to assume, satisfy, perform, pay, discharge and
otherwise be responsible for the Assumed Liabilities (the “Assignment and Assumption
Agreement”); and

          (v) a bill of sale, substantially in the form of Exhibit D hereto, transferring
all rights of Seller in and to the Purchased Assets, including the Assumed Contracts, to Buyer
(the “Bill of Sale”);

          (vi) such instruments of assignment and other instruments or documents, in form and
substance reasonably acceptable to Seller and Buyer, as may be reasonably necessary to effect
Seller’s assignment to Buyer of all rights of Seller in and to the Purchased Assets, including
the Assumed Contracts, in accordance with the terms of this Agreement and the Bill of Sale; and

          (vii) completed and executed copies of the documents referred to in Section 8.10(d).

          (b) Closing Deliveries by Buyer.

     At the Closing, Buyer shall deliver or cause to be delivered to Seller:

          (i) the Intellectual Property Assignment Agreement;

          (ii) the Assignment and Assumption Agreement;

          (iii) the Bill of Sale;

6

 

          (iv) such instruments of assumption and other instruments or documents, in form and
substance reasonably acceptable to Seller and Buyer, as may be reasonably necessary to effect
Buyer’s assumption of the Assumed Liabilities in accordance with the terms of this Agreement
and the Assignment and Assumption Agreement; and

          (v) a certificate, executed by an executive officer of Buyer, attaching a certified copy
of the resolutions of the Board of Directors of Buyer approving the transactions contemplated.

ARTICLE 6

REPRESENTATIONS AND WARRANTIES OF SELLER

     Seller represents and warrants to Buyer as of the date hereof, subject to such exceptions as
are specifically disclosed in the disclosure schedule referencing the appropriate Section or
Sections hereof as shall be supplied by Seller to Buyer and dated as of the date hereof (the
“Seller Disclosure Schedule”), as follows:

     6.1 Organization, Etc.

     Seller is a corporation duly incorporated, validly existing and in good standing under the
laws of the State of Delaware, and has all requisite corporate power and authority (a) to conduct
the Business in the manner in which it is currently being conducted, and (b) to own and use the
Purchased Assets in the manner in which such assets are currently owned and used. Seller does not
have any subsidiaries, direct or indirect, which own or control or otherwise have any rights with
respect to the Purchased Assets.

     6.2 Authority; Binding Nature. Seller has all necessary power and authority and has taken all
actions necessary to enter into this Agreement and the other Transaction Documents and to carry out
the transactions and perform the obligations contemplated hereby. Each of this Agreement and the
other Transaction Documents to which Buyer is a party has been duly and validly authorized,
executed and delivered by Seller and, when executed and delivered by Buyer, will constitute a
legal, valid and binding obligation of Seller enforceable against it in accordance with its terms
except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other
laws of general application affecting enforcement of creditors rights generally, and (b) as limited
by laws relating to the availability of specific performance, injunctive relief or other equitable
remedies.

     6.3 Non-Contravention; Consents.
The execution, delivery and performance of this Agreement and each of the other Transaction
Documents and the sale of the Purchased Assets to Buyer do not and will not contravene, conflict
with or result in a violation of any (a) Laws applicable to the Purchased Assets, any Assumed
Contract or the Business; (b) any provision of any Assumed Contract; (c) any of the provisions of
Seller’s organizational documents or any resolution adopted by Seller’s Board of Directors (or any
committee thereof) or stockholders; or (d) any material agreement or other material instrument or
arrangement to which Seller is subject. No consent, order, authorization, approval, declaration or
filing, including with or from the stockholders of Seller or with or from any Governmental or
Regulatory Authority, is required on the part of Seller for or in connection with the execution,
delivery or performance of this Agreement and each of the other Transaction Documents, and the
purchase by Buyer of the Purchased Assets.

7

 

     6.4 Purchased Assets. The Purchased Assets collectively constitute all of the properties,
rights, interests and other tangible and intangible assets owned by Seller and used by Seller
exclusively to conduct the Business.

     6.5 Title to Purchased Assets. Seller has good and marketable title to all of the Purchased
Assets, including the Product Materials, free and clear of all Encumbrances, and Seller has not
received any written notice of any adverse claim asserting ownership of any Purchased Asset. The
execution, delivery and performance by Seller of this Agreement and the sale of the Purchased
Assets to Buyer will not result in the imposition of any Encumbrance on the Purchased Assets.

     6.6 Assumed Contracts.

          (a) Section 6.6 of the Seller Disclosure Schedule sets forth a complete and correct list of
each Contract to which Seller is a party that relates exclusively to Purchased Assets.

          (b) (i) Seller is not presently in violation or breach of, and has not declared or committed
any default under and, to the Knowledge of Seller, no Person is presently in violation or breach
of, or has declared or committed any default under, any Assumed Contract, (ii) Seller has not
received any written notice regarding any breach of, or default under, any Assumed Contract,
(iii) no event has occurred, and no circumstance or condition exists (including the Closing of
the transactions contemplated by this Agreement), that would give any Person the right to cancel,
terminate or modify any Assumed Contract, and (iv) each Assumed Contract sets forth the entire
agreement and understanding between Seller and the other parties thereto and is valid, binding
and in full force and effect. Seller has made available to Buyer complete and correct copies of
all Assumed Contracts.

     6.7 Intellectual Property Rights.

          (a) Section 6.7(a) of the Seller Disclosure Schedule sets forth a complete and correct list of
all Registered Intellectual Property.

          (b) Seller owns good and marketable title in and to all of the Intellectual Property
(including the Registered Intellectual Property and other Intellectual Property set forth on
Section 6.7(a) of the Seller Disclosure Schedule), free and clear of all Encumbrances other than
Permitted Encumbrances.

          (c) All documents and instruments necessary to perfect the rights of Seller in the Patents
included in the Intellectual Property have been validly executed, delivered or filed in a timely
manner with the appropriate Governmental or Regulatory Authorities.

          (d) Except as set forth on Section 6.7(d) of the Seller Disclosure Schedule, Seller has
disclosed trade secrets of Seller included in the Intellectual Property only to Persons that have
executed written confidentiality agreements governing the use and disclosure of such trade secrets,
except to the extent Seller was required to disclose such information in connection with making
filings related to any Purchased Assets with Governmental or Regulatory Authorities.

          (e) The Intellectual Property constitutes all patents, patent applications and technology,
know-how, information and other intellectual property rights owned or licensed to Seller relating
exclusively to the Business, the manufacture of the Compound or the Product or the use or sale of
the Product.

          (f) No interest in any of the Intellectual Property has been assigned, transferred, licensed
or sublicensed by Seller to any Person, nor has Seller agreed not to assert, or to permit the

8

 

assertion of, any Intellectual Property against any Person. Seller has not executed or granted to
any third party, directly or indirectly, or entered into any agreement for, any license or other
right to make, use, offer to sell, sell or import the Compound or a Product or otherwise to conduct
the Business.

          (g) None of the Intellectual Property is (nor to Seller’s Knowledge is any of the Intellectual
Property likely to become) subject to any outstanding and final order, judgment, decree or
stipulation from a Government or Regulatory Authority having jurisdiction over Seller restricting
the use thereof by Seller with respect to the Business or restricting the licensing thereof by
Seller to any Person.

          (h) No interference, opposition, reissue, reexamination or other Action or Proceeding of any
nature is pending or, to Seller’s knowledge, threatened in writing in which the scope, validity or
enforceability of any of the Patents within the Intellectual Property is being, has been or could
reasonably be expected to be contested or challenged.

          (i) Seller has not made any claim of any violation or infringement by others of its rights in
the Intellectual Property, and, to Seller’s knowledge, no grounds for any such claims exist.
Seller has not received any notice nor does it believe that it is in conflict with or infringing
upon the asserted rights of others in connection with the Intellectual Property and, to Seller’s
Knowledge, the use of the Intellectual Property by Seller is not infringing and has not infringed
upon any rights of any other Person.

          (j) To the extent any Intellectual Property or any component thereof was created in whole or
in part by or on behalf of Seller, each Person who contributed to the creation of such Intellectual
Property has irrevocably assigned to Seller in writing all intellectual property or other ownership
rights in such Person’s contribution to such Intellectual Property or component thereof, and such
Person has waived all moral rights in such Person’s contribution to such Intellectual Property or
component thereof. Seller has provided to Buyer true, correct and complete copies of all such
assignments.

     6.8 Litigation. There are no pending Actions or Proceedings and no Person has threatened in
writing to commence any Action or Proceeding, (a) that involves the Purchased Assets; or (b) that
challenges, or that may have the effect of preventing, delaying, making illegal or otherwise
interfering with, the transactions contemplated by this Agreement. There are, and there have been,
no claims made in writing against Seller alleging any material defects in the Product, the Compound
or the Product Materials or alleging any failure of the Product, the Compound or the Product
Materials to meet specifications.

     6.9 Permits; No Debarment.

          (a) No license, franchise, permit or other similar authorization (each, a “Permit”) is
necessary for the conduct of research using the Purchased Assets. No event has occurred, and
Seller has not received any notice in writing from any Governmental or Regulatory Authority or
otherwise of that any such Permit is required.

          (b) Seller has not made any Regulatory Filings with respect to the Compound or any Product.

          (c) Seller represents and warrants that Seller is not debarred and has not used in any
capacity relating to the Purchased Assets the services of any Person debarred under subsections
306(a) or (b) of the Generic Drug Enforcement Act of 1992.

9

 

     6.10 Product Materials.

          (a) Section 6.10 of the Seller Disclosure Schedule lists (i) the lot numbers associated with
the Compound included in the Product Materials and (ii) the locations where all Product Materials
are located. Seller will deliver all Product Materials to Buyer within seven (7) Business Days
after the Closing. Seller represents and warrants that the Product Materials manufactured by or
for Seller that will be provided to Buyer hereunder were at the time of creation collected or
manufactured, packaged and stored in compliance with all relevant, applicable Laws, including those
governing clinical biopharmaceutical supplies.

          (b) The Product Materials represent all raw materials, Compound and finished goods directly
related to the Product that are currently owned and on hand or in the control of Seller at any of
its warehouses, blenders, toll manufacturers, suppliers, or other third parties.

     6.11 Product Data. Seller represents and warrants that the Product Data constitutes all of
the information, including all manufacturing information in Seller’s tangible possession as of the
Closing that was generated and/or used by Seller or any of Seller’s Affiliates exclusively in
connection with the development and/or manufacture of the Compound or the Product by Seller or any
such Affiliate.

     6.12 Brokers. Seller has not retained any broker in connection with the transactions
contemplated hereunder. Buyer has no, and will have no, obligation to pay any brokers, finders,
investment bankers, financial advisors or similar fees in connection with this Agreement or the
transactions contemplated hereby by reason of any action taken by or on behalf of Seller.

     6.13 Taxes.

          (a) Seller has duly and timely filed with the appropriate Tax authorities all Tax Returns
required to be filed with respect to the Purchased Assets. All such Tax Returns are complete and
accurate in all material respects. All Taxes due and owing with respect to the Purchased Assets
(whether or not shown on any Tax Returns) have been paid or reserved for.

          (b) No deficiencies for Taxes with respect to the Purchased Assets have been claimed, proposed
or assessed by any Tax authority or other Governmental Authority. There are no
pending or, to the Knowledge of Seller, threatened audits, assessments or other actions for or
relating to any Liability in respect of Taxes with respect to the Purchased Assets. There are no
matters under discussion with any Tax authority, or known to Seller, with respect to Taxes that
could result in an additional Liability for Taxes with respect to the Purchased Assets.

          (c) There are no Encumbrances for Taxes on the Purchased Assets (other than for current Taxes
not yet due and payable).

          (d) There are no Tax sharing agreements or similar arrangements (including indemnity
arrangements) with respect to or involving the Purchased Assets.

          (e) No Purchased Assets (i) is property required to be treated as owned by another person
pursuant to the provisions of Section 168(f)(8) of the Internal Revenue Code of 1954, as amended
and in effect immediately prior to the enactment of the Tax Reform Act of 1986, (ii) constitutes
“tax-exempt use property” within the meaning of Section 168(h) of the Code, (iii) is “tax-exempt
bond financed property” within the meaning of Section 168(g) of the Code, (iv) secures any debt the
interest of which is tax-exempt under Section 103(a) of the Code or (v) is subject to a 467 rental
agreement as defined in Section 467 of the Code.

10

 

          (f) No part of the Purchase Price payable hereunder will be considered an amount received from
the sale or exchange of a United States real property interest subject to Section 897(a) of the
Code.

     6.14 No Other Representations.

     SELLER MAKES NO REPRESENTATION OR WARRANTY OTHER THAN AS SET FORTH IN THIS AGREEMENT AS TO THE
COMPOUND, THE PRODUCT, THE PURCHASED ASSETS (INCLUDING, BUT NOT LIMITED TO, THE PRODUCT MATERIALS)
OR THE BUSINESS, WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR
A PARTICULAR PURPOSE, OR INFRINGEMENT OF THIRD PARTY RIGHTS, AND ALL SUCH WARRANTIES ARE EXPRESSLY
DISCLAIMED.

ARTICLE 7

REPRESENTATIONS AND WARRANTIES OF BUYER

     Buyer represents and warrants to Seller as of the date hereof as follows, subject to such
exceptions as either (a) are specifically disclosed in the disclosure schedule referencing the
appropriate Sections hereof supplied by Buyer to Seller and dated as of the date hereof (the
“Buyer Disclosure Schedule”) or (b) as to Sections 7.1, 7.2, 7.4 and 7.5 only, are
disclosed in the SEC Reports:

     7.1 Organization, Etc.Buyer is a corporation duly incorporated, validly existing and in good
standing under the laws of the State of Delaware, and has all requisite corporate power and
authority (a) to conduct its business in the manner in which it is currently being conducted, and
(b) to own and use its assets in the manner in which its assets are currently owned and used.

     7.2 Authority; Binding Nature of Agreement.
Buyer has all necessary power and authority and has taken all actions necessary to enter into
this Agreement and the other Transaction Documents and to carry out the transactions and perform
the obligations contemplated hereby. Each of this Agreement and the other Transaction Documents
has been duly and validly authorized, executed and delivered by Buyer and, when executed and
delivered by Seller, will constitute a legal, valid and binding obligation of Buyer enforceable
against it in accordance with its respective terms except (a) as limited by applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application affecting enforcement
of creditors rights generally, and (b) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies.

     7.3 Non-Contravention; Consents. The execution, delivery and performance of this Agreement
and each of the other Transaction Documents and the purchase of the Purchased Assets by Buyer do
not and will not contravene, conflict with or result in a violation of any (a) Laws to which Buyer
or any of the assets owned or used by Buyer is subject, (b) any of the provisions of Buyer’s
organizational documents or any resolution adopted by Buyer’s Board of Directors (or any committee
thereof) or stockholders or (c) any material agreement or other instrument or arrangement to which
Buyer is subject. No consent, order, authorization, approval, declaration or filing, including
with or to any Governmental or Regulatory Authority, is required on the part of Buyer for or in
connection with the execution, delivery or performance of this Agreement and each of the other
Transaction Documents, and the purchase by Buyer of the Purchased Assets.

     7.4 Litigation. There are no pending Actions or Proceedings, and to the Knowledge of Buyer,
no Person has threatened to commence any Action or Proceeding, (a) that involves Buyer and that has
an

11

 

Adverse Effect; or (b) that challenges, or has the effect of preventing, delaying, making
illegal or otherwise interfering with, the transactions contemplated by this Agreement.

     7.5 Brokers. Buyer has not retained any broker in connection with the transactions
contemplated hereunder. Seller has no, and will have no, obligation to pay any brokers, finders,
investment bankers, financial advisors or similar fees in connection with this Agreement or the
transactions contemplated hereby by reason of any action taken by or on behalf of Buyer.

ARTICLE 8

COVENANTS OF THE PARTIES

     8.1 Public Announcements. Neither Seller, Buyer nor any of their respective Affiliates shall
issue any press release or make any public announcement with respect to this Agreement and the
transactions contemplated hereby without obtaining the prior written consent of the other Party,
which consent shall not be unreasonably withheld, except as may be required by applicable Law upon
the advice of counsel and only if the disclosing Party provides the non-disclosing Party with an
opportunity to first review the release or other public announcement. Following the Closing, Buyer
shall be entitled to make such public announcements as it deems appropriate related to the Product
and the Compound; provided, that, without Seller’s prior written consent, no such announcement
shall contain any reference to Seller or actions taken with respect to the Product or Compound
prior to the Closing Date other than as previously approved by Seller. For clarity, in addition to the provisions of Section 10.1, the foregoing shall not
restrict in any way the making of any filing or disclosure by either Party with respect to this
Agreement or the transactions contemplated hereby if required by any federal or state securities
law or other law upon advice of counsel.

     8.2 Corporate Names.

          (a) Following the Closing, Buyer shall not have any rights by virtue of this Agreement or any
of the transactions or agreements contemplated hereby to any names, trademarks, trade names, trade
dress or logos relating to Seller or any of the Affiliates of Seller or any of their products other
than those included in the Purchased Assets.

          (b) Following the Closing, Seller shall not have any right to use any names, trademarks, trade
names, trade dress or logos included within the Purchased Assets.

     8.3 Regulatory Matters. From and after the Closing, Buyer, at its sole cost and expense,
shall be solely responsible and liable for taking all actions, paying all fees and conducting all
communication with the appropriate Governmental or Regulatory Authority required by Law in respect
of any Regulatory Filing, including preparing and filing all reports (including adverse drug
experience reports) with the appropriate Governmental or Regulatory Authority.

     8.4 Adverse Experience Reports. Seller shall promptly submit to Buyer all adverse drug
experience information brought to the attention of Seller in respect of the Compound or the
Product, as well as any material events and matters concerning or affecting the safety or efficacy
of the Compound or the Product, each as they relate to activities of Seller prior to the Closing
but which are received or as to which Seller becomes aware following the Closing. After the
Closing, Buyer shall have all responsibility for required reporting of adverse experiences for the
Compound and the Product, but such reporting shall not limit Seller’s obligation for any actions
necessary with respect to Products distributed prior to the Closing based upon the facts and
circumstances contained in such adverse drug experience information.

12

 

     8.5 Affiliates. Each Party hereto shall cause its respective Affiliates to comply with the
terms of this Agreement.

     8.6 Access. Following the Closing and for a period of not less than five (5) years, Seller
will maintain and grant Buyer and its legal, accounting and other advisors access, upon reasonable
notice and during normal business hours, to any corporate records, Tax records, contracts and other
documents of Seller that are related to the Business as are reasonably required for Buyer to
complete any required Tax filings with any Governmental or Regulatory Authority.

     8.7 Additional Seller Covenants.

     (a) Section 8.7(a) of the Seller Disclosure Schedule lists all of the patents and patent
applications developed in Seller’s nasal delivery technology program which claim formulations
consisting of a particular active pharmaceutical ingredient (“API”) or class of APIs
together with excipients (the “Nasal Formulation Patents”). In furtherance of its
undertaking to amend as promptly as practicable any
patent or patent application included in the Non-Assert IP in order to remove all Carbetocin
Claims (as such terms are defined below), Seller hereby perpetually covenants, warrants and agrees
that it will not (and will cause its Affiliates, successors, and assigns not to) commence or pursue
any action or proceeding claiming infringement of a Nasal Formulation Patent based on the
manufacture, use, development, sale, offer for sale, import or other commercialization by Purchaser
or any of its Affiliates or licensees, successors or assigns of either (A) the Compound or (B) a
Product which is a formulation consisting solely of the Compound as the API together with
excipients.

          (b) Subject to paragraph (c) of this Section 8.7, Seller hereby covenants, warrants and agrees
that, for a period of ten (10) years following the Closing Date:

               (i) it will not (and will cause its Affiliates, successors and assigns not to) pursue the
prosecution of any claims in the Non-Assert IP which are specifically directed to the composition
of matter of the Compound or the development, manufacture or commercialization of the Compound or
the Product (the “Carbetocin Claims”) and will amend as promptly as practicable any patent
or patent application included in the Non-Assert IP in order to remove all Carbetocin Claims;

               (ii) it will not (and will cause its Affiliates not to) include, or pursue the prosecution of,
any claim in any patent or patent application filed after the date hereof which is a Carbetocin
Claim;

               (iii) it will not (and will cause its Affiliates not to) directly or indirectly, individually
or as a partner or other owner or participant in any business entity or joint venture, for itself
or for the benefit of any unrelated third party, engage in the manufacture, use, development, sale,
offer for sale, import or other commercialization of the Compound or the Product; and

     For purposes of this Agreement, “Non-Assert IP” means all patents or applications
owned or Controlled by Seller or any of its Affiliates as of the date hereof (other than Patents
and Know-How included in the Purchased Assets).

          (c) (i) The prohibitions set forth in paragraph (b) shall not apply to any Affiliate of or
successor to Seller which becomes such an Affiliate or successor after the Closing Date as a result
of a change of control, merger, acquisition or other similar transaction (such Affiliates or
successors, hereinafter collectively, an “Acquiror”) to the extent that (A) the prohibited
patent or patent application does not derive from the Non-Assert IP or (B) the prohibited activity
by the Acquiror constitutes (1) a continuation of activities that such Acquiror was engaged in
prior to the closing of the Acquiror’s

13

 

acquisition of Seller, (2) an activity engaged in by another
Person which is acquired by the Acquiror after the Acquiror’s acquisition of Seller or (3) an
activity engaged in by Acquiror without use of or reference to the Non-Assert IP, as evidenced by
contemporaneous documentation.

               (ii) If Seller identifies or otherwise becomes aware of a potential business opportunity
related to the Compound or the Product, Seller may notify Buyer of such opportunity and, if so
notified, Buyer may pursue such opportunity or not, in its sole discretion. For clarity, Seller
shall not be permitted to pursue such business opportunity until the prohibitions set forth in
paragraph (b) of this Section 8.7 have lapsed; provided, however, that it shall not
be a violation of the prohibitions set forth in said paragraph (b) if Seller grants rights to any
unrelated third party (on such terms as Seller in its sole discretion may determine) for use of any
Seller patent, technology or know how which is not included in the Purchased Assets and which is
not specifically directed to the composition of matter of the Compound or the development,
manufacture or commercialization of the Compound or the Product.

     8.8 Further Assurances.

          (a) Following the Closing, Seller and Buyer each agree to execute and deliver such other
documents, certificates, agreements and other writings and to take such other actions as may be
necessary or desirable in order to consummate or implement expeditiously the transactions
contemplated by this Agreement and to vest in Buyer good and marketable title to the Purchased
Assets. In furtherance of the foregoing, Seller agrees that if, after the Closing, Buyer
reasonably believes that Seller holds any patents or patent applications which relate exclusively
to the Business, Buyer shall provide Seller with notice thereof, together with a written
description in reasonable detail of the basis for such belief (the “Follow-On Request”).
If Seller has no objection to the Follow-On Request, Seller shall, at its sole expense, as promptly
as practicable assign and transfer or cause to be assigned or transferred such patents or patent
applications to Buyer. If Seller objects to the Follow-On request, Seller shall promptly provide
Buyer with notice thereof, together with a written description in reasonable detail of the reasons
why Seller rejects the Follow-On Request, including, if applicable, Seller’s position that Buyer’s
belief is not reasonable (the “Rejection Notice”). If the parties cannot resolve their
dispute within thirty (30) days from the date of the Rejection Notice, either party may submit the
dispute to arbitration in accordance with Section 10.10(b). If the Rejection Notice does not
specifically assert that Buyer’s belief is not reasonable, Seller agrees that it will not (and will
cause its Affiliates not to) commence any action or proceeding alleging infringement by Buyer of
the subject matter of any Follow-On Request unless and until any dispute regarding the Follow-On
Request has been resolved by such arbitration.

          (b) Seller hereby constitutes and appoints, effective as of the Closing Date, Buyer and its
successors and assigns as the true and lawful attorney of Seller with full power of substitution in
the name of Buyer or in the name of Seller, but for the benefit of Buyer (i) to collect for the
account of Buyer any items of Purchased Assets and (ii) to institute and prosecute all proceedings
that Buyer may in its sole discretion deem proper in order to assert or enforce any right, title or
interest in, to or under the Purchased Assets, and to defend or compromise any and all actions,
suits or proceedings arising after the Closing in respect of the Purchased Assets. Buyer shall be
entitled to retain for its account any amounts collected pursuant to the foregoing powers,
including any amounts payable as interest in respect thereof.

     8.9 Diligence.

          (a) After the Closing Date, Buyer shall devote commercially reasonable efforts to develop and
market at least one (1) Product in the United States; provided that Buyer may determine in its sole
discretion to cease the development or commercialization of the Compound or the Product at any time
in which case upon request of Seller, the Parties shall use good faith diligent efforts to agree
upon reasonable terms pursuant to which Seller can reacquire the Purchased Assets. Buyer shall
provide to

14

 

Seller written updates as to its progress in such efforts within each calendar year
following the Closing Date no later than January 31 of the following calendar year.

          (b) After the Closing Date, Buyer shall devote commercially reasonable efforts to the
prosecution and maintenance of the Registered Intellectual Property and to enforce and defend such
Registered Intellectual Property.

          (c) If Seller believes that Buyer is not devoting commercially reasonable efforts as set forth
in this Section 8.9,, Seller shall so notify Buyer in writing, such notice to include Seller’s
specific concerns and recommendations. Within [...***...] days
after receipt of such notice from Seller, appropriate individuals from Buyer and Seller shall meet
to discuss Seller’s concerns and recommendations in good faith.

     8.10 Tax Matters.

          (a) Buyer and Seller agree to furnish or cause to be furnished to the other, upon request, as
promptly as practicable, such information and assistance relating to the Purchased Assets,
including access to books and records, as is reasonably necessary for the filing of all Tax Returns
by Buyer or Seller, the making of any election relating to Taxes, the preparation for any audit by
any taxing authority, and the prosecution or defense of any claim, suit or proceeding relating to
any Tax. Buyer and Seller shall cooperate fully with each other in the conduct of any audit,
litigation or other proceeding relating to Taxes involving the Purchased Assets. Buyer and Seller
further agree, upon request, to use their best efforts to obtain any certificate or other document
from any Governmental Authority or any other Person as may be necessary to mitigate, reduce or
eliminate any Tax that could be imposed (including with respect to the transactions contemplated
hereby).

          (b) Seller shall be responsible for and shall promptly pay when due all Property Taxes levied
with respect to the Purchased Assets attributable to the Pre-Closing Tax Period, and Buyer shall be
responsible for and shall promptly pay when due all Property Taxes levied with respect to the
Purchased Assets attributable to the Post-Closing Tax Period. All Property Taxes levied with
respect to the Purchased Assets for the Straddle Period shall be apportioned between the
Pre-Closing Tax Period and the Post-Closing Tax Period, as follows: the portion allocable to the
Pre-Closing Tax Period shall be deemed to be the amount of such Tax for the entire Straddle Period
multiplied by a fraction the numerator of which is the number of days from the beginning of the
Straddle Period through the Closing Date and the denominator of which is the number of days in the
entire Straddle Period. Upon receipt of any bill for such Taxes relating to the Purchased Assets,
Buyer, on one hand, and Seller, on the other hand, shall present a statement to the other setting
forth the amount of reimbursement to which each is entitled under this Section 8.10(b) together
with such supporting evidence as is reasonably necessary to calculate the proration amount. The
proration amount shall be paid by the party owing it to the other within ten (10) days after
delivery of such statement. In the event that Buyer or Seller shall make any payment for which it
is entitled to reimbursement under this Section 8.10(b), the applicable party shall make such
reimbursement promptly but in no event later than ten (10) days after the presentation of a
statement setting forth the amount of reimbursement to which the presenting party is entitled along
with such supporting evidence as is reasonably necessary to calculate the amount of reimbursement.

          (c) Seller shall promptly notify Buyer in writing upon receipt by Seller of notice of any
pending or threatened federal, state, local or foreign Tax audits or assessments relating to the
income, properties or operations of Seller that reasonably may be expected to relate to the
Purchased Assets.

 

			
	***	 	Confidential Treatment Requested

15

 

          (d) At the Closing, Seller shall deliver to the Buyer such forms and certificates, duly
executed and acknowledged, in form and substance reasonably satisfactory to Buyer, certifying that
the transactions contemplated under this Agreement are exempt from withholding under Section 1445
of the Code.

          (e) Any payments made pursuant to Sections 4.1, 4.2 or 8.10 or Article 9 shall constitute an
adjustment to the Purchase Price for Tax purposes and shall be treated as such by the parties on
their Tax Returns to the extent permitted by law.

ARTICLE 9

INDEMNIFICATION

     9.1 Survival of Representations, Warranties, Etc.

     The representations and warranties made by either Party in this Agreement shall survive the
Closing and shall expire twenty four (24) months after the Closing Date, provided that the
representations and warranties contained in Section 6.13 hereof shall expire sixty (60) days
following the expiration of any applicable Tax statute of limitation, and any Liability of either
Party with respect to such representations and warranties (other than for Damages attributable to
fraud) shall thereupon cease; provided, however, that if, at any time prior to such expiration
date, notice of any claim for indemnification pursuant to Section 9.2(a)(i) or Section 9.2(b)(i),
as the case may be, shall have been given prior to the applicable expiration date and such notice
describes the circumstances with respect to which such indemnification claim relates, such
indemnification claim shall survive until such time as such claim is finally resolved.

     9.2 Indemnification.

          (a) By Seller. Subject to Sections 9.3 and 9.4, from and after the Closing, Seller
shall indemnify, reimburse, defend and hold harmless Buyer, its Affiliates and their respective
officers, directors, employees, agents, successors and assigns (collectively, the “Buyer
Indemnified Parties”) from and against any and all costs, losses, Liabilities, damages,
lawsuits, deficiencies, claims and expenses (including interest, penalties and reasonable fees and
disbursements of attorneys paid in connection with the investigation, defense or settlement of any
of the foregoing) (collectively, the “Damages”) to the extent arising or resulting from:

          (i) any inaccuracy or breach of any representation or warranty of Seller herein;

          (ii) any breach of any covenant or other agreement of Seller or any of its Affiliates
herein;

          (iii) the conduct of the Business by Seller or any of its Affiliates prior to the
Closing;

          (iv) the failure of Seller or any of its Affiliates to pay, perform or discharge any
Excluded Liabilities;

          (v) any and all Liabilities and obligations arising out of or resulting from product
liability claims caused by a Product administered, provided or sold by or on behalf of Seller
before the Closing; or

16

 

          (vi) except as otherwise provided herein, any and all other Liabilities and obligations
that arise out of or are related to the Purchased Assets, the Business, the Compound or the
Product, attributable to occurrences and circumstances arising before the Closing.

          (b) By Buyer. Subject to Sections 9.3 and 9.4, from and after the Closing, Buyer
shall indemnify, reimburse, defend and hold harmless Seller, its Affiliates and their respective
officers, directors, employees, agents, successors and assigns (collectively, the “Seller
Indemnified Parties”) from and against any and all Damages to the extent arising or resulting
from:

          (i) any inaccuracy or breach of any representation or warranty of Buyer herein;

          (ii) any breach of any covenant or other agreement of Buyer herein;

          (iii) the conduct of the Business by Buyer or any of its Affiliates from and after the
Closing;

          (iv) any and all Liabilities and obligations arising out of or resulting from product
liability claims caused by a Product administered, provided or sold by or on behalf of Buyer
after the Closing; or

          (v) except as otherwise provided herein, any and all other Liabilities and obligations
that arise out of or are related to the Purchased Assets, the Business, the Compound or the
Product, attributable to occurrences and circumstances arising after the Closing.

          (c) Procedures. The indemnified party (the “Indemnified Party”) shall give
the indemnifying party (the “Indemnifying Party”) prompt written notice (an
“Indemnification Claim Notice”) (but in no event more than thirty (30) days after
discovery) of any Damages or discovery of fact upon which such Indemnified Party intends to base a
request for indemnification under Section 9.2(a) or Section 9.2(b); provided, however, in no event
shall the Indemnifying Party be liable for any Damages that result from any delay in providing such
notice except to the extent that the rights of the Indemnifying Party are not materially prejudiced
by the failure to give notice. Each Indemnification Claim Notice must contain a reasonable
description of the claim and the nature and amount of such Damages (to the extent that the nature
and amount of such Damages are known at such time). The Indemnified Party shall furnish promptly
to the Indemnifying Party (but in no event more than thirty (30) days after discovery) copies of
all papers and official documents received in respect of any Damages. All indemnification claims
in respect of a Party, its Affiliates or their respective directors, officers, employees and agents
(collectively, the “Indemnitees” and each an “Indemnitee”) shall be made solely by
such Party to this Agreement.

          (d) Third Party Claims. The obligations of an Indemnifying Party under this Section
9.2 with respect to Damages arising from claims of any third party that are subject to
indemnification as provided for in Section 9.2(a) or Section 9.2(b) (a “Third Party Claim”)
shall be governed by and be contingent upon the following additional terms and conditions:

          (i) At its option, the Indemnifying Party may assume the defense of any Third Party Claim
by giving written notice to the Indemnified Party within thirty (30) days after the
Indemnifying Party’s receipt of an Indemnification Claim Notice. The assumption of the defense
of a Third Party Claim by the Indemnifying Party shall not be construed as an acknowledgment
that the Indemnifying Party is liable to indemnify any Indemnitee in respect of the Third Party
Claim, nor shall it constitute a waiver by the Indemnifying Party of any defenses it may assert
against any Indemnitee’s claim for indemnification. Failure by the Indemnifying Party to
notify the Indemnified Party of its election to defend any such action within thirty (30) days
after notice thereof shall have

17

 

been given to the Indemnifying Party shall be deemed a waiver
by the Indemnifying Party of its right to defend such action. Upon assuming the defense of a
Third Party Claim, the Indemnifying Party may appoint as lead counsel in the defense of the
Third Party Claim any legal counsel selected by the Indemnifying Party that is reasonably
acceptable to the Indemnified Party. In the event the Indemnifying Party assumes the defense
of a Third Party Claim, the Indemnified Party shall promptly deliver to the Indemnifying Party
all original notices and documents (including court papers) received by any Indemnitee in
connection with the Third Party Claim. Should the Indemnifying Party assume the defense of and
continue to defend a Third Party Claim with counsel reasonably acceptable to the Indemnified
Party, except as provided in subsection (ii) below, the Indemnifying Party shall not be liable
to the Indemnified Party or any other Indemnitee for any legal expenses subsequently incurred
by such Indemnified Party or other Indemnitee in connection with the analysis, defense or
settlement of the Third Party Claim. In the event that it is ultimately determined that the
Indemnifying Party is not obligated to indemnify, defend or hold harmless an Indemnitee from
and against the Third Party Claim, the Indemnified Party shall reimburse the Indemnifying Party
for any and all costs and expenses (including attorneys’ fees and costs of suit)
and any Damages incurred by the Indemnifying Party in its defense of the Third Party Claim
with respect to such Indemnitee.

          (ii) Without limiting Section 9.2(d)(i), any Indemnitee shall be entitled to participate
in, but not control, the defense of such Third Party Claim and to employ counsel of its choice
for such purpose; provided, however, that such employment of separate legal counsel shall be at
the Indemnitee’s own expense unless (A) the employment thereof has been specifically authorized
by the Indemnifying Party in writing, (B) the Indemnifying Party has failed to assume the
defense and employ counsel in accordance with Section 9.2(d)(i) (in which case the Indemnified
Party shall control the defense) or (C) if the Indemnified Party and the Indemnifying Party are
both named parties to the proceeding and the Indemnified Party has reasonably concluded that
there may be one or more legal defenses that are different from or in addition to those
available to the Indemnifying Party (in which case the Indemnifying Party shall not have the
right to assume the defense of such action on behalf of the Indemnified Party and the
Indemnifying Party shall be liable for all legal expenses incurred by the Indemnified Party in
furtherance thereof).

          (iii) With respect to any Damages relating solely to the payment of money damages in
connection with a Third Party Claim and that will not result in the Indemnitee’s becoming
subject to injunctive or other relief or otherwise adversely affect the business of the
Indemnitee in any manner, and as to which the Indemnifying Party shall have acknowledged in
writing the obligation to indemnify the Indemnitee hereunder, the Indemnifying Party shall have
the sole right to consent to the entry of any judgment, enter into any settlement or otherwise
dispose of such Damages, on such terms as the Indemnifying Party, in its sole discretion, shall
deem appropriate. With respect to all other Damages in connection with Third Party Claims,
where the Indemnifying Party has assumed the defense of the Third Party Claim in accordance
with Section 9.2(d)(i), the Indemnifying Party shall not have authority to consent to the entry
of any judgment, enter into any settlement or otherwise dispose of such Damages unless it
obtains the prior written consent of the Indemnified Party (which consent shall not be
unreasonably withheld, conditioned or delayed). The Indemnifying Party shall not be liable for
any settlement or other disposition of Damages by an Indemnitee that is reached without the
written consent of the Indemnifying Party (which consent shall not be unreasonably withheld or
delayed). Regardless of whether the Indemnifying Party chooses to defend or prosecute any
Third Party Claim, if an Indemnitee shall admit any liability with respect to, or settle,
compromise or discharge, any Third Party Claim without the prior written consent of the
Indemnifying Party (which consent shall not be unreasonably withheld, conditioned or delayed),
the Indemnitee shall have deemed to have waived all rights to indemnification hereunder by the
Indemnifying Party with the respect to such Third Party Claim.

18

 

          (iv) If the Indemnifying Party chooses to defend or prosecute any Third Party Claim, the
Indemnified Party shall, and shall cause each other Indemnitee to, cooperate in the defense or
prosecution thereof and shall furnish such records, information and testimony, provide such
witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as
may be reasonably requested in connection therewith. Such cooperation shall include access
during normal business hours afforded to the Indemnifying Party to, and reasonable retention by
the Indemnified Party of, records and information that are reasonably relevant to such Third
Party Claim, and making Indemnitees and other employees and agents available on a mutually
convenient basis to provide additional information and explanation of any material provided
hereunder. The Indemnifying Party shall reimburse the Indemnified Party for all its reasonable
costs and expenses in connection with any of the foregoing.

          (e) Expenses. Except as provided above, the costs and expenses, including fees and
disbursements of counsel, incurred by the Indemnified Party in connection with any claim shall be
reimbursed on a quarterly basis by the Indemnifying Party, without prejudice to the
Indemnifying Party’s right to contest the Indemnified Party’s right to indemnification and subject
to refund in the event the Indemnifying Party is ultimately held not to be obligated to indemnify
the Indemnified Party.

     9.3 Limitations. Notwithstanding anything to the contrary contained in this Agreement, each
of the following limitations shall apply:

          (a) Seller will not be required to indemnify Buyer under Section 9.2(a)(i) except to the
extent that the cumulative amount of the Damages under Section 9.2(a)(i) actually incurred by the
Buyer Indemnified Parties exceeds [...***...] at which point Seller
will be required to pay, and will have Liability for, the cumulative amount of the Damages under
Section 9.2(a)(i) actually incurred by the Buyer Indemnified Parties (including the first [...***...]).

          (b) Buyer will not be required to indemnify Seller under Section 9.2(b)(i) except to the
extent that the cumulative amount of the Damages under Section 9.2(b)(i) actually incurred by the
Seller Indemnified Parties exceeds [...***...] at which point Buyer will be required to pay, and will
have Liability for, the cumulative amount of the Damages under Section 9.2(b)(i) actually incurred
by the Seller Indemnified Parties (including the first [...***...]).

          (c) In no event shall the aggregate out-of-pocket Liability of Seller for any Damages pursuant
to Section 9.2(a)(i) exceed the aggregate Purchase Price received by Seller as of the date such
Damages are finally determined. For clarity, Seller shall not be permitted to offset any such
amounts due hereunder against the Milestone Payments.

          (d) In no event shall Seller or Buyer have any Liability under Section 9.2(a)(i) or 9.2(b)(i),
as the case may be, with respect to claims that are not properly asserted in writing prior to the
date that is (i) twenty four (24) months after the Closing Date in the case of claims related to
breaches of representations and warranties other than those contained in Section 6.13 hereof, and
(ii) sixty (60) days following the expiration of any applicable Tax statute of limitation in the
case of claims related to breaches of the representations and warranties contained in Section 6.13
hereof. In addition, there shall be no limitation on Liability with respect to breaches of the
representations and warranties contained in Section 6.13 hereof.

          (e) The amount of any Damages under Section 9.2 shall be reduced by the amount of any
insurance proceeds actually received by the Indemnified Party relating to such claim.

 

			
	***	 	Confidential Treatment Requested

19

 

          (f) No Party shall be entitled to indemnification under this Article 9 to the extent Damages
result from the gross negligence or intentional misconduct of the Party seeking indemnification.

          (g) Except with respect to claims based on fraud or willful misconduct, after the Closing:

          (i) the right of the Buyer Indemnified Parties to indemnification under this Article 9
shall be the exclusive remedy of the Buyer Indemnified Parties with respect to claims arising
or resulting from (A) any inaccuracy or breach of any representation or warranty of Seller or
any of its Affiliates in this Agreement; (B) any breach of any covenant or other agreement of
Seller or any of its Affiliates in this Agreement; (C) Seller’s or any of its Affiliates’
conduct of the Business prior to the Closing except to the extent the same constitutes Assumed
Liabilities which
were assigned to Buyer pursuant to this Agreement and the Assignment and Assumption
Agreement; or (D) the failure of Seller or any of its Affiliates to pay, perform or discharge
any Excluded Liabilities; and

          (ii) the right of the Seller Indemnified Parties to indemnification under this Article 9
shall be the exclusive remedy of the Seller Indemnified Parties with respect to claims arising
or resulting from (A) any inaccuracy or breach of any representation or warranty of Buyer in
this Agreement; (B) any breach of any covenant or other agreement of Buyer in this Agreement;
(C) Buyer’s conduct of the Business from and after the Closing; or (D) the failure of Buyer to
pay, perform or disclose any Assumed Liabilities.

     9.4 Consequential Damages.

     NO PARTY TO THIS AGREEMENT SHALL BE LIABLE FOR ANY PUNITIVE OR EXEMPLARY DAMAGES OR
INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR RELATING TO THIS AGREEMENT, PROVIDED
THAT THE FOREGOING SHALL NOT LIMIT THE INDEMNIFICATION OBLIGATION OF EITHER PARTY HEREUNDER WITH
RESPECT TO DAMAGES RESULTING FROM A THIRD PARTY CLAIM.

ARTICLE 10

MISCELLANEOUS

     10.1 Confidentiality.

          (a) In addition to the restrictions set forth in Section 8.1, each Party agrees that at and
after the Closing, it shall not, without the prior written consent of the other Party, (i) disclose
to any Person such other Party’s Confidential Information (as defined below), except to those of
its employees or representatives who need to know such information for the purpose of exploiting
its rights or fulfilling its obligations under this Agreement (and then only to the extent that
such persons are under an obligation to maintain the confidentiality of the Confidential
Information), or (ii) use any of such other Party’s Confidential Information for any reason other
than as contemplated by this Agreement. If a Party has been advised by legal counsel that in the
opinion of such counsel disclosure of Confidential Information of the other Party is required to be
made under applicable Law (including the requirements of a national securities exchange or another
similar regulatory body) or pursuant to documents subpoena, civil investigative demand,
interrogatories, requests for information, or other similar process, the Party required to disclose
the Confidential Information shall (to the extent legally permitted) provide the other Party with
prompt written notice of such request or demands or other similar process so that such other Party
may seek an appropriate protective order or waive the disclosing Party’s compliance with the
provisions of this Section 10.1(a). In the absence of a protective order or waiver or other
remedy, the Party required to disclose the other Party’s

20

 

Confidential Information may disclose only
that portion of the Confidential Information which its legal counsel advises that it is legally
required to disclose, provided that it exercises good faith, diligent efforts to preserve the
confidentiality of such other party’s Confidential Information, including by cooperating with such
other Party to obtain an appropriate protective order or other reliable assurance that confidential
treatment will be accorded the Confidential Information.

          (b) The term “Confidential Information” as used in this Section 10.1 means (i) as to
Buyer, all confidential information relating to Buyer’s business, the Business, and the Purchased
Assets and the Assumed Liabilities, and (ii) as to Seller, all confidential information relating to
the business and operations of Seller, including the Excluded Assets and the Excluded Liabilities
or other obligations, or other than the Assumed Liabilities, but not including the Business or
Purchased Assets, in each of (i) and
(ii) whether disclosed prior to or after the date hereof. The term “Confidential Information”
does not include information which (A) becomes generally available to the public other than as a
result of disclosure by the disclosing Party, (B) becomes available to the non-disclosing Party on
a non-confidential basis from a source other than the disclosing Party provided that such source is
not bound by a confidentiality agreement with the non-disclosing Party, or (C) was previously known
by the non-disclosing Party as evidenced by the non-disclosing Party’s written records.

     10.2 Notices. All notices, requests and other communications hereunder must be in writing and
will be deemed to have been duly given only if delivered personally against written receipt or by
facsimile transmission with answer back confirmation or by nationally recognized overnight courier
that maintains records of delivery to the Parties at the following addresses or facsimile numbers:

	 	 	 	 	 

	 

	 	If to Buyer to:
	 	Cypress Biosciences, Inc.

4350 Executive Drive, Suite 325

San Diego, California 92121

Attention: Dr. Jay D. Kranzler

With a copy to: Legal Department

Facsimile: +1 (858) 452-1222
	 
	 	 	 	 
	 	 	With a copy to (which shall not constitute notice):
	 
	 	 	 	 
	 

	 	 	 	Latham & Watkins LLP

12636 High Bluff Drive, Suite 400

San Diego, CA 92130

Attention: Faye H. Russell, Esq.

Facsimile: +1 (858) 523-5450
	 
	 	 	 	 
	 

	 	If to Seller to:
	 	Marina Biotech, Inc.

3830 Monte Villa Parkway

Bothell, WA 98021

Attention: Chief Financial Officer

Facsimile: +1(425) 908-3653
	 
	 	 	 	 
	 	 	With a copy to (which shall not constitute notice):
	 
	 	 	 	 
	 

	 	 	 	Pryor Cashman LLP

7 Times Square

New York, NY 10036

Attention: Lawrence Remmel, Esq.

Facsimile: +1(212) 798-6365

21

 

     All such notices, requests and other communications will (a) if delivered personally to the
address as provided in this Section 10.2, be deemed given upon receipt, (b) if delivered by
facsimile to the facsimile number as provided in this Section 10.2, be deemed given upon receipt by
the sender of the answer back confirmation and (c) if delivered by overnight courier to the address
as provided in this Section 10.2, be deemed given upon receipt (in each case regardless of whether
such notice, request or other communication is received by any other Person to whom a copy of such
notice, request or other communication is to be delivered pursuant to this Section 10.2). Any
Party from time to time may change
its address, facsimile number or other information for the purpose of notices to that Party by
giving notice specifying such change to the other Parties hereto in accordance with the terms of
this Section 10.2.

     10.3 Entire Agreement. This Agreement (and all Exhibits and Schedules attached hereto and all
other documents delivered in connection herewith) supersedes all prior discussions and agreements
among the Parties with respect to the subject matter hereof and contains the sole and entire
agreement among the Parties hereto with respect to the subject matter hereof.

     10.4 Waiver. Any term or condition of this Agreement may be waived at any time by the Party
that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in
a written instrument duly executed by or on behalf of the Party waiving such term or condition. No
waiver by any Party hereto of any term or condition of this Agreement, in any one or more
instances, shall be deemed to be or construed as a waiver of the same or any other term or
condition of this Agreement on any future occasion.

     10.5 Amendment. This Agreement may be amended, supplemented or modified only by a written
instrument duly executed by each Party hereto.

     10.6 Third Party Beneficiaries. Except as provided in Article 9, the terms and provisions of
this Agreement are intended solely for the benefit of each Party hereto and their respective
successors or permitted assigns and it is not the intention of the Parties to confer third-party
beneficiary rights upon any other Person.

     10.7 Assignment; Binding Effect. Neither this Agreement nor any right, interest or obligation
hereunder may be assigned by any Party hereto without the prior written consent of the other Party
hereto (which consent shall not be unreasonably withheld) and any attempt to do so will be void;
provided however, such prior written consent will not be required with respect to an assignment by
either Party (a) to an Affiliate of such Party so long as such Party remains bound by the terms
hereof, or (b) in connection with a merger, sale or transfer involving all or substantially all of
the assets of such Party; provided further ̧ such prior written consent will not be required with
respect to an assignment by Cypress in connection with a merger, sale or transfer involving all or
substantially all of the assets related to the Business. This Agreement is binding upon, inures to
the benefit of and is enforceable by the Parties hereto and their respective successors and
permitted assigns.

     10.8 Headings. The headings used in this Agreement have been inserted for convenience of
reference only and do not define or limit the provisions hereof.

     10.9 Severability. If any provision of this Agreement is held to be illegal, invalid or
unenforceable under any present or future law, and if the rights or obligations of any Party hereto
under this Agreement will not be
materially and adversely affected thereby, (a) such provision will be fully severable, (b)
this Agreement will be construed and enforced as if such illegal, invalid or unenforceable
provision had never comprised a part hereof, (c) the remaining provisions of this Agreement will
remain in full force and effect and will not be affected by the illegal, invalid or unenforceable
provision or by its severance herefrom, and (d) in lieu of such illegal, invalid or unenforceable
provision, there will be added

22

 

automatically as a part of this Agreement a legal, valid and
enforceable provision as similar to terms to such illegal, invalid or unenforceable provision as
may be possible and reasonably acceptable to the Parties herein.

     10.10 Governing Law; Dispute Resolution.

          (a) This Agreement shall be construed in accordance with, and governed in all respects by, the
laws of the State of Delaware (without giving effect to principles of conflicts of laws that would
require the application of any other law).

          (b) Except with respect to any claim seeking injunctive relief hereunder, in the
event of any controversy or claim arising out of, relating to or in connection with any provision
of this Agreement or the rights or obligations of the parties hereunder, the parties will try to
settle their differences amicably between themselves as contemplated herein. To the extent not
provided for herein, any party may initiate such informal dispute resolution by sending written
notice of the dispute to the other party, and within [...***...]
after such notice, the Chief Executive Officer (or his or her designee) of Buyer will meet with the
Chief Executive Officer (or his or her designee) of Seller, for attempted resolution by good faith
negotiations. If such Persons are unable to resolve promptly such disputed matter, such dispute
shall be finally settled by arbitration in accordance with the commercial arbitration rules of the
American Arbitration Association (“AAA”), then in force, by one (1) arbitrator appointed in
accordance with said rules, provided that the appointed arbitrator shall have appropriate
experience in the biopharmaceutical industry. The place of arbitration shall be [...***...]. The
award rendered shall be final and binding upon all parties participating in such arbitration. The
judgment rendered by the arbitrator may, at the arbitrator’s discretion, include costs of
arbitration, reasonable attorneys’ fees and reasonable costs for any expert and other witnesses.
Judgment upon the award may be entered in any court having jurisdiction, or application may be made
to such court for judicial acceptance of the award and/or an order of enforcement as the case may
be. The parties agree to use their good faith efforts to resolve the dispute within [...***...] of
receipt of the original notice of dispute. Notwithstanding the foregoing, any disputes regarding
the scope, validity, enforceability or inventorship of any patents or patent applications shall be
submitted for final resolution by a court of competent jurisdiction.

     10.11 Expenses. Except as otherwise provided in this Agreement, each Party hereto shall pay
its own expenses and costs incidental to the preparation of this Agreement and to the consummation
of the transactions contemplated hereby.

     10.12 Counterparts. This Agreement may be executed in any number of counterparts and by
facsimile or pdf file contained in an email, each of which will be deemed an original, but all of
which together will constitute one and the same instrument.

     10.13 Schedules, Exhibits and Other Agreements. The Exhibits, Schedules, other agreements,
certificates and notices specifically referred to herein, and delivered pursuant hereto, are an
integral part of this Agreement. Any disclosure that is made in any of the Schedules or
certificates delivered pursuant to this Agreement shall be deemed responsive to any other
applicable disclosure obligation hereunder where it is reasonably apparent that such disclosure is
responsive to such other applicable disclosure obligation.

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

 

			
	***	 	Confidential Treatment Requested

23

 

          IN WITNESS WHEREOF, this Agreement has been executed by the Parties hereto as of the date
first written above.

	 	 	 	 	 	 	 

	 	 	CYPRESS BIOSCIENCE, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Jay Kranzler	 	 
	 

	 	Name:
	 	 

Jay D. Kranzler, M.D., Ph.D.
	 	 
	 

	 	Title:
	 	Chief Executive Officer	 	 
	 
	 	 	 	 	 	 
	 	 	MARINA BIOTECH, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ J. Michael French	 	 
	 

	 	Name:
	 	 

J. Michael French
	 	 
	 

	 	Title:
	 	President & CEO	 	 

[SIGNATURE PAGE TO ASSET PURCHASE AGREEMENT]

 

 

Exhibit A

DEFINITIONS

     “AAA” has the meaning set forth in Section 10.10(b).

     “Acquiror” has the meaning set forth in Section 8.7(c)(i).

     “Action or Proceeding” means any action, suit, proceeding, arbitration, Order,
hearing, assessment with respect to fines or penalties or litigation (whether civil, criminal,
administrative, investigative or informal) commenced, brought, conducted or heard by or before any
Governmental or Regulatory Authority.

     “Adverse Effect” means an effect or condition that individually or in the aggregate is
materially adverse to the ability to take possession of, own or use the Purchased Assets.

     “Affiliate” means, with respect to any Person, any other Person which controls, is
controlled by or is under common control with such Person. A Person shall be regarded as in
control of another Person if it owns or controls, directly or indirectly, (i) in the case of
corporate entities at least fifty percent (50%) (or the maximum ownership interest permitted by
law) of the equity securities in the subject entity entitled to vote in the election of directors
and, (ii) in the case of an entity that is not a corporation, at least fifty percent (50%) (or the
maximum ownership interest permitted by law) of the equity securities or other ownership interests
with the power to direct the management and policies of such subject entity or entitled to elect
the corresponding management authority, or such other relationship as, in fact, constitutes actual
control.

     “Agreement” has the meaning set forth in the Preamble hereto.

     “Allocation” has the meaning set forth in Section 4.5(a).

     “API” has the meaning set forth in Section 8.7(a).

     “Assets and Properties” of any Person means all assets and properties of any kind,
nature, character and description (whether real, personal or mixed, whether tangible or intangible,
whether absolute, accrued, contingent, fixed or otherwise and wherever situated), including the
goodwill related thereto, operated, owned or leased by such Person, including cash, cash
equivalents, accounts and notes receivable, chattel paper, documents, instruments, general
intangibles, regulatory approvals, equipment, inventory, goods and intellectual property.

     “Assignment and Assumption Agreement” has the meaning set forth in Section 5.2(a)(iv).

     “Assumed Contract” means the Contracts or portions of the Contracts identified in
Section 6.6 of the Seller Disclosure Schedule.

     “Assumed Liabilities” means any and all Liabilities and obligations of Seller or any
of its Affiliates under the Assumed Contracts to be incurred after the Closing or arising from the
Buyer’s performance under the Assumed Contracts after the Closing but not including such
Liabilities incurred, paid, performed or otherwise arose on or prior to the Closing or Liabilities
arising out of any breach or default by Seller or any of its Affiliates under the Assumed Contracts
on or prior to the Closing.

     “Bill of Sale” has the meaning set forth in Section 5.2(a)(v).

A-1

 

     “Books and Records” means all files, documents, instruments, papers, books and records
(other than Marketing Materials) owned by Seller or any of its Affiliates relating exclusively to
the Business or to the research, clinical development, use or manufacture of the Compound or the
Product, including any vendor lists, financial data, written and pending orders and all
documentation relating to the Intellectual Property.

     “Business” means the activities of research, development and manufacturing conducted
by or on behalf of Seller related exclusively to the Compound or the Product in the Territory.

     “Business Day” means a day other than Saturday, Sunday or any day on which banks
located in the State of California are authorized or obligated to close.

     “Buyer” has the meaning set forth in the Preamble to this Agreement.

     “Buyer Disclosure Schedule” has the meaning set forth in Article 7 hereof.

     “Buyer Indemnified Parties” has the meaning set forth in Section 9.2(a).

     “Carbetocin Claims” has the meaning set forth in Section 8.7(b)(i).

     “Closing” has the meaning set forth in Section 5.1.

     “Closing Date” means the date that the Closing actually occurs as provided in Section
5.1.

     “Code” means the Internal Revenue Code of 1986, as amended.

     “Compound” means carbetocin, including any salts, esters, solvates, polymorphs or
other non-covalent derivatives thereto.

     “Confidential Information” has the meaning set forth in Section 10.1(b).

     “Contract” means any and all commitments, contracts, purchase orders, leases, or other
agreements, whether written or oral related to the Compound or the Product.

     “Damages” has the meaning set forth in Section 9.2(a).

     “Encumbrance” means any mortgage, pledge, assessment, security interest, deed of
trust, lease, lien, adverse claim, levy, charge or other encumbrance, restriction, limitation or
third party right of any kind, or any conditional sale or title retention agreement or other
agreement to give any of the foregoing in the future.

     “Excluded Assets” means all Assets and Properties of Seller and its Affiliates
(including Seller’s rights under this Agreement) except the Purchased Assets.

     “Excluded Liabilities” means (i) any and all Liabilities in respect of any Excluded
Assets, including (a) the outstanding amount of all principal, interest, fees and expenses in
respect of borrowed money, capital leases, installment purchases and other indebtedness of Seller,
(b) any Liability of Seller, or otherwise imposed on the Purchased Assets, in respect of any Tax,
including (i) any Liability of Seller for the Taxes of any other Person under Reg. 1.1502-6 (or any
similar provision of state, local, or foreign law), as a transferee or successor, by contract, or
otherwise, and (ii) any Transaction Taxes, but excluding any Transaction Taxes or Property Taxes to
the extent that they are specifically allocated to Buyer pursuant to Section 4.4 or 8.10(b), (c)
any environmental Liabilities of Seller, (d) any Liabilities to

A-2

 

directors, officers or employees of Seller or in respect of Seller employee benefit, profit
sharing or health care plans, (e) any Liabilities of Seller with respect to any Action or
Proceeding pending or threatened against Seller, (f) any Liabilities of any Person other than
Seller and (g) any Liabilities of Seller (including expenses to be borne by Seller) under this
Agreement or any of the other agreements, instruments and certificates executed in connection
herewith, (ii) any Liabilities of Seller or any of its Affiliates which arise out of or are related
to the Purchased Assets, the Business or the Product attributable to occurrences and circumstances
arising on or prior to the Closing, and (iii) any Liabilities of Seller arising from or relating to
any action taken by Seller, or any failure on the part of Seller to take any action, at any time
after the Closing Date.

     “FDA” means the U.S. Food and Drug Administration.

     “First Commercial Sale” means the first sale of a Product by Buyer, its Affiliates, or
its licensees to a Third Party in a given regulatory jurisdiction within the Territory after
receipt of regulatory approval (including pricing and reimbursement approvals, if necessary to
begin marketing) for such Product has been obtained in such jurisdiction.

     “Fifth Milestone” has the meaning set forth in Section 4.1.

     “First Milestone” has the meaning set forth in Section 4.1.

     “Follow-On Request” has the meaning set forth in Section 8.8(a).

     “Fourth Milestone” has the meaning set forth in Section 4.1.

     “Generic Product” means , with respect to a Product in the Territory, another
pharmaceutical product that is: (a) a Product; (b) is bioequivalent to such Product with respect to
pharmacokinetic properties; and (c) is either (i) approved for use in the Territory by the
Governmental or Regulatory Authority, or (ii) launched by a Third Party in the Territory pursuant
to Paragraph IV of the Drug Price Competition and Patent Term Restoration Act of 1984, as amended,
or any successor regulations (or its comparable regulation in a jurisdiction within the Territory).

     “Governmental or Regulatory Authority” means any court, tribunal, arbitrator,
authority, agency, commission, official or other instrumentality of the United States or other
country, or any supra-national organization, state, county, city or other political subdivision
thereof.

     “Indemnification Claim Notice” has the meaning set forth in Section 9.2(c).

     “Indemnified Party” has the meaning set forth in Section 9.2(c).

     “Indemnifying Party” has the meaning set forth in Section 9.2(c).

     “Indemnitee” and “Indemnitees” have the respective meanings set forth in
Section 9.2(c).

     “Independent Accountant” has the meaning set forth in Section 4.2(g).

     “Intellectual Property” means any and all of the following intellectual property
rights owned by or licensed to Seller and used by Seller exclusively in connection with the conduct
of the Business or the research, development, manufacture or commercialization of the Compound or a
Product: all (i) Patents; (ii) Know-how; (iii) copyrights, copyright registrations, applications
therefor and renewal rights therefor; and (iv) software, data, covenants not to assert and trade
secrets, and in each case all documentation

A-3

 

associated therewith; including those items identified in Section 6.7(a) of the Seller
Disclosure Schedule. For clarity, Intellectual Property shall not include any patents,
applications, discoveries, know-how or technical information owned or controlled by Seller which
relate to RNA interference.

     “Intellectual Property Assignment Agreement” has the meaning set forth in Section
5.2(a)(iii).

     “Know-How” means the following information owned by or licensed to Seller: all
tangible and intangible know-how, trade secrets and inventions (whether or not patentable), and all
engineering, production and other designs, drawing, specifications, formulas, technology, software,
data, analytic reference materials and methods and all confidential or proprietary chemical
substances, assays and information, in all cases that is identifiable and used exclusively in
connection with the use or manufacture of a Product.

     “Knowledge” means such knowledge which a reasonable person should have obtained after
reasonable inquiry.

     “Law” means any federal, state or local law, statute or ordinance, or any rule,
regulation, or published guidelines promulgated by any Governmental or Regulatory Authority.

     “Liability” means any liability (whether known or unknown, asserted or unasserted,
absolute or contingent, accrued or unaccrued, liquidated or unliquidated, and due or to become
due).

     “Nasal Formulation Patents” has the meaning set forth in Section 8.7(a).

     “Net Sales” means, with respect to a particular time period, the total amounts
invoiced during such time period by Buyer and its Affiliates or licensees for sales of Products to
unrelated Third Parties in the Territory, less the following deductions to the extent actually
allowed or incurred with respect to such sales:

     (a) trade discounts, credits or allowances including cash and quantity discounts provided by
means of chargebacks, rebates and administrative fees charged by customers or health care
organizations determined based upon sales;

     (b) credits or allowances (other than those specified in clause (a)), granted for damaged,
outdated, spoiled, returned or rejected Products, including in connection with recalls;

     (c) freight, shipping and insurance charges, to the extent included in the invoiced amount and
identified in the applicable invoice;

     (d) taxes, tariffs, duties or other governmental charges (other than income taxes) levied on,
absorbed or otherwise imposed on sales of the Products in the Territory, as adjusted by any
refunds, provided that such Taxes, tariffs, duties and other governmental charges are included in
the applicable invoiced amount and identified in the applicable invoice; and

     (e) rebates, discounts or other payments to Third Parties on sales of Products to such Third
Parties that are mandated by a Governmental or Regulatory Authority.

     Notwithstanding the foregoing, amounts invoiced by Buyer and its Affiliates or licensees for
the sale of Products between Buyer and its Affiliates or licensees for resale to Third Parties
shall not be included in the computation of Net Sales hereunder. For purposes of determining Net
Sales, a “sale” shall

A-4

 

not include reasonable transfers or dispositions, at no cost, as samples or for charitable
purposes, or transfers or dispositions at no cost for preclinical, clinical or regulatory purposes.

     Each of the deductions set forth above shall be in accordance with United States Generally
Accepted Accounting Principles.

     For the purpose of determining royalties due to Seller, Buyer shall calculate Net Sales of
Combination Products (as defined below) by multiplying Net Sales of such Combination Product by a
fraction A/A+B, where A is the sale price of the Product portion of such Combination Product when
sold separately and B is the sale price of the other active ingredient(s) in such Combination
Product when sold separately; provided, however, that if the Product portion of such Combination
Product or any of the other active ingredients in such Combination Product is not then sold
separately, then Buyer shall calculate Net Sales of such Combination Products by the fraction
C/C+D, where C is a reasonable estimate of the fair market value of the Product portion of such
Combination Product, D is a reasonable estimate of the fair market value of the other active
ingredients in such Combination Product, and the estimates of C and D are determined by mutual
agreement of the Parties. As used in this Agreement, “Combination Product” means a product
in which one or more active ingredients that are not Products are sold in a single formulation with
a Product.

     “NDA” means a New Drug Application filed with the FDA pursuant to 21 U.S.C. Section
357 and 21 C.F.R. Section 314.

     “NDA Filing” means the receipt of a written acceptance for filing of an NDA for a
Product by the FDA.

     “Non-Assert IP” has the meaning set forth in Section 8.7(b).

     “Order” means any writ, judgment, decree, injunction or similar order of any
Governmental or Regulatory Authority (in each such case whether preliminary or final).

     “Parties” means Buyer and Seller.

     “Party” means each of Buyer and Seller.

     “Patents” means (a) any patents, patent applications, provisional patent applications
and similar instruments identified in Section 6.7(a) of the Seller Disclosure Schedule; and (b) to
the extent related thereto or derived therefrom, any and all substitutions, reissues, renewals,
extensions, utility models, reexaminations, patents of addition, supplementary protection
certificates, inventors’ certificates, pediatric data package exclusivity extensions, requests for
continued examinations, designs, divisions, re-filings, continuations and continuations-in-part
thereof, or the like and any foreign equivalents thereof (including certificates of invention and
any applications therefor) and all documentation associated therewith.

     “Permits” has the meaning set forth in Section 6.9(a).

     “Permitted Encumbrance” means (a) Encumbrances for Taxes or assessments which are not
delinquent or which are being contested in good faith by appropriate proceedings or (b) statutory
mechanics’, carriers’, workmen’s, landlords’ or other similar liens arising or incurred in the
ordinary course of business which are not yet delinquent or the validity of which are being
contested in good faith by appropriate proceedings.

A-5

 

     “Person” means any natural person, corporation, general partnership, limited
partnership, limited liability company, proprietorship, other business organization, trust, union,
association or Governmental or Regulatory Authority.

     “Post-Closing Tax Period” means (a) any Tax period beginning after the Closing Date
and (b) with respect to any Straddle Period, the portion of such period beginning after the Closing
Date.

     “Pre-Closing Tax Period” means (a) any Tax period ending on or before the Closing Date
and (b) with respect to any Straddle Period, the portion of such period ending on the Closing Date.

     [...***...]

     “Product” means any pharmaceutical composition or preparation, in any dosage strength
or size, containing Compound as an active pharmaceutical ingredient.

     “Product Data” means all toxicology, pre-clinical, clinical, regulatory and
manufacturing information and data and technology, and all submissions and correspondence with or
to any Governmental or Regulatory Authority in the Territory related exclusively to the Compound or
a Product, including the manufacturing, packaging and release of a Product, e.g., all validation
data and documentation supporting the process of manufacturing the Compound or a Product, in any
form whatsoever including notebooks, but only to the extent the foregoing may be in Seller’s
possession or control.

     “Product Materials” means (a) all inventory of expired Compound owned or controlled by
Seller as of the Closing and (b) all blood samples owned or controlled by Seller as of the Closing
derived from research studies of the Compound or the Product.

     “Property Taxes” means all real property Taxes, personal property Taxes and similar ad
valorem Taxes.

     “Purchase Price” has the meaning set forth in Section 4.1(g).

     “Purchased Assets” means, subject to Section 2.3: (i) the Intellectual Property
(including the Registered Intellectual Property); (ii) the Assumed Contracts; (iii) the Books and
Records; (iv) the Product Data; (v) the Product Materials; (vi) all other assets used by Seller
exclusively in the research or clinical development of the Compound or the Product (other than
Excluded Assets); and (vii) all other assets owned or controlled by Seller and used exclusively for
the research, development, manufacture or commercialization of the Compound or the Product.

     “Registered Intellectual Property” means all of the Patents identified in Section
6.7(a) of the Seller Disclosure Schedule.

     “Regulatory Filings” means the investigational and new drug applications, and drug
submissions, licenses and marketing authorizations (and the equivalent foreign registrations and
approvals) for the Compound or the Product in the Territory (including marketing approvals, pricing
or reimbursement approvals, manufacturing approvals, technical, medical, and scientific licenses,
and clinical and non-clinical study authorization applications or notifications), and all,
amendments, supplements, supporting files, data, studies, and reports relating thereto (in hard and
electronic form) and all technical and other information contained therein.

 

			
	***	 	Confidential Treatment Requested

A-6

 

     “Rejection Notice” has the meaning set forth in Section 8.8(a).

     “Royalties” has the meaning set forth in Section 4.2(a).

     “Royalty Term” has the meaning set forth in Section 4.2(b).

     “SEC Reports” means (i) Buyers’ Annual Report on Form 10-K for the year ended December
31, 2009 (the “10-K”); (ii) Buyer’s Quarterly Reports on Form 10-Q for the periods ended
March 31, 2010 and June 30, 2010; (iii) Buyer’s Current Reports on Form 8-K filed subsequent to the
filing of the 10-K; (iv) Buyer’s definitive proxy statement for the 2010 annual meeting of
stockholders, as amended; and (v) such other reports, schedules and documents filed subsequent to
the filing of the 10-K by Buyer or its stockholders and available on the web site of the Securities
and Exchange Commission (www.sec.gov).

     “Second Milestone” has the meaning set forth in Section 4.1.

     “Seller” has the meaning set forth in the Preamble to this Agreement.

     “Seller Disclosure Schedule” has the meaning set forth in the preamble to Article 6 of
this Agreement.

     “Seller Indemnified Parties” has the meaning set forth in Section 9.2(b).

     “Straddle Period” means any Tax period beginning before the Closing Date and ending
after the Closing Date.

     “Tax” means all of the following tax in connection with the operations of the Business
or the transactions contemplated hereby: (i) any net income, alternative or add-on minimum tax,
gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, license,
excise, severance, stamp, occupation, premium, property, environmental or windfall profit tax,
custom, duty or other tax, governmental fee or other like assessment imposed by a governmental,
regulatory or administrative entity or agency responsible for the imposition of any such tax
(domestic or foreign); (ii) any Liability for the payment of any amounts of the type described in
(i) as a result of being a member of any affiliated, consolidated, combined, unitary or other group
for any taxable period; and (iii) any Liability for the payment of any amounts of the type
described in (i) or (ii) as a result of any express or implied obligation to indemnify any other
Person.

     “Tax Return” shall mean any return, declaration, report, claim for refund, or
information returned or statement relating to Taxes, including any schedule or attachment thereto,
and including any amendment thereof.

     “Territory” means the entire world.

     “Third Milestone” has the meaning set forth in Section 4.1.

     “Third Party” means any Person other than a Party or its Affiliates.

     “Third Party Claim” has the meaning set forth in Section 9.2(d).

     “Third Party Interference Costs” has the meaning set forth in Section 4.2(c)(ii).

     “Third Party Payment” has the meaning set forth in Section 4.2(c)(i).

A-7

 

     “Transaction Documents” means this Agreement, the Assignment and Assumption Agreement,
the Bill of Sale and the Intellectual Property Assignment Agreement.

     “Transaction Taxes” has the meaning set forth in Section 4.3.

     “Valid Claim” means, with respect to any country, a claim of an issued and unexpired
Patent (as may be extended through supplementary protection certificate or patent term extension or
the like) included within the Intellectual Property to the extent such claim has not been (i) held
invalid or unenforceable by a non-appealed or un-appealable decision of a court or government
agency or other appropriate body of competent jurisdiction and has not been admitted invalid
through disclaimer or dedication to the public, and (ii) has not expired, been determined to be
unenforceable, been cancelled, withdrawn, abandoned.

A-8

 

Exhibit B

FORM OF INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT

[OMITTED]

 

 

Exhibit C

FORM OF ASSIGNMENT AND ASSUMPTION AGREEMENT

[OMITTED]

 

 

Exhibit D

FORM OF BILL OF SALE

[OMITTED]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}]]